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Abstract 
Quantitative pathology as a tool in gynaecological pathology is fairly new. Such 
techniques allow greater objectivity than histological grading, typing, and residual tumour 
estimation. This study aims to determine: whether basic morphometry data can predict 
outcome and chemotherapeutic response, whether newer semi-automated methods of 
tumour morphometry provide similar results to older methods, and whether advanced 
image analysis methods can offer further tumour outcome data in ovarian carcinoma. 
The study was performed on a well-selected group of serous ovarian carcinomas. 
Tumour outcome, survival and chemotherapeutic response, were investigated in 132 
patients treated with the same platinum containing regimes. 
Traditional clinicopathologic parameters, p53 & Bcl2, mitotic activity index (MAI) 
and angiogenesis determinants were initially investigated. Semi-automated analysis, using 
immunohistochernically based techniques, were applied to estimate volume percentage 
epithelium (VPE) and nuclear morphometric parameters. Syntactic structure analysis 
including, minimum spanning tree, and neighbourhood features, was also investigated. 
Multivariate analysis revealed residual disease status, FIGO stage, MAI, VPE, 
equivalent nuclear diameter, and angiogenesis parameters to be strong prognosticators for 
overall and disease free survival. Residual disease status, VPE, nuclear length and 
angiogenesis parameters were found significant predictors of chemotherapy response. 
Angiogenesis parameters, as determined by semi-automated image analysis techniques, 
were found overall to be the strongest prognosticators. 
Morphometric data can predict outcome and chemotherapeutic response in ovarian 
serous carcinoma. Sen-d-automated morphometry techniques provide similar results to 
older methods, and advanced image analysis can offer further outcome data. The rationale 
for the application of scmi-automated and automated detection is that it may provide an 
unbiased sampling of a lesion and possibly a more representative estimate of areas that a 
human expert might label. Such determined, quantitative pathological findings were found 
to have important value in predicting prognosis in ovarian carcinoma and, if not to 
supersede, certainly to add to classical prognostic factors. 
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Chapter 1. Introduction: Traditional Clinicopathologic Features Used as 
Predictive Factors 
1.1 Preface: Ovarian carcinoma and the need for reliable prognosis 
Ovarian cancer is the most common gynaecological cancer in the UK with 6,900 newly 
diagnosed cases and 4,600 deaths each year. It is the fourth most common cancer death in 
women and accounts for 6% of all female cancer deaths. The 5year survival for all female 
cancers combined is approximately 43%, yet the 5year survival for ovarian cancer is 
29.2%. 113 Prognosis is poor, as patients tend to present with advanced disease, with earlier 
stage disease being relatively asymptomatic. 
With the advent of combined platinum-based chemotherapy in 1975, a significant 
influence upon survival in ovarian cancer was achieved, but little improvement has 
occurred since. In principle mortality could be reduced by more aggressive treatment of 
those at risk of disease recurrence, but therapeutic strategies such as platinum 
chemotherapy agents have considerable side effects (see appendix 1). Hence a reliable 
means of distinguishing between those patients at risk and those not is needed. 
Prognostic indicators are factors defined at a given time point which give information 
on subsequent clinical outcome. Predictive factors give information useful in the selection 
of patients likely to benefit from a specific treatment such as targeted systemic therapy. 121 
Prognostic tools should ideally allow an individualised therapy that optimises survival and 
minimises the risk of severe side effects. [31 A reliable prognostic, or indeed predictive tool, 
may enable accurate patient selection, and select only those patients who will benefit from 
therapy. [41 We must consider that patients with very progressive ovarian cancer may have 
only a very short term survival (FIGO stage IV < 5%, 5yr survival) and, that in spite of 
their good overall prognosis, a considerable number of FIGO stage I patients will die from 
recurrent disease (20 - 40% in different series). 
151 Reliable prognostic tools might 
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therefore enable us to select out those short-term survivors and offer a much less toxic 
palliative therapy and select in those early stage patients who will benefit from more 
aggressive therapy, who, would perhaps have traditionally not been felt to benefit. As 
current therapeutic results in ovarian cancer are reached at the expense of severe side 
effects, with most patients undergoing radical treatment, knowledge of predictive factors 
could lead to a better selection of patients who will benefit from aggressive therapy. 121 
Prognostic and predictive factors have been widely studied in ovarian cancer as a 
means of predicting both patient survival and chemotherapeutic outcome. Evidence is 
available that, in ovarian cancers, the prognostic value of morphometric and cytometric 
features, either alone or in combination, and as multivariate combinations with, for 
example, FIGO stage exceeds that of classical pathological features. This thesis is 
concerned with the development and application of such techniques to ovarian cancer data 
in order to attempt to predict both patient survival and response to platinum-based 
chemotherapeutic regimes. In addition advanced digital imaging techniques will be 
employed to study tumour architecture and nuclear morphology to determine whether such 
procedures can add further to the predictive value of routine techniques in such turnours. In 
this introductory section I shall discuss traditional clinicopathologic factors and their 
prognostic ability in ovarian carcinoma. 
1.2 Traditional Prognostic Indicators in Ovarian Epithelial Malignancy 
Knowledge of prognostic factors may help to explain and perhaps diminish the 
unchanged high mortality in epithelial ovarian cancer and perhaps be used to select 
patients for adjuvant cytotoxic therapy or rather provide clinicians with guidelines for 
decisions on treatment strategies. 
Traditional prognostic factors include clinical factors such as patient age, turnour stage 
and extent of residual disease post primary laparotomy, serum markers such as Ca125 and 
14 
classic pathologic features of histological type and grade. 
1.2.1 Patient age at presentation 
Advanced ovarian cancer (stage 1H & IV) in the >50yrs age group has been 
associated with a higher probability of death, [71 with multivariate analysis showing 
increased age as a predictor of death during the first 5 years of diagnosis and patients > 
65yrs having a2 fold higher risk of death compared with those patients <45yrs. [81 Age has 
also been shown as an independent prognostic factor of survival with patients under 65yrs 
surviving significantly longer than those >65yrs, but this observation may have also 
resulted from poorer performance status. 191 Results from the gynaecological oncology 
group (GOG) trial data (n=2123) showed patients older than 69yrs exhibited significantly 
poorer survival than those younger, even after correction for stage, residual disease and 
performance status. 1101 A significant reduction in survival has also been noted among 
patients 80yrs or older as compared to their younger counterparts, but it appears that 
conservative treatments contributed to the decreased survival of older ovarian cancer 
patients. I' 'I 
A study of women in the :5 25 yrs age group with grade I or grade H tumours 
showed excellent prognosis, those with grade III turnours showed a lesser improvement on 
5 yr survival. [121 Five year survival, median survival and progression free survival have 
been found better in younger patients, as compared to older patients, with younger women 
having significantly better survival when adjusted for stage. [131 When considering however 
only a sub-population of women with late stage ovarian cancer the 5yr survival rate for 
young women was found to be 22.9%, a number in keeping with the literature for post 
menopausal women suggesting that young age does not confer an improved prognosis. [141 
Age was also not found to be an independent prognostic factor in Stage IV disease (151, nor 
as an independent prognostic factor for ovarian carcinoma in women younger than 40yrs. 
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[21 
It is not clear why younger women might have better outcome than older patients. 
It is questionable whether age is an independent prognostic factor, or whether better 
performance status, earlier presentation, more aggressive tumour biology, tumour grade, 
impaired immunologic response or inability to tolerate more intensive treatment may bias 
the prognostic significance of age. 
1.2.2 Tumour stage 
Appropriate staging of a turnour is to define categorical descriptors that allow 
general conclusions to be made regarding the likelihood of relapse and survival for an 
individual patient. [21 It is widely accepted that staging of ovarian cancer is performed by 
the FIGO (International Federation of Gynaecology & Obstetrics) system. This system 
stages ovarian turnours largely on the basis of turnour site and the presence of metastases 
where, stage I turnours have turnour growth limited to the ovaries, stage H turnours have 
growth involving one or both ovaries with pelvic extension, stage HI have tumour 
involving one or both ovaries with peritoneal implants outside the pelvis and / or positive 
retroperitoneal or inguinal nodes and stage IV turnours involve distant metastases (see 
table la: FIGO staging for primary carcinoma of the ovary). Staging in ovarian cancer is 
based on laparotomy findings, histological assessment and cytology of peritoneal. fluid 
(including washings taken in the absence of clinical ascites). [173 Devised in 1974, the 
FIGO system was later revised in 1985 to reflect an improved understanding of tumours' 
natural history and the prognostication value of parameters such as turnour rupture, surface 
excrescences, positive peritoneal cytology and size of abdominal implants. 1181 
FIGO staging is widely used not only as a tool for predicting 5 year survival but 
also as a means of decision making regarding further treatment with chemotherapeutic 
agents. Numerous studies 
[18-21,22,231 have evaluated patient survival with regard to tumour 
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stage. Despite some minor discrepancies, these studies, on the whole, have shown 
reasonable correlation, with approximate 5yr SUrvival estimations in stage I tLIIIIOUrs being L- 
70-80%, stage 11 40-6017c, stage 111 10-40%, and Stage IV 2-10(Yc. (See Table lb: FIGO C- C- 
staoln- and 5yr survival in ovarlan carcinonia). Tumour stage is generally regarded as one I t-- C- Z-- 
of the most important variables for prognosis. Surgical staging is a Ludy extensive process 
being best perfOrmed by gynaecological oncologists. Importantly FIGO staging should not L- L- rl 
be altered on the basis of clinical response or indeed after treatment has ensued. In (lie 
event that SUrgical intervention is inappropriate, staging may be perl'Ornied using Imaollh, L, Z-1 -- I- I- L" 
techniques such as computerised tonlooraphy (C'F) or magnetic resonance imaoino (MRI) L- I- I- t- 
but formal tissue diagnosis should be obtained (e. g. biopsy) pl-ior to commencing L- L- 
chemotherapeutic treatments. 
Table la: International Federation of Crynaecology & Obstetrics: Staging for 
Primary Carcinoma ofthe Ovary 
1: Growth limited to the Ovaries. 
Stage I a: (ý Io \ý IIIIIIIII tckl it ý 011C M, 11 N, Mw asc itc,,. N () Iu mom on the c\ lei nal ,m lace , cap"111k, I h: Growth limited to botil mýjrjcs, 11o ascitcs. No 11.11110ur on the external surface: capsules 
in tac t. 
11c: Tumour either Stage Ia or I b. but with tunioul, present Oil Surface of one Or both 0% arics, 01' 
"1111 capý, ulc rupturedi or kkith 'I'scite" pi'C"CIII cont, 11111111-1 I 11,11 I'L" 11,1111 cells or ýklth 1)()Sltl\, c 
2: Growth involving one or both ovaries with pelvic extension. 
Stage 2a: Lxtciisiori wid / or nietastases to the uterus arid / or tLihe". 
2b: F, xtcrision to otlicr pcivic tissucs. 
2c: Tuinour citlier Sta-c 11a or Stage 11b. hLit witli tunioLir prccrit ori sLirface ofolle or both 
ov, irics: or "Itli cap, ýtflew rLipwred: or witil a"Cite" pre. "Clit Colit'61111q., 111allt, 11,1111 Cells or 
Stage 3: Tumour involving one or both ovaries with peritoneal implants outside tile pelvis and 
or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals 
stage 3. Tumour is limited to the true pelvis, but with histologically proven malignant 
extension to the small bowel or omentum. 
Stage 3a: 1,11111oul 1111111Cd I() 111C mic ýý1111 IIcL-a1I\C 11odc". hut mIll 
confirined inicroscopic seeding ot'abdonnnal pentoneal surfaces. 
3b: Turnour imolving one or both ovaries with histologically conl'inned iniplants ol'ah(lonnnal 
peritoneal surl'aces none exceeding Lin in diameter. Nodes are negative. z C, 
3c: Abdoininal inilflants grcaler than 1-CIII III dianicter and / or positl\ C rell ol)CI'llone'll or 
IIILL1111ý11 11odc". 
Stage 4: Growth involving one or both ovaries with distant metastases. If pleural effusion is 
present, there must he positive cytology to allot a case to stage 4. Parenchymal 
liver metastases equals stage IV. 
Table 1b: FIGO staging and 5yr survival in ovarian carcinoma 
Study FIC01191 
1979 
Sigurdsson 12"' 
1983 
1211 Einhorn 
1985 
1181 1231 
9ý 
Nguyen 81 Fl(ýO 
1993 1998 
n 4892 494 770 9 5156 ? 
5 Year Survival 
Stage 1 72% 82% 88.9% 8.9 c/c 
la 
lal 
la2 
80% 
86% 
75% 
Stage Ib 62.5% 75% 60 71.3% 
lbI 
lb2 
67% 
55% 
Stage Ic 57.4% 83% 59% 79.2% 
Stage 2 57.1% 
2a 
2b 
2c 
52.2% 
37.5% 
37.5% 
79% 
39 "Ic 
61 cl( 
75% 
51% 
41% 
66.61/c 
55.1% 
57.014 
Stage 3 10.8% 8% 11% 23.8% 
3a 
A 
3c 
4 1.1 c1c 
2 4.9 (/( 
2 3.4 I/c 
Stage 4 4.6% 2% 4% 11.6% 11.1% 
1.2.3 Residual Disease 
The early local spread and metastasis of ovarian C', InCer I-eSLI1(S III C0111I)ICIC 11111101.11' 
resection at laparotorny being often not possible in view of for example, site ofnietastases, 
and involvement of adjacent structures. The extent of residual discasc followitio primary t- 
debulking surgery is considered an important prognosticator in advanced ovarian cancer tn L- C- 
with numerous studies reporting the completeness of primary CytOl-CdUCtlVC SLII*('el*y L- 
positively intluence survival. 
Initial surgical options in advanced ovarian cancer inclUde biopsy alone, limited 
Cý L- --" 
The 110al Of SUI-OiCal resection of the primary ti-111101-Ir and aggressive cytoreduction. 
debulking is to leave the smallest Volume of residual disease possible IN and the primary 
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purpose of cytoreductive surgery is to prolong median survival. E263 Primary cytoreductive 
surgery has been defined as a surgical procedure in which the aim is to achieve a residual 
tumour mass of <2cm in total and sub-optimal cytoreductive surgery as when residual 
tumour mass exceeds 2cm. [271 
The concept of cytoreductive surgery for advanced ovarian cancer has been present 
since the 1930's, [281 but it was Griffith's [293 in the 1970's who was credited with first 
indicating that improved survival in advanced ovarian cancer was related to the diameter of 
the largest residual tumour. In the 1980's Wharton [301 showed that patients undergoing 
partial tumour removal had survival no better than patients undergoing biopsy alone. 
Cytoreductive surgery allows histological confirmation of the diagnosis and proper 
disease staging. [311 In addition to relief from direct tumour insult, bulk resection may 
result in an improved response to post-operative chemotherapeutic agents. [291 Large 
tumour masses with poor blood supply are less likely to receive adequate chemotherapy 
doses, [321 thus removal of necrotic tumour mass may provide improved delivery of 
therapeutic agents, and improved drug availability to metastases, [331 as well as remove 
cherno-resistant cells. Tumour reduction surgery may stimulate remaining turnour cells 
into active cell division therefore enhancing susceptibility to chemotherapeutic cell kills, 
[251 and may reduce the number of chemotherapy cycles required to eliminate disease and 
diminish development of subsequent drug resistance. [331 
Multiple series have reported completeness of primary cytoreductive surgery to 
independently influence the survival of patients with advanced epithelial ovarian cancer. 
In bulky disease, patients uncommonly survive at 5 years, and it has been suggested that 
survival varies inversely with the volume of residual tumour. 1291 
Critics argue that the survival advantage associated with minimal residual disease 
has more to do with the inherent biologic predisposition of the tumour than with the 
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predisposition and skill of the surgeon. 
[26,33-341 Optimal and complete cytoreduction is 
more easily achieved for small turnours 
[331 but the rate of complete cytoreduction is related 
to case selection and surgical technique. [241 It is questionable whether large volume 
turnours are biologically different and more aggressive and it is suggested that residual 
tumour bulk does not influence survival as it is due to the fact of tumour biology allowing 
[351 - easier resection, i. e. the apparent improvement in survival is a result of limited tumour 
growth which in fact makes maximal resection feasible. E291 In fact it has been demonstrated 
that patients with tumour seedlings <lcm. have a significantly inferior survival compared 
with patients with bulk residual disease. [261 
Peri-operative morbidity and quality of life must be considered when debating the 
benefits of maximal cytoreductive surgery. Multi-organ resection may be required to 
achieve maximal cytoreduction in some cases with a high rate of complications found . 
13 11 
Therefore consideration is needed of whether the added risk of higher morbidity and 
mortality outweighs the potential survival benefit to the patient. 
Primary debulking surgery remains the gold standard in the management of 
advanced ovarian cancer. Secondary cytoreductive surgery involves repeat surgical effort 
after first line chemotherapy to further debulk the cancer. Secondary cytoreductive surgery 
may be complex with an associated increase in morbidity and mortality although patients 
with no residual disease have been found to have a 70% relative risk reduction compared 
to those with disease > lcm. 1361 If the extent of residual disease is regarded as being a 
significant prognosticator for survival then, interval debulking surgery (IDS), 'a surgical 
procedure with debulking intent preceded and followed by chemotherapy, " (371 should be 
considered in patients with sub-optimal primary surgery. IDS after primary chemotherapy 
in patients with advanced stage ovarian cancer seems to offer the same chance of survival 
as does initial debulking surgery but with a possible reduction in morbidity. [27,38-391 
20 
Although the volume of residual turnour after debulking surgery appears to relate 
well to the clinical outcome there is no accurate measure and the critical volume for long- 
term survival remains unknown. That is the precise definition of 'what is optimal surgery' 
has not been established. Present methods of quantifying residual tumour are imprecise 
[261 
and the maximal diameter of residual disease is a very crude estimate. 
E321 The 
gynaecological oncology group (GOG) definition of optimal cytoreduction is that in which 
the largest residual tumour nodule measures <lcm or less, [403 however a survey of 393 
gynaecological oncologists showed the definitions of optimal cytoreductive surgery chosen 
varied markedly. [4 11 Therefore there may be variation in the meaning of optimal 
cytoreduction and caution needs to be taken in its interpretation with regards to survival 
benefit. 
1.2.4 The Value of Ca125 in Epithelial Ovarian Cancer Management 
In 1981 Bast developed a murine monoclonal antibody that reacted with a 
glycoprotein antigen (Ca125) derived from a human ovarian tumour cell line using a 
mouse somatic cell hybridisation technique. 1421 Ca125 is -a high molecular weight 
glycoprotem found in the coelomic epithelium [431 and is found distributed in the 
endothelium of the fallopian tubes, endometrium, endocervix and ovary and in the 
mesothelial cells of the pleura, peritoneum and pericardium. 1441 Ca125 was found raised in 
1% of the general population when a level of 35u/mI was taken as the upper limit of 
normal. E441 It has been found to be raised in 29% of cancers other than ovarian including 
breast, lung, pancreas and colon, [451 and in other benign conditions such as cirrhosis with 
ascites, acute pancreatitis, pelvic inflammatory disease, endometriosis, [451 ovarian 
hyperstimulation syndrome (OHSS), pregnancy and lymphoma. [461 In fact a large study of 
22,000 healthy participants found that a serum Cal25 elevation was a risk factor for death 
not only from gynaecological cancers, but also from a wide spectrum of benign and 
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malignant diseases. 
[471 
Ca125 is raised in >80% of epithelial ovarian carcinomas where the upper limit of 
normal is regarded as 35u/mI and in 74% when 65u/ml. [44,481 The upper limit of normal 
values of Ca125 is therefore largely regarded as 35u/ml, which is clearly able to 
distinguish sera from healthy individuals and ovarian cancer patients. [481 Other studies 
however have used 65u/ml as the upper limit of normal, which does not cause substantial 
effect on sensitivity. 
Approximately 20% of epithelial ovarian carcinoma patients do not express Ca125 
(especially mucinous turnours comprising 5-10% of all EOC). [491 Ca125 has been found to 
be raised in only 50 - 55% of stage I turnours [46,50] and 42% FIGO 11 (but positive in 87% 
FIGO IH & IV). [50] Therefore a normal Ca125 does not exclude tumour. it is commonly 
accepted that serum Cal 25 levels are used only to monitor the course of disease in patients 
who had positive Cal25 levels before surgery. A study however of 56 Ca125 negative 
turnours showed excellent correlation of serum Ca125 with the development of recurrent 
disease 001 indicating that patients with a low Ca125 ovarian carcinoma marker level 
perhaps should have Ca125 tumour marker levels monitored during and after follow-up 
treatment. 
The prognostic significance of pre-operative Ca125 levels is controversial. 
Significantly longer survival has been suggested when pre-op levels are <65u/ml. [44,51-531 
In stage I epithelial ovarian cancer pre-operative Cal25 levels have significantly predicted 
survival on both univariate and multivariate analysis. [541 Initial Cal 25 levels however have 
also been found to be of no prognostic significance. [45,55-561 
It has been suggested that high pre-operative Ca125 values indicate advanced 
disease and thus poor response to following cytotoxic therapy, [511 with Ca125 reflecting a 
larger tumour burden. [451 It has therefore been postulated that pre-operative serum Ca125 
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levels correlate with the probability of attaining optimal cytoreduction as mean Ca125 
levels in optimally cytoreduced patients has been shown lower than in patients sub- 
optimally debulked, [571 but as no correlation has been found between ovarian mass volume 
and Cal25 levels, [581 the effects of ascites, ovarian mass volume and peritoneal 
carcinornatosis on Ca125 levels should be known before pre-operative prediction of 
optimal respectability in advanced cases is considered. 
The pre-chemotherapy level of Ca125 in itself has been correlated with progression 
rate and the probability of progression within three years, 1593 but immediately post surgery, 
Cal25 levels have been found to be elevated at highest 5-14 days post surgery and to 
normalise between three and four weeks after surgery. [601 Therefore use of Ca125 as a 
tumour marker in the early post-operative period may well be of only limited value. 
Elevated post-operative levels however have corresponded with post-operative residual 
tumour bulk resulting in poor prognosis. [511 
In general, with raised Ca125 levels, patients have shown greater turnour bulk than 
those with low values, [46,611 with strong associations seen between the size of residual 
tumour mass and the pre-chemotherapy level of Ca125. 
[49,56,59,62-631 In patients with 
residual tumour mass of >2cm, post-operative Cal25 levels may reflect tumour burden and 
perhaps should not be used as independent prognostic factors. [51,621 
Falling Ca125 levels have long been associated with turnour regression or 
responding turnours. Decreasing Ca125 levels have correlated with objective regression of 
ovarian carcinoma in 95% of cases [64)] and when halving of antigen levels was considered 
to be significant, Ca125 levels have correlated with clinical course in 93%. [641 Either a 
50% decrease after 2 samples or a 50% decline over 3 samples (28 day gap in each sample) 
is generally accepted as a responding patient. [4344,6 11 An average ten fold fall in Ca125 
level from pre-treatment to post-treatment has been found both in complete and partial 
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responses. (491 Patients with a short serum half-life of Ca125 have shown a significantly 
better probability of survival with an orderly trend to better survival with shorter half-life 
[651 
Ca125 has shown to be a valid marker for recurrence in the follow up period, and 
of considerable value in the monitoring of effect during treatment. [663 Rising levels are 
indicative of poor tumour response to chemotherapy, with Ca125 levels being useful in 
demonstrating disease persistence following completion of chemotherapy. If the Ca125 
level remains abnormal there is a >95% certainty that residual disease is present. [611 
rising Ca125 level may indicate progressive disease during initial chemotherapy (20% 
progression during initial treatment). E441 
Ca125 kinetics, defined as the rate at which Cal25 levels decrease during 
chemotherapy, [631 has been used as predictors of prognosis. A half-life of <20 days has 
been correlated with longer survival compared with a half-life of > 20 days correlating 
with significantly shorter survival with patients having 1.8 times longer survival. [633 When 
considering patients with FIGO stage III and IV ovarian carcinoma median survival was 
found to be significantly greater in patients with a shorter half-life. [621 
Although Ca125 has not been found a significant predictor of progression free 
survival (PFS) immediately after surgery, Cal25 and PFS after one cycle, and throughout 
primary chemotherapy, was found a significant predictor of survival. [491 After 2 courses of 
chemotherapy patients with a Cal25 <35u/ml were found more likely to achieve complete 
remission and better prognosis than if levels >35u/ml, i. e. gave the greatest discrimination 
between patients alive at 12 months and those who did not respond that long. [521 Fayers et 
al [671 found the best predictive measurement of Ca125 was the value prior to the 3ddose 
of chemotherapy. Patients in whom the Ca125 levels did not normalise until the third cycle 
had 30% less chance of survival compared with those with response in Ca125 levels after 
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the first 2 cycles of induction chemotherapy. [631 An abnormal level Ca125 after 3 courses 
of chemotherapy is indicative of a very bad prognosis. [661 
Therefore if serial Cal25 measurements and Ca125 half-life are able to provide 
early information with regard to the effectiveness of induction chemotherapy it is possible 
to adapt individual therapies and modify early treatments avoiding early cytotoxic effects 
and development of drug resistance. 
Early detection of disease recurrence is the primary goal of patient follow-up, after 
completion of therapy. 1591 Although Ca125 may generally be regarded as a poor predictor 
of long-term prognosis it is generally regarded as an accurate predictor of tumour 
progression or recurrence. A rising Ca125 level in patients whose Ca125 level has 
previously normalised indicates progression, but a single elevation in the absence of 
confirmatory data should not be accepted. 1611 
Traditionally there has been no specific guideline on the percentage increase in 
Ca125 level, which should be accepted as evidence of disease progression. A >25% rise in 
Ca125 level was shown to indicate progressive disease, 1591 but disease progression is 
generally reflected as a doubling of levels in 80% - 90% of cases 
[43-44,49,55,68-711 
with two 
consecutively elevated levels being strongly suggestive of progressive disease. 
Progression, defined as doubling by the North Thames ovary trial, has shown a positive 
predictive value of 80% - 98% with regard to disease progression. 
[4445,68-70J A significantly 
positive correlation between Ca125 half-life and disease progression rate has also been 
reported with a half-life of 20 days or more being associated with a progression rate of 3.2 
times higher than if <20 days. 
[591 
A rising Cal25 may be the first indication of relapse preceding clinical detection of 
progression in 55% - 95% of cases 
[4344,59,68-701 
with Ca125 increase preceding clinical 
relapse (i. e. lead time) by a median of 3-4 months. 
[44,56,70-711 Therefore pre-clinical 
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detection of recurrent disease in post-treatment follow up may encourage the clinician to 
implement higher imaging for tumour progression or recurrence, may encourage 
implementation of therapy in those previously untreated, or additional therapy / further - 
active therapy which may improve survival. 
Several studies have investigated the use of Ca125 in conjunction with second look 
surgery i. e. repeat laparotomy following chemotherapy. A rising Ca125 is associated with 
turnour progression at second look laparotomy in 94% - 100% of cases. 
[43,51,59,70,721 Thus 
clcvatcd lcvcls, hclp to cstablish the discase status of paticnts and probably indicatcs the 
presence of intraperitoneal tumour. A negative Cal25 (Ca125 <35u/ml) however may, or 
may not be, associated with complete clinical response at surgical restaging [641 and so does 
not obviate the need for second look laparotomy. A negative Ca125 has been found as 
giving a false negative rate in approximately 40% - 50% of cases. 
[43,51,54,59,61,69,721 
Therefore second look surgery is probably not indicated where Ca125 levels are increased, 
but when Ca125 is normal the need for second look surgery is certainly not eliminated and 
may perhaps be regarded as obligatory. 
1.2.5 Histological Type 
Histological typing depends on the constituent cell types of the turnour. The 
majority of ovarian turnours are of common epithelial type comprising serous (60%), 
mucinous (15-20%), endometrioid (10%), clear cell (5%) and Brenner / un-differentiated 
(>5%). 
Histological sub-types in ovarian cancer are known to be associated with different 
epidemiological risk factors [73-771 and are in some instances felt to have varying prognosis. 
Serous turnours tend to present at an older age [731 and have a greater tendency to spread to 
the upper part of the abdomen, 1151 mucinous turnours tend to present at a lower stage and 
grade to other types and be associated with a better prognosis, (20,79-801 and endometrioid 
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tUrnours tend to present as well to moderately differentiated. 11" Mucinous and clear cell 
tUII1OLirs presenting at late stages ho\vever are generally accepted to result in adverse I- -- 
outcome because oftheir poor chemotherapy response. 181-821 
Assi-nment of tuniour cell type has been fraught with reproducibility problems C, L- 
because it is performed by simple microscopic examination and so includes a subýjective 
element: histopatholopsts often disagree. Discriminating between moderate to poorly 
differentiated serous and endonletrioid ovarian carcinomas is difficull due to the fact they 
are closely related Mulleriian tuniours. Poorly differentiated mucinous carcinomas may 
focally resemble serous carcinomas, and discrimination between moderately differentiated 
endometriold and mucinous carcinomas may also be ditTICUlt- 
1171 Studies concerning I- 
repi-odLiCibility have shown varying results, 181-ml \vith intraobserver reproducibility (70.6"/c 
- 87.3"/(, ) tending to be better than interobserver reproduci Z, L (60(7c - 69%). 
Agreement is 
generally improved following panel discussions 1871 with differences in typing felt largely 
due tO ti. 111101,11- cell heterogeneity and difficulty discriminating between set-OLIs and 
undifferentiated tumours. 's" (See table Ic: Reproducibility of Histological Type in 
Ovarian Carcinoma) 
Table Ic: Reproducibility of Histological Type in Ovarian Carcinoma 
rerl StudN Yea r - )pulation N" of Type Agreement Type Agreement r 
(n) Observers (Intraobserver) (Interobserver) 
Hernandez 18.41 
1984 34 Obserwrs Observer a. 70.6% 6014 
(a & b) Observer b. 73.517( 
Roulld I Round 2 
4 Ohscrý ers 4= 29.8'/( 4= 36.4(7( 
Baak 1841 1986 198 (1.13 & 4) n/s 3= 20.7% 3= 20.2(7( 
2= 22.3(/( 
2) = 
33.3(/( 
I=27.2 (7( 11= 10. Vh 
3 Observers Observer b. 87.3(7( 61(7( 
Brugghe 1995 102 (a, b, & c) Observer c. 79.4(/(, (observer a vs b vs c) 
Lund 1861 1991 221 21 ()bscr\crs n/s 681/( 
(a & B) 
1 -7 
Table Ic illustrates studies of reproducibility for histological sub-type in ovarian 
carcinoma. Studies sho", varying results. Intraobserver reproducibility tends to be better 
than interobserver reproducibility, yet marked disagreement may be observed. 
Histological type is generally considered to be of limited prognostic value but, as 
there seems to be inherent differences in the biological behaviour of the various types of 
epithelial ovarian cancer, including grade and stage of presentation, likelihood of 
metastases and chemotherapeutic response, it seems probable to assume different 
histological sub-types may be associated with different prognoses. Therefore to exclude 
any influence that histological sub-type may confer on patient outcome prognostic factors 
in epithelial ovarian cancer should perhaps be investigated on a type specific basis. 
1.2.6 Histological Grade 
Differentiation means the extent to which a tumour resembles, histologically, its 
cell or tissue of origin i. e. it determines the tumour grade. Grading is an attempt to assign a 
rough numerical value to the extent of histological deviation from normal, 1881 and again is 
somewhat subjective. 
As histological grading in epithelial ovarian malignancy is considered by many 
pathologists and clinicians to have prognostic significance, grading is widely performed. 
[83,87,89-921 Therapeutically, a difference between grades I to grade 3 may result in decision 
for use of adjuvant treatments such as chemotherapy. 
Problems arise in tumour grading as there are no universally accepted standardised 
systems of grading for any tumour site. E901 Numerous systems of grading however do 
actually exist but are based on varying criteria. Broder's 1926,193, Czernobilsky 1977,194, 
and Russell 1979 1951 graded ovarian malignancy in the clinical context, the FIGO grading 
system [961 is based on architectural features, the World Health Organisation (WHO) 
system is based on architectural and nuclear features, and the Shimzu system [971 is based 
on architectural grade, nuclear pleomorphism and mitotic activity. Pathologists may 
therefore rely upon and establish their own grading criteria thus giving the subjective 
element. 
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It' pathologists establish their own criteria, the prognosis Of tUrnours assigned to a L- -- CN 
partICUlar grade by different pathologists may show considerable differences. 
1871 
C, L- 
Differences in grading, resulting in marked intra- and interobserver variability, have shown I -- 4--l 
univariate proonostic iniplications for survival in ovarian cancer. 
184-8ý1 Several studies 
183- 
L, 
87.981 (, see table Id: Reproducibility of Histological Grade in Ovarian Carcinoma) have 
reported significant differences of opinion between pathologists when grading the same C- -- L- C-- 
tuniours. Considerable intra and interobserver variability has been established. Intra- 
observer variability has generally been shown to be smaller than inter-observer variability. L, 
186 1 EvalWltion of a greater nUmber of features has not seemed to produce better internal 
consistency in diagnosis IN71 and studies have shown the more observer pairs the greater the L, C- 
'S 85 disagreement. Agreement on -rade between centres has also been shown to be poor, 
' 
L- I- -- 
and complete agreement between observers rare. 1871 
Table Id: Reproducibility of Histological Grade in Ovarian Carcinoma 
Study lRefl Year (n) 
Observer Grading Agreemew Grading Agreement 
Number (Interobserver) observer) (Intra 
_ __ 
HemaiiLlc/ 1984 34 2 ()hscrýcr a= 03. )(/, 
(a&b) 061/( )bsm cr h79.0'/( 
Round I Round 2 Observer a 9(-). 2(/( 4 d= 18.7 d =12.8 6(/( ()b,, cr,,, cr b 63 Baak 
[841 1996 198 (a. b. c & d) c =30.8 c =40.0 . Ohserý er c= 78.0'/( b =34.4 b =26.6 Ohscrý cr d= 62.01/( a =16.1 a =0.6 
2 
Hitapasalo 1990 75 (compared 3 
Mclhod a 74.617( 
methods) 
Method b 73.3(/( 11/s 
Method c 81.3(/( 
Brugghe 
-- - - 
1995 10- n/s 75.5(/( 
E un d F l S(, j 1991 
=22"' 
1 41 x 
Table Id illustrates studies of reproducibility for histological grading in ovarian 
carcinoma. Studies sho" varying results. Intraobserver reproducibility tends to be better 
than interobserver reproducibility, yet marked disagreement may be observed. 
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Due to this diagnostic discrepancy and deemed importance of grade, more objective 
methods are required as accepted prognostic factors should in the least be reproducible. 
1.2.7 Study Aims 
Quantitative pathology as a tool in gynaecological pathology is fairly new, though 
the techniques used, are generally well established and accepted in other fields. Such 
techniques allow greater objectivity than histological grading, typing, estimation of 
residual turnour etc. and have been shown in ovarian turnours to have considerable 
prognostic importance. Previous studies have, however, suffered from poor patient 
selection and trial design and have often included poorly selected turnours, which have 
themselves different outcomes to the main turnours which were under study. 
Most previous work on morphometry and stereology in ovarian turnours has relied upon 
manual measurements, which are reproducible, but very time consuming, and require 
specialist knowledge of tissue appearances and the ability by the operator to separate 
tumour and non-tumour tissues. To date the best work on outcome in ovarian turnours has 
originated from northern Europe, though for a number of reasons such techniques have not 
been widely used elsewhere. Studies by Baak et al have shown that, in cisplatin treated 
patients, strong prognostic information can be obtained from the measurement of a range 
of nuclear characteristics, the mitotic index and the volume percentage epithelium. 
Mathematical scores have been proven of value in advanced ovarian cancer and it has been 
suggested that such techniques should be used extensively. On the whole this study aims: - 
1. To determine whether basic morphometry data can predict outcome and 
chemotherapeutic response in ovarian serous carcinoma. 
2. To determine whether newer semi-automated method of tumour morphometry provides 
similar results to older methods. 
3. To determine whether advanced image analysis methods can offer further turnour 
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outcome data etc in serous ovarian cancer. 
The study intends to determine, whether the morphometric prognostic variables 
delineated by other workers hold when performed in a large routine teaching hospital 
setting and provide prognostic information, which is useable and useful for clinical 
oncology. 
The study will be initially performed on carefully selected group of serous 
carcinomas of the ovary. Tumour outcome, survival and chemotherapeutic response will be 
investigated in patients treated with the same platinum containing regimes, after 
histological confirmation of diagnosis, and where good follow up and survival data are 
available. 
Outcomes will be primarily investigated using traditional prognostic parameters 
including: - clinicopathologic features, apoptotic markers (p53 & bcl2), mitotic activity and 
angiogenesis determinants. Semi-automated analysis, using immunohistochernically based 
techniques, will also be applied to estimate volume percentage epithelium and nuclear 
morphometric parameters, In recent years spatial and textural analysis in turnours has 
expanded dramatically and there are considerable expectations that it will have a greater 
predictive value and higher reproducibility than other simpler morphometric techniques. 
The effectiveness of various spatial textural features (e. g. those derived from certain grey 
level transformations of a group of neighbouring image pixels) will be investigated. 
A search of morphometric parameters will be made to attempt to define any that 
predict clinical outcome in a hope that the results will allow more accurate prediction of 
outcome and therapeutic response in serous ovarian cancer and be useable for patient 
selection in earlier turnours. The methodology would also allow more accurate assessment 
of clinical trial data. 
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The end point of the study would be essentially to provide ovarian prognostic 
scores or morphometric data allowing prediction of likely outcome in individual ovarian 
serous carcinoma cases and to help to define those patients likely to benefit from 
chemotherapy with platinum containing or taxol containing regimes. 
This MD considers clinicopathologic features, apoptotic markers, mitotic activity, 
volume percentage of epithelium, nuclear morphometric parameters, spanning tree 
parameters and angiogenesis determinants in separate chapters, including an introduction 
to each parameter, methodology, results, and discussion. A final analysis of all parameters 
will be performed followed by final conclusions. 
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Chapter 2: Common Methodology 
2.1 Patients 
This study assessed 184 patients who underwent initial surgery for ovarian cancer at 
University Hospitals Coventry & Warwickshire NHS Trust and Birmingham Women's 
Hospital NHS Trust, UK, from July 1994 to July 2002. Tumour stage and histological 
diagnosis of each case were determined according to the criteria of FIGO and The World 
Health Organisation (WHO). Tumours were graded as well (Gl), moderate (G2) or poorly 
(G3) differentiated by an experienced pathologist. Extent of disease residuum was taken as 
< or >2cm as determined by the operator with all surgical procedures being undertaken by 
a gynaecological oncologist. Survival was taken as date of primary surgery to date of death 
or study closure. Cause of death was determined from patient records or via the West 
Midlands Cancer Registry. 
2.2 Coefficient of Error 
Coefficients of error (CE) were used to calculate the number of parameters, and 
fields of vision, required for measurements to attain adequate sample sizes. The CE 
expresses standard error (SE) as a percentage of the mean. (CE =(SE/mean) X100%). 
When repeated measurements reach a value of : 55% a high degree of measurement 
precision is indicated, thus when measurement's remained stable over several fields (55% 
variation), this was accepted as a representative sample. 
2.3: Immunohistochemistry - Peroxidase Anti-Peroxidase Technique 
Immunohistochernical studies were performed using a standard peroxidase anti- 
peroxidase technique. 
1. Take sections to water (i. e. de-wax, and re-hydrate). 
2. Block endogenous peroxidase in hydrogen peroxide / Optimax. wash buffer 50150 
33 
(20 minutes). 
3. Wash with Optimax wash buffer (5 minutes). 
4. Incubate in normal horse serum diluted 1: 100 in TBS (20 minutes) -to block non- 
specific antibody binding. 
5. Incubate with primary antibody at appropriate dilution (60 minutes). 
6. Wash with Optimax wash buffer pH 7.4 (2 X5 minutes). 
7. Incubate with appropriate secondary biotinylated antibody diluted 1: 50 (30 
minutes) - i. e. labels primary antibody with secondary antibody. 
8. Wash with TBS (2 X5 minutes). 
9. Incubate with horseradish peroxidase streptavidin (30 minutes) - labels secondary 
antibody. 
10. Wash with TBS (2 X5 minutes) 
11. Incubate in DAB peroxidase substrate solution (4 minutes) - visualises secondary 
antibody. 
12. Rinse in water and counterstain as required (30 seconds) 
13. Wash well in tap water 
14. Dehydrate, clear and mount. 
2.4 Statistical Analysis 
Statistical analysis was performed using SPSS10 for Windows, Version 13.0, 
Copyright bc 2003, SPSS inc., USA. Intra and inter-observer reproducibility was assessed 
with linear regression analysis. For a better understanding of the biologic meaning all 
individual parameters were analysed for correlations with clinicopathologic features again 
by linear regression analysis. Overall survival (OS) - time between date of first operation 
and death, or time to study closure, and disease free survival (DFS) - time between initial 
surgery and detectable increase in disease on CT scan, (Univariate Cox model) was 
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performed on both individual and clinicopathologic parameters to evaluate their individual 
prognostic value. Multivariate OS and DFS analysis (Cox Forward stepwise likelihood 
ratios with OS or DFS time as the dependent factor) was performed to test whether 
combinations of features could improve the prognostic value of individual features. 
To evaluate the ability of covariates to predict response to chemotherapy multi-logistic 
regression analysis was perfonned (forward stepwise likelihood ratios) using, as per WHO 
criteria, no response (no decline or increase in Ca125 levels), partial response (up to 50% 
reduction in Ca125 levels) and complete remission (normalisation of Cal25 levels at 6 
months) as dependent variables and measurement parameters of interest as covariates. 
Individual parameters were primarily entered into the model, followed by consideration of 
individual and clinicopathologic parameters. Analysis was performed using mean values 
for each measurement parameter. P values <0.05 were regarded as being significant. 
2.5 Prediction of Chemotherapy response 
Ca125 data was available for 69 cases, 5 of which did not receive primary 
chemotherapy so results of 64 patients were analysed. All patients were treated with 
primary carboplatin or carboplatin / paclitaxel regimes. 
Complete remission was achieved in 60% of patients, partial response in 34% and 
no response in 6%. As there was only a small number of cases in the no response group, 
these cases were combined with the partial response group and analysed together i. e. 
no/partial response (Group 1, n =26) versus complete response (Group 2, n =38). 
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Chapter 3: Clinicopathologic Parameters: Results 
3.1 Introduction 
Clinicopathologic parameters were analysed as to their prognostic and predictive 
ability with regard to overall survival (OS), disease free survival (DFS), and prediction of 
chemotherapy response. Analysis was performed to ensure that base clinicopathologic 
results, in this group of patients, were comparable with prior study findings. 
3.2 Results 
3.2.1 Patients 
Of an initial 184 identified cases of serous ovarian cancer, 132 cases were investigated. 
52 cases (28%) were excluded from analysis as these cases were regarded as being 
arguably metastatic in origin, borderline turnours, of mixed histological sub-type or 
technically unsatisfactory (poor preservation, small tumour sample etc). Of those analysed 
16% were stage 1,14% stage H, 63% stage IH and 7% stage IV, as determined by FIGO. 
Seventeen percent were grade 1,40% grade 2 and 43% grade 3 as determined by WHO. 
Thirty five percent had an estimated disease residuum of <2cm and 65%> 2cm as defined 
by the operator. Mean age was 61.4 years (range 26-82 years). Ca125 pre-operative levels 
were available for evaluation in 91 cases. Post-operative Ca125 levels were taken at 
varying intervals following surgery and therefore disregarded for further survival analysis 
in this study. Ascites was regarded as either being present or absent as documented by the 
operator or as assessed by histocytopathology. All surgery was performed in tertiary 
referral centres by recognised gynaecological oncologists hence operator dependent 
variables were also disregarded in this study. Overall 5year survival was 26%. (See Table 
3a: Summary of Clinicopathologic Data. ) 
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Table 3a: Summary of Clinicopathologic Data (n=132) 
Parameter n 17c 
Alive 5-Year 
Survival (% 
Age 
<65 79 60 25 22 
>65 53 40 26 23 
Ca 125 91 
>35 92 90 33 26 
<35 9 10 33 22 
Ascites 
Present 87 66 3 8 
Absent 45 34 6-1 47 
Residual Disease 
<2cni 46 35 50 41 
>2cm 96 65 13 12 
FIGO Stage 
1 21 16 62 67 
11 19 14 42 47 
111 83 63 14 18 
IN, 9 7 11 It 
Tumour Grade 
1 22 17 59 64 
2 53 40 19 23 
3 57 43 19 21 
3.2.2 Correlations Between Clinicopathologic Parameters 
Linear regression analysis of the clinicopatholo-ic pararneters pararneter's found 
turnour grade, FIGO stage, extent of residual disease, and ascitcs to strongly correlate. 
Tuniour grade also correlated with patient age. Pre-operative Cal 25 levels were fOLInd 10 
correlate with FIGO stage, ascites, Lind extent of residual disease. (See Table 3b: 
Correlations ot'Clinicopathologic Paranieters). C_ 
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3.2.3 Survival Analysis 
3.2.3.1 Overall Survival Analysis 
OS data was available for all 132 patients. P values below 0.05 were regarded as 
significant. 
Clinicopathologic variables were analysed using the univariate Cox model. Of the 
clinicopathologic data, FIGO stage (p=<0.01), turnour grade (p=0.002), pre-operative 
Ca125 levels (p=0.016), presence of ascites (p=<0.01) and extent of disease residuum 
(p=<0.01) were found to be significant predictors of OS. Age (p=0.065) was found to be 
insignificant. (Cox overall survival curves are illustrated in Figure 3.1). 
To estimate the simultaneous influence of prognostic factors all clinicopathologic 
variables were entered into Cox regression analysis. Analysis showed extent of disease 
residuum (p=<0.01) to be a significant predictor for OS. The other factors did not retain 
independent prognostic significance. (See table 3c & 3d for univariate and multivariate 
analysis of clinicopathologic data). 
3.2.3.2 Disease Free Survival Analysis 
DFS data was available for 94 cases. P values below 0.05 were regarded as 
significant. 
Clinicopathologic variables were analysed using the univariate Cox model. Of the 
clinicopathologic data FIGO stage (p=<0.01), turnour grade (p=0.001), pre-operative 
Ca125 levels (p=0.004), presence of ascites (p=<0.01) and extent of disease residuum 
(p=<0.01) were found to be significant predictors of DFS. Age (p=0.722) was found to be 
insignificant. (DFS curves are illustrated in Figure 3.2). 
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To estimate the simultaneous influence of prognostic factors all clinicopathologic Z- LI 
variables were entered into Cox regression analysis. This analysis showed FIGO stage 
(p=<0.01) to be a significant predictor for DFS. Age was of borderline significance (p=0.059). Z: ) Z-- 
The other factors were not of additional prognostic relevance. (See table 3c & 3d for univariate LI 
and multivariate analysis of clinicopathologic data). 
Table 3c: Univariate Analysis of Clinicopathologic Parameters 
Overall Survival (OS) Disease Free survival (DFS) 
Mean Survival % Alive P % Mean Relapse P Parameter n Time (n) Value Parameter Alive 
Time Value 
(months) (n) (months) 
FIGO Stage FIC .0 Stage <0.0 I Stage 1 21 64.9 (8-123) 62%(13) <0.0 I Stage 1 19 69.1 (19-123) 11.037 
Stage 11 19 49.53 (7-96) 35% (8) <0.01 Stage 11 15 40.73 (8-96) 0.417 
Stage 111 83 31.65 (1-106) 15%(12) 0.003 Stage 111 56 23.52 (1-100) 0.555 
Stage IV 9 22.56 (1-104) 11% (1) 
0.158 Stage IV 4 36.5 (9-104) 
Tumour Grade Tumour Grade 
Grade 1 22 56.55 (6-123) 59% (13) 0.01 Grade 1 20 60.5 (9-123) 
0.00 1 
Grade 2 53 34.26 (1-119) 19%(10) 0.004 0 846 Grade 2 33 33.76 (1-119) 
0.001 
0.384 Grade 3 57 34.72 (1-106) 19%(Il) . Grade 3 41 25.93 (4-96) 
Age 132 0.065 Age 94 0.722 
Ascites 
Absent 45 47% (21) <0.0 I Ascites 94 <0.01 
Present 87 15%(14) 
Pre-op Cal 25 91 0.016 Pre-op Cal 25 94 0.004 
Residual Residual 
Disease 
<2cm 
46 28.29 (1-104) 50%(23) <0.0 I 
Disease 40 51.63 (1-123) <0.0 I 
L >2cm 
86 58.69 (1-123) 13% (11) <2cm 54 24.48 (2-104) 
Table 3c illustrates results of univariate Cox survival analysis (forward logistic regression). 
FIGO stage, tumour grade, residual disease status, ascites status, and pre-operative Ca125 
levels were found significant predictors of both OS (time between date of first operation 
and death, or time to study closure), and DFS (time between initial surgery and detectable 
increase in disease on CT scan). Patient age at presentation was not significant. 
p values <0.05 were regarded as significant. 
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Table 3d: Multivariate Analysis of Clinicopathologic Data 
Overall Survival Disease Free survival 
Exp 95% 95% 
95% 95% 
Parameter df Sig. ci cl Parameter Exp ci ci 
(B) Lower Upper df Sig. (B) Lower Upper 
Residual 
I <0.0 1 . 
272 J50 . 
494 FIGO Stage 1 <. O I Disease . 
Tumour 
097 Stage(l) 1 00 1 090 
021 T- . 391 Grade . . 
Grade(l) 1 . 115 Stage(2) 1 . 
019 
. 
198 . 051 . 
767 
Grade(2) 1 
. 053 Stage(3) 1 . 
348 . 
566 . 173 
1.959 
FIGO Stage 3 
. 
091 Age I 1 . 059 
Stage(l) 
1 
. 
106 Tumour 2 2 . 145 Grade 
Stage(2) 1 
. 
206 Grade (1) 1 1 . 
050 
Stage(3) 1 
. 
065 Gi rade (2) 1 1 . 
374 
Ascites 1 . 118 Ascites 1 1 . 195 
Ca125 
1 
. 
499 Residual 1 1 . 
183 
pre op Disease 
Age 
. 
143 Ca125 1 . 
077 
preop 
Table 3d illustrates results of multivariate Cox survival analysis (forward logistic regression). 
Overall residual disease status and FIGO stage were found to retain independent significance for OS (time 
between date of first operation and death or time to study closure), and DFS (time between initial surgery and 
detectable increase in disease on CT scan) respectively. 
n values <0.05 were reparded a-, siL-nificant. 
3.2.4 Prediction of Chemotherapy Response 
3.2.4.1 Patients 
All patients were treated with primary carboplatin or carboplatin / paclitaxel reginies. 
(See table 3e for distribution of clinicopathologic data and chemotherapy response). 
In the no/partial response group 4% were FIGO stage 1,15% FIGO 11,73% FIGO III 
and 8% FIGO IV as compared to the complete response group where 31% were FIGO stage 
1,29% FIGO 11,37% FIGO III and 3% FIGO IV. In the no/partial response group 
distribution of turnour grade was 8% grade one, 31% grade two and 61% grade three as 
compared to the complete remission group of 42%, 32% and 26% in grade 1-3 respectively. 
Fifteen percent of the no/partial response group had <2cm disease residuum as compared to 
61% in the complete remission group, and 85% of the no/partial response group had >2cm 
disease residuum as compared to 39% in the complete remission group. The no/partial 
response group was also twice as likely to have ascites as compared to the complete 
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response group. Mean survival in the no response group was 16 months with no patents 
alive at 5yrs, in the partial response group 32.8 months with nine percent alive a 5yrs and in 
the complete response group 63.34 months with sixty one percent alive at 5yrs. (See table 
3e fOr distribution of clinicopathologic parameters and chernotherapy response). 
3.2.4.2 Prediction of Chemotherapy Response - Results 
Univariate logistic regression analysis found tuniour grade (p=0.02), FIGO staoe L, C- L- 
(P=0.004), extent of residual disease (p=<0.01) and presence of ascites (p=0.004) to be 
significant predictors of chemotherapy response, with correct overall classification to 
chemotherapy response group being 70.317c, 68.8(/c, 68.8(/(, and 67.2% respectively. 1-1 1- 
'rable 3e: Distribution of Clinicopathologic Parameters and Response to Chemotherapy 
Clinicopathologic No Response Partial Response Complete Response 
Parameter (n=4) (n=22) (n=38) 
Mean Age (range) 57(46-63) 63(46-82) 60(26-82) 
yrs 
Tumour Grade: 
1 16 
2 0 8 12 
3 3 13 10 
FIGO Stage: 
1 0 1 12 
1 3 11 
2 17 14 
IV I I 
Residual Dise ise: 
<2cm 
2 23 
>2cm 
20 15 
Ascites: 
Present 3 16 14 
Absent 1 6 24 
Su rvival 
Alive (%) 0% 9% 61 (/c 
Mean (months) 16.25 (7-24) 32.8(7-72) 63.34(10-123) 
Table 3e illustrates the distribution of clinicopathologic parameters and response to 
chemotherapy For prediction of chemotherapy response where: - No response = no decline or increase in Ca125 levels. Partial response = up to 5011c reduction in 
Ca125 levels, and Complete remission = normalisation of Ca125 levels at 6 months. 
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Multivariate logistic regression analysis found extent of residual disease (p=0.0005) 
a significant predictor of chemotherapy response with a correct overall classification to 
chemotherapy response group of 66.1%. The remaining parameters failed to retain 
independent significance. (See Table Y for logistic regression analysis and chemotherapy 
response). 
Table 3f: Clinicopathologic Data: Logistic Regression Analysis and Chemotherapy 
Response 
Parameter 95.0 % C. 1 for EXP(B) Overall 
df Sig. Exp(B) 
Lower Upper 
Correct 
Classification 
Univa riate Analysis 
Tumour Grade 2 . 010 
Grade(l) 1 . 003 12.800 2.412 
67.918 817c 68 
Grade(2) 1 . 151 
2.400 . 728 
7.917 . 
Constant I 
, . 
244 . 
625 
FIGO stage 3 . 025 
Stage(l) 1 . 048 24.000 1.028 
560.178 
Stage(2) 1 . 
209 5.500 . 385 
78.573 68.8 c1c 
Stage(3) 1 . 761 1.474 . 
121 17.913 
Constant 1 . 
571 . 
500 
Residual Disease 1 . 001 
8.433 2.420 29.383 70 3% 
Constant 1 . 
253 . 
682 . 
Ascites 1 . 006 4.653 1.566 
13.822 67 2% 
Constant 1 . 386 . 
737 . 
Age 1 . 858 
Pre-op Ca125 1 . 
289 
Multivariate Anal ysis 
Residual Disease 1 . 
009 5.500 1.524 19.849 66.117c 
Age 1 . 858 
Grade 2 . 173 
Grade(l) 1 . 069 
Grade(2) 1 . 680 
Stage 3 . 194 
Stage(l) 1 . 
249 
Stage(2) 1 . 192 Stage(3) 1 . 
045 
Ascites 1 . 106 
Pre-op Ca125 1 . 289 
Table 3f illustrates univariate and multivariate logistic regression analysis of clinicopathologic 
parameters and chemotherapy response. Residual disease status was found to retain independent 
significance. p values <0.05 were regarded as being significant. 15 
3.3: Discussion 
Results of the clinicopathologic analysis were as expected. On the whole extent of 
disease residuum retained independent prognostic significance for both overall survival 
and prediction of chemotherapy response. FIGO stage retained independent prognostic 
significance for disease free survival. Grouped analysis of turnours into low stage (FIGO I 
& H) or high stage (FIGO HI & IV), or low-grade (grade 1) and high-grade (grade 2 and 3) 
did not improve prognostic significance. Therefore FIGO stage (MV), tumour grade (1-3), 
presence or absence of ascites, pre-operative Ca125 levels (< or >35u/ml) and extent of 
disease residuum (< or >2cm) were analysed as categorical variables. 
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Chapter 4: Expression of Oncogene / Apoptotic Regulators 
- p53 and Bcl-2 
4.1: Introduction 
4.1.1 Background 
The cell cycle is a string of events that results in duplication of genetic material and 
segregation of these 2 copies into 2 daughter cells. The cell cycle has 4 stages: Gi 
(preparation for entering DNA synthesis), S (DNA synthesis occurs), G2 (cell assembles 
machinery for distributing the newly replicated chromosomes equally to the two daughter 
cells), M (mitosis stage - formation of 2 daughter cells, chromosomes condense, nuclear 
envelope dissolves). Non-cycling cells are said to be in Go (growth arrest) phase. 
The rate of cell accumulation is not only dependent on cell proliferation, but also on the 
rate of physiological cell death. 1993 Apoptosis, or genetically programmed cell death, is a 
process in which a cell actively degrades itself, forming membrane-bound bodies which 
are phagocytosed by other cells without stimulating inflammatory processes. Apoptosis 
provides an efficient mechanism for eliminating cells that are unwanted for some reason 
and may furthermore be of significance for keeping cell numbers at constant levels in 
different organs. 11001 
A major feature of cancer is the inappropriate division of cells. It is well recognised 
that many human cancers arise as a result of the accumulation of genetic mutations that 
occur during DNA replication with normal cellular proliferation. E1011 Apoptosis is tightly 
linked to cell cycle controls, [1021 and loss of apoptosis pathways, by mutation or abnormal 
expression of genes, appears to be an important contributor to the development of turnours 
by contributing to the survival of cells in inappropriate physiological situations. (1021 
Apoptosis is controlled by regulators, which have either an inhibitory effect on 
programmed cell death (anti-apoptotic) or block the protective effect of inhibitors (pro- 
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apoptotic). Numerous apoptotic markers have been identified but this study will 
concentrate upon p53, which plays a pivotal role in inducing apoptosis, [1031 and Bcl-2 an 
apoptosis inhibitor. 
4.1.2 p53 
P53 is a 53 kDa nuclear phosphoprotein, [104-51 whose gene, TP53, is located on the 
short arm of chromosome 17.11061 The p53 protein binds to specific regions of DNA and 
inhibits inappropriate cellular proliferation through activating expression of a range of 
genes, particularly p2l. Its action suppresses cell growth, controls the Gi checkpoint 
response to DNA damage, 
[1021 
and controls entry into s-phase of the cell cycle. 
[1071 It also 
plays a key role in activation of apoptosis through induction of bax. Loss of p53 suppressor 
function thus renders the cells susceptible to uncontrolled growth, with mutation or 
deletion of p53 believed to result in uncontrolled cell proliferation, and failure of 
apoptosis. The p53 gene is shown to acquire mutations during development of many 
human malignancies [1051 and mutation of the p53 gene is a common genetic alteration in 
human cancer, 
[1021 
with most mutations occurring in exons 5-8. 
[1081 It is thought that p53 
protein alterations attributable to missense mutations, nonsense or frameshift mutations 
provide a selective advantage for clonal expansion of neoplastic cells. 11081 In ovarian 
cancer p53 mutation is the most frequently observed molecular alteration, reported in 
approximately 50-80% of cases. 
[101,106,109-1101 
Mutated p53 accumulates in the cell and is readily detected by IHC techniques 
because of the increased stability of the mutated form of the protein [1071 and the resultant 
proteins having a significantly increased half-life. 1104,1111 Because wild-type p53 is quickly 
degraded, it cannot be detected by IHC in normal cells, therefore p53 positivity usually 
corresponds to a dysfunctional protein, with a mutation of the gene in most cases. [1121 io- 
20% of p53 mutations may occur outside exons 5-9 and these mutations do not lead to over 
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accumulation of protein. 11011 IIHC does not detect nonsense or frameshift mutations 
because these will result in truncated proteins, 11111 but immunostaining has a sensitivity of 
approximately 90% for detecting missense mutations in exons 5-9 of the p53 gene in 
ovarian cancers. 11011 Over-expression of p53 and occurrence of mutation of the p53 gene 
are significantly correlated events. [105,108-1091 
4.1.3 BcI-2 
Bcl-2, so called because of its over-expression in B cell lymphoma, was the first 
1 
1107,1131 
gene identified (1988) as part of the apoptotic process. It is an integral inner 
mitochondrial membrane protein of relative molecular mass 26 kDa [1141 encoded by 
chromosome 18. [1071 Bcl-2 is expressed in tissues with rapidly proliferating and 
differentiating cells [1131 with-its main effect being prolongation of cell survival by 
avoidance of apoptosis, 11151 i. e. it is an apoptotic inhibitor or inhibitor of programmed cell 
death. This is achieved by forming heterodimers with pro-apoptotic proteins such as bax. 
Over-expression of Bcl-2 contributes to neoplastic-transformation. [1161 
4.2 Methods 
4.2.1 Immunostaining Techniques 
IHC studies were performed on 4-6gm formalin-fixed, paraffin-embedded tissue 
using the peroxidase-anti peroxidase (PAP) complex technique. Areas representative of the 
invasive component of the tumour were selected from archival sections stained with H&E. 
Two sections containing areas of worst atypia were selected and immunostained from each 
case. Sections were immunostained using the monoclonal antibody p53, (DAKO 
Monoclonal Mouse Anti-Human p53 Protein, Clone DO-7, Code No M 7001), and Bcl-2 
(Monoclonal Mouse Anti-Human BCL Oncoprotein, Clone 124, Code No 0887). A 
positive and negative control slide was included in each staining run. Haernatoxylin was 
used as a counter-stain. Sections were again washed then dehydrated, cleaned and 
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mounted. 
4.2.2 p53 Assessment 
Sections containing areas of worst atypia were initiafly re-cut and stained with p53 
using a haernatoxylin counter-stain. Sections were scanned, in parallel to original turnour 
sections, for areas containing the highest p53 staining. Areas containing the highest p53 
staining were selected and assessments made, in a meandering technique, at a final 
magnification of 40OX. Staining for p53 was regarded as being positive when strong and 
widespread granular staining of the turnour cell nuclei was found. Turnours were assessed 
as to being either p53 positive or negative, graded as 1-4 depending on staining intensity, 
and p53 positive nuclei were counted and expressed as a percentage of total nuclei within 
the field of vision (percent p53 expression). Coefficients of error (CE) were calculated to 
ensure adequate measurement fields were attained (55% variability) for percent expression 
of p53, and up to 20 fields were counted per case, encompassing a count of approximately 
1000 nuclei per case (See Fig 4.1: Percent Expression of p53 Coefficient of Error). 
4.2.3 Bcl-2 Assessment 
Sections containing areas of worst atypia were initially re-cut and stained with Bcl-2 
using a neutral red counter-stain. Sections were scanned, in parallel to original turnour 
sections, for areas containing the highest Bcl-2 staining. Areas containing the highest Bcl-2 
staining were selected and assessments made in a meandering technique at a final 
magnification of 40OX. Staining for Bcl-2 was regarded as being positive when tumour 
cells exhibited strong staining of the cytoplasmic membrane with strong granular 
perinuclear cytoplasmic staining. Bcl-2 was assessed as being either -positive or negative 
and graded as 1-4 depending on staining intensity. Initially Bcl-2 positive nuclei were 
counted and expressed as a percentage of total nuclei within the field of vision but this 
technique proved difficult due to marked heterogeneity of staining thus Bcl-2 was assessed 
50 
by positivity and staining grade alone over a maximurn of 20 fields per case 
Fig 4.1: Percent Expression of p53 - Coefficient ofError 
% p53: Coeff icie nt of Error 
Percent 
CE <5 (I'c Indicates a high level of measurement precision. Twenty visual fields were 
counted per case, encompassing a count of approximately 1000 nuclei per case 
4.3 Results 
Analysis was pert'Ormed Using mean values for each parameter. All 132 cases were 
examined for p53 & Bcl-2 measurcment parameters. P values <0.05 were regarded as t- 
being significant. L- L- 
4.3.1 P53 Immunostaining 
P53 staining was confined to the nucleus and p53 positivity was observed in 1)61/( L- 
of cases. Only 3 cases were p53 negative and these cases werc of' mixed grades, staoe and L- L- LI 
differing aniounts ofresidUal disease. Mean p53 pet-cent expression was 671/( (range 16.3 - L_ 
96.6%). P53 gradinu revealed 10% to be grade one, 201/c grade two, 24(Yc prade three and LI LI 
46(/'(- orade four. 
Table 4a: Mean p53 & Bcl-2 Measurement Parameters and Clinicopathologic Data 
Parameter p53 percent T P15, 
Grade p53 Positive T Bcl-2 llcl-2 positive expression (%) grade 
FICO Stage 
FIGO 1 49.58 2 1) 5 2 -5 2 FIGO 11 61.88 3 96 3 35 
FIGO 111 78.47 4 96 3 42 
FIGO IV 73.54 3 100 1 22 
Grade 
Grade 1 46.31 2 91 3 32 
Grade 2 68.85 3 94 3 45 
Grade 3 67.1 4 100 3 42 
Residual Disease 
<2cm 58.04 
1 
3-j 9 -5 2 4; T- >2cm 67.1 4 96.5 3 
t) .11 
4.3.2 P53 expression and relation to clinicopathologic data 
Positive p53 staining was found in 95%, 96%, 96% and 100% of turnours at FIGO 
stage I-IV respectively and in 91%, 94% and 100% of turnour grades 1-3 respectively. For 
extent of residual disease, those turnours with <2cm disease residuum, showed 95% of 
cases with positive p53 staining and 97% in turnours with >2cm disease residuum. 
However the extent (% cells positive and staining grade) of staining varied with turnour 
stage and grade (table 4a). Grading of p53 showed FIGO stage I-IV as having mean grades 
of 2,3,4 and 3 respectively and tumour grades 1,2 and 3 as having mean p53 staining 
grades of 2,3 and 4 respectively. For extent of residual disease turnours with a disease 
residuum of < or > 2cm had mean p53 grades of 3, and 4 respectively. 
4.3.3 Bcl-2 immunostaining 
Positive staining for Bcl-2 was observed in 42% of cases. Of those positively 
stained for Bcl-2,15 % were Bcl-2 grade 1,3 1% grade 2,26% grade 3 and 28% grade 4. 
4.3.4 Bcl-2 expression and relation to clinicopathologic data 
Positive Bcl-2 staining was found in 52%, 35%, 42% and 22% of turnours at FIGO 
stage I-IV respectively and in 32%, 45% and 42% of turnour grades 1-3 respectively. For 
extent of residual disease, those turnours with <2cm disease residuum, showed 45% of 
cases with positive Bcl-2 staining and 40% in turnours with >2cm. disease residuum. 
Grading of Bcl-2 showed FIGO stage I-IV as having mean grades of 2,3,3 and 3 
respectively and all tumour grades as having mean Bcl-2 staining grades of 3. For extent of 
residual disease, turnours with a disease residuum of < 2cm had a mean Bcl-2 staining 
grade of 2 and those > 2cm had a mean Bcl-2 grade of 3. Table 4a illustrates mean p53 and 
Bcl-2 parameters and their relationship with clinicopathologic data. 
4.3.5 Reproducibility 
For p53 percent expression intraobserver error was calculated by repeating 
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measurements for ten cases at a 6-month interval. Inter-observer error was calculated over 
ten cases for each measurement variable. Intra- (p<0.0001) and interobserver (p<0.0001) 
reproducibility was excellent for percent p53 expression. (See Table 4b: Reproducibility of 
percent p53 expression). Two observers simultaneously assessed turnours for p53 and Bcl- 
2 positive staining and staining grades. A 99% concordance rate was achieved. 
Table 4b: Reproducibility Percent p53 Expression 
Patient Number 
Intra Observer 
I Ob 
Round I Round 2 nter server 
Patient 11 86.57 85.542 87.2200 
Patient 19 90.553 90.606 92.502 
Patient 25 95.1645 92.598 93.6645 
Patient 37 83.907 84.325 89.5 
Patient 38 75.4855 74.928 80.66 
Patient 79 39.4695 43.691 48.1 
Patient 154 93.5615 90.8355 90.265 
Patient 165 69.6025 69.918 74.2 
Patient 169 93.623 92.4175 93.2 
Patient 183 91.7335 91.4515 88.9275 
r 
r2 
p 
0.9983 
0.9966 
<0.000 I 
0.9985 
0.9772 
ý 0.01101 
spearman 
2-tailed p 
0.98T9 
<0.000 1 
0.8909 
11.0011 
Table 4b illustrates reproducibility of percent expression of p53 Ten cases were counted 
with measurements repeated at a6 month interval. Excellent reproducibility was found at 
both at inta- and interobserver level. 
p values <0.05 were regarded as significant 
4.3.6 Correlation between parameters 
On linear regression analysis p53 percent expression strongly correlated with FIGO Zý LI 
stage (p=0.0002), tumour grade (p=0.0003), the presence of ascites (p=0.015), and extent 
of residual disease (p=0.0053). Positive p53 staining also correlated with turnour grade C- L- 
(P=0.0229) and P53 ý, rade correlated with the presence of ascites (p=0.0293). Bcl-2 was C 
not found to correlate with any clinicopathologic parameter. None of the Bcl-2 or p53 C, 
variables showed any correlation with one another. (See Table 4c). 
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4.3.7 Surviva na ysis 
OS data was available for all 130 cases. DFS data was available for 94 cases. P 
values below 0.05 were regarded as significant. 
4.3.7.1 Significance of single parameters to predict survival / Univariate Analysis 
Clinicopathologic variables, p53 and Bcl-2 were analysed using the univariate Cox 
model. Of the clinicopathologic data, FIGO stage (p=<0.01), tumour grade (p=0.002), pre- 
operative Ca125 levels (p=0.016), presence of ascites (p=<0.01) and extent of disease 
residuum (p=<0.01) were found to be significant predictors of OS. Age (p=0.065) was 
found to be insignificant. None of the p53 or Bcl-2 measurement parameters were found to 
be significant on univariate analysis for OS. For DFS, FIGO stage (p=<0.01), turnour grade 
(p=0.001), pre-operative Cal25 levels (p=0.004), presence of ascites (p=<0.01) and extent 
of disease residuum (p=<0.01) were found to be significant. Percent p53 expression 
(p=0.012) and p53 grade (p=0.01) were also found to be significant predictors of DFS. The 
remaining parameters were insignificant. 
Expression of p53 and Bcl-2 was combined into four groups and analysed 
separately. Group I comprising p53 -ve & Bcl-2 -ve tumours; group 2, p53 +ve & Bcl-2 - 
ve; group 3, p53 -ve & Bcl-2 +ve and group 4, p53 +ve & Bcl-2 +ve. Repeat analysis was 
neither significant for prediction of OS nor DFS. 
4.3.7.2 Multivariate Analysis 
Multivariate analysis revealed extent of disease residuum to be an independent 
prognosticator of OS (p=<0.01). Analysis of p53 and Bcl-2 parameters alone revealed 
p53 percent expression (p=0.013) an independent prognosticator of DFS, with the 
remaining parameters adding no additional prognostic relevance. Combined analysis of all 
p53, Bcl-2 and clinicopathologic variables revealed FIGO stage (p=<0.01) to be an 
independent prognosticator for DFS. See table 4d for univariate and multivariate analysis. 
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Table 4d: Univariate and Multivariate Analysis - OS & DFS 
Parameter df 
Sig. 
(p) 
Exp 
(B) 
95% 
C1 
Ir Lowe 
95% 
C1 
Ir Uppe 
Parameter Sig. 
(p) 
Exp 
(B) 
I 95% 
Lower 
C1 
95% 
Upper 
Cl 
Univariate nalysis 
Overall Survival (OS) Disease Free Survival (DFS) 
Clinicopatho ogic Variables Clinicopathol gic Var iabl-I es 
Grade 2 . 11118 Grade . 004 
Grade(l) 1 . 1104 . 344 1_ýý . 705 Grade(l) . 00 1 . 288 . 138 . 603 
1 Grade(2) . 394 . 799 . 479 
1.327 
Stage 3 <. O I Stage <. O I 
Stage(l) I <. O 1 . 151 . 056 . 
403 Staee(l) . 037 . 
229 1 . 057 . 
913 
Stage(2) 1 . 003 . 256 . 103 . 639 Stage(2) . 417 . 592 . 167 2.101 
I Stage(3) . 555 1.421 . 442 4.569 
Residual 
Disease 
I <. Ol . 341 . 204 . 568 Residual 
Disease 
<. O 1 . 341 . 204 . 
568 
Presence of 
Ascites 
I <. O 1 . 377 . 237 . 599 Presence of 
Ascites 
<. 0 1 
I 
. 358 . 212 . 605 
Pre- 
operative 
Ca125 
1 . 016 LWO 1.000 LMO Pre-operative 
Ca125 
. 00 1 HOO 1.000 LOW 
p53 & Bcl-2 
p53 Percent 
Expression 
1 0.74 p53 Percent 
Expression . 012 1.013 1.003 1.024 
p53 Grade 1 0.28 p53 Grade 0.0 1 1.046 H) 11 1.082 
p53 Positive 1 0.91 p53 Positive 0.216 
Bcl-2 Grade 1 0.88 Bcl-2 Grade 0.257 
bcl-2 Positive 1 0.98 Bcl-2 Positive 0.658 
p53[Bcl-2 
Lombined 
1 0.94 p53/Bcl-2 
combined 
0.607 
_ Multivariate Analysis 
P53 & Bcl-2 Data 
Nil significant p53 Percent 
Expression 013 1.013 1.003 1.024 
Morphometric & Clinicopathologic Data 
Residual 
Disease I 
I 
<. O 1 '174 
ý 
.2 151 - 497 
I- FIGO Stage I 
<. O 1 
I 
2.428 
I 
1.663 3.544 
I 
Table 4d illustrates results of univariate and multivariate Cox survival analysis. Percent expression of p53, 
and p53 grade were found significant predictors of DFS on univariate analysis, but failed to retain 
independent significance, being superseded by FIGO stage. None of the p53 parameters were significant for 
prediction of OS. Bcl-2 parameters were not found to be of prognostic signicance for either OS or DFS. 
4.3.8 Prediction of Chemotherapy Response 
Of the clinicopatholo-ic data turnour grade (p=0.02), FIGO stage (p=0.004), extent 
of residual disease (p=<0.01) and presence of ascites (p=0.004) were found significant 
predictors of chemotherapy response with correct classification to chemotherapy response 
group being 70.3%, 68.8%, 68.8% and 67.2% respectively. Neither the p53 nor the Bcl-2 
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parameters showed any significance for prediction of chemotherapy response on univariate 
analysis. Multivariate analysis revealed extent of disease residuum (p=0.003) to offer 
independent prognostic ability with an overall correct classification to chemotherapy Z-1 
response group of 70%. (See table 4e for prediction of chemotherapy response results. 
Table 4e: Logistic Regression Analysis: p53, Bcl-2 and clinicopathologic data 
& chemotherapy response 
Parameter df 
ý S'? " 
I 
(p) 
Correct 
Classification 
95% CI 
Lower 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Variables 
Grade 2 . 002 68.81, ( 
Grade(l) 2.412 67.919 
Grade (2) . 729 7.917 
Stage 3 . 004 68.81, /( 
Stage(l) 1.029 560.179 
Stage(2) . 385 79.573 Stage (3) . 121 17.913 Residual Disease I <. O 1 70.3 (1c 2.420 29.393 
Presence of Ascites 1 . 004 67.2 r1c 1.566 13.822 Pre-operative 
Ca125 . 093 
Age 
P53 & bcl-2 Variables 
P53(; rade 1 . 217 
p53 positivity 1 . 235 
p53 percent 
expression 
1 . 663 
Bcl-2 grade 1 . 718 Bcl-2 positivity T -1 . 771 Multivariate Analysis 
P53, Bcl-2 & Clinicopathologic Data 
- Residual Disease I11 . 0)3 
1 70.3(ý 1.960 25.738 
Table4e illustrates univariate and multivariate logistic regression analysis of 
p53, bcl-2 & clinicopathologic parameters and chemotherapy response. Neither 
p53 nor bcl-2 parameters were found to be of significance. 
4.4 Discussion 
In agreement with prior ovarian carcinoma studies, this study found p53 positivity 
and over-expression to correlate with advancing FIGO stage, 
[99,104.106,108,110-111,117 -1201 
worsenincy tumour cyrade, 
199.101,104,106-109,111,117 -12 21 increased amounts of residual disease, t- -- 
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[99,104,108,11118-1201 and the presence of ascites. [1201 Considering that p53 gene mutation in 
ovarian cancer appears with lower frequency in early stage disease, Ell" it could be argued 
that p53 mutation is a late event in ovarian carcinogenesis, this is however, contradicted by 
the generally large levels of positivity found at all stages. As p53 over-expression is more 
likely found in turnours with increased amounts of residual disease, and in disseminated 
disease, it may be indicative of a more aggressive nature in p53 positive turnours. The fact 
that only 3 turnours were found to be p53 negative in this study was not surprising as p53 
over-expression is observed more frequently in serous tumours than in any other 
histological sub-types, [101,110,119,121,1231 with serous type being associated with moderate to 
high p53 expression, 11091 and this study also has a higher number of patients presenting 
with advanced stage disease. 
Bcl-2 over-expression is also reportedly seen most frequently in serous ovarian 
turnours [1071 yet, using strict criteria for assessment, 58% of turnours were found to be Bcl- 
2 negative in this study. In fact, in agreement with prior study data, Bcl-2 was not found to 
correlate with any clinicopathologic 11181 or p53 parameter. 
P53 accumulation is felt generally to be associated with adverse prognosis, E991 yet 
prior study findings are contradictory. In early stage ovarian carcinoma positive staining 
for p53 has been associated, in some studies, with significantly worse survival rates [1071 
and p53 expression status has been found both a strong negative prognosticator 11 201 and an 
independent prognostic factor for survival. [1231 When considering all stages of ovarian 
carcinoma, p53 over-expression on the whole has shown prognostic significance on 
univariate analysis, [ 103-104,111,118,124,1 but often failed to retain independent prognostic 
significance on multivariate analysis. [120-1211 Like this study however, numerous prior 
investigations have also found no correlation between p53 and OS. [ 106,108,110,115,123,125-71 
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Bcl-2 up-regulation has occasionally been related to better clinical outcome in 
ovarian cancer and has been reported as a marker of poor prognosis. 
[1281 Decreased 
apoptosis correlating to high Bcl-2 expression should in theory increase cell mass and 
decrease cell loss therefore enabling tumour expansion. Although it may seem counter 
intuitive that expression of an anti-apoptotic protein would result in a favourable 
prognosis, it has been postulated that Bcl-2, by virtue of inhibiting apoptosis, retards the 
rate of proliferation in solid tumours (i. e. cells do not die, but they do not divide either) and 
hence results in slow growing tumours with a favourable outcome. [1291 Whilst in advanced 
stage ovarian cancer, Bcl-2 has shown a tendency to decline with increasing tumour 
aggressiveness, this did not reach statistical significance, [1121 and more studies have agreed 
with the present findings that Bcl-2 expression does not have any correlation with survival 
in epithelial ovarian carcinoma. [99,110,115,122,1301 (See Table 4f. Prior Study Data: Expression 
of p53 & Bcl-2 in relation to overall survival in epithelial ovarian cancer). 
It has been suggested that an inverse relationship exists between Bcl-2 and p53 
expression in many cancers, with the most favourable survival rate being when p53 
expression is negative and Bcl-2 positive. [1161 When positive expression of p53 exists with 
non-expression of Bcl-2 then a significantly worse survival is suggested, 11071 with death 
due to disease being most frequent in this group. [1161 Conversely, as in this study, other 
studies have found no relationship between p53 and Bcl-2 expression. [99,112,1301 We must 
consider however that in this study very few tumours were p53 negative thus evaluation of 
differences between groups may not be particularly informative in our series. 
Mutated p53 over-expression has been found to be associated with a higher risk of 
relapse [1071 and both excessive [109,1231 and negative [1231 p53 expression to be associated 
with poor DFS. This study found both percent expression of p53 (p=o. 01 1) and p53 grade 
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(p=0.04) to be significant predictors of DFS with worsening levels corresponding to 
shorter DFS times. Of the apoptotic markers, percent expressivity of p53 (p=0.013) was 
found to be the strongest predictor of DFS, but like other studies 11191 failed to retain 
independent prognostic significance when compared with clinicopathologic parameters. 
Research on cancer treatments indicate that cell death induced by both radiotherapy 
and chemotherapy is predominantly due to apoptosis. 
[107,116,1321 P53 has been shown to 
play a role in apoptosis in response to chemotherapy-induced DNA damage, [1251 and 
evidence exists that wild type p53 product is involved in the cellular response to a number 
of cytotoxic agents. J1321 Cells with p53 gene transduction have shown higher sensitivity to 
cisplatin, and p53 gene transduction to enhance cisplatin-induced apoptosis. [1031 
Chemotherapeutic drug resistance may be a resistance to apoptosis. E116, Mutation of the 
p53 gene has been associated with a lack of response to platinum agents. (1321 Inactivation 
of p53 could confer resistance to cisplatin and other DNA damaging agents [1321 and 
progressive accumulation of p53 has been observed during the development of drug 
resistance. 11131 
Bcl-2 inhibits apoptosis and has been shown to exert anti-apoptotic activity in 
ovarian cancer cells responding to chemotherapy, 11101 and hence should be correlated with 
chemoresistance. [1121 Progressive Bcl-2 accumulation has been observed during the 
development of drug resistance, and over-expression of Bcl-2 has been shown to confer 
resistance to cisplatin. E1131 Bcl-2 is also an additional intracellular target of taxanes and its 
down-regulation is also involved in taxane resistance. [1341 
Expression of p53 and prediction of chemotherapy response has been found 
significant in prior studies [113,1321 with p53 expression associated with platinum resistance. 
1108,1131 Conversely, however, like our study no data has been found to support the view that 
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p53 [1241 or Bcl-2 expression is associated with response to chemotherapy. 
Although it is well accepted that there is a concordance between genetic methods 
that detect p53 gene mutations, and IHC methods that measure mutant p53 protein 
accumulation, [135-81 variations in study findings on p53 may relate to the use of differing 
types of p53 antibodies or indeed marked variation in the interpretation of nuclear staining. 
Differing proportions of early stage tumours may also contribute to varying findings 
between studies and we must consider that this study includes a large proportion of 
advanced stage turnours. On the whole this study has found Bcl-2 of no value as a 
prognostic marker in this group of serous ovarian tumours, and p53 of limited value only, 
being largely overshadowed by the prognostic capability of FIGO stage and extent of 
residual disease. 
If mutation of p53 and its consequent over-expression is an early event in ovarian 
turnorigenesis then p53 assessment is more likely to be beneficial in the assessment of 
either borderline [1301 ovarian turnour as a possible indicator for malignant progression, or 
in early stage [1401 ovarian turnours as a marker of tumour aggression or likelihood of 
recurrence. P53 analysis in a large group of stage I ovarian turnours may also, theoretically 
be able to identify those early stage turnours that may benefit from chemotherapeutic 
intervention. 
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Chapter 5. Mitotic Activity Index 
5.1. Introduction 
5.1.1 Mitotic Counting 
Mitotic counts (i. e. proportion of cells in mitosis) have been used to assess the 
growth fraction, or proliferation index, of a turnour. Mendelsohn 1962 [1411 defined the 
growth fraction (GF) as the relation between the number of proliferating cells (P) and the 
total number of cells, including quiescent cells (Q), which are out of the mitotic cycle 
(GF=P/P + Q). The proliferation Index (PI) is defined as the ratio of nuclear area stained to 
the total nuclear area. 11421 In theory, the greater the mitotic activity, or the greater the 
number of proliferating cells, the greater a tumour's potential to invade and metastasise. The 
rate at which turnour cells proliferate has long been considered to bear a relationship to the 
clinical course. [1431 Counting techniques are used to deduce the number of mitotic figures 
per high power field, or as an expression of the percentage of mitotic figures to the total 
number of cells per high power field. Mitotic counting must be done reproducibly and 
rigorously to be useful 11443 and has indeed shown excellent intra- and interobserver 
reproducibility. 
[145-61 
5.1.2 Ki67 
Light microscopic methods of estimating mitotic index only identify cells in 
metaphase and telophase, [142] so detect only cells in those parts of the cell cycle, and are not 
able to distinguish non-cycling cells (GO) from cells in other phases of the cycle. The 
application of immunohistochemical (IHQ methods is therefore popular in assessing the 
state of cellular proliferation in histological material, [1473 because they can be used to detect 
cells in all phases of the cycle. 
Ki67 is commonly used as a marker for cell proliferation. It is an IgG murine 
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monoclonal antibody used to assess the growth fraction of a tumour. [7,81 its gene is located 
at chromosome lOq25. Ki67 is present in cycling cells (all phases) but not non-cycling 
(GO) cells, [7,91 and reacts with a nuclear non-histone protein of 395 and 343 kDa. 110,111 In 
general Ki67 expression is an excellent indicator of proliferation in histological material, 
[1471 but expression seems to be influenced by cell nutritional supply, so tissue taken from a 
central tumour area may give an erroneously low value for the growth fraction. [1481 Tissue 
taken from a small biopsy may also not reflect the predominant proliferation rate of a 
tumour and, although Ki67 reflects the number of proliferating cells, 11 51 1 it only provides 
information about whether a cell is in cycle or not and does not tell us about cell cycle 
length. [1481 This study utilizes Ki67 immunostaining to assess MAI. 
5.2 Methods 
5.2.1 Immunostaining Technique 
IHC studies were performed on 4-6gm formalin-fixed, paraffin-embedded tissue 
using the peroxidase-anti peroxidase (PAP) complex technique. Areas representative of the 
invasive component of the turnour were selected from archived sections stained with H&E. 
Two sections containing areas of worst atypia were selected and immunostained from each 
case. Sections were immunostained using the monoclonal antibody Ki-67, (DAKO 
Monoclonal Mouse Anti-Human Ki-67 Antigen Clone Ki-S5, Code No M 7187). A 
positive and negative control slide was included in each staining run. Haernatoxylin was 
used as a counter-stain for Ki-67. Fig. 5.1 shows examples of Ki67 staining of carcinomas 
from three different women showing the range of staining found. 
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Fig 5.1: Ki67 staining and related survival in Serous Ovarian Tumours 
It 
P: 
Panel a: frequent Ki67 
staining in a patient who 
survived one month 
Panel b: rather less 
frequent staining, patient 
survived 26 months 
Panel c: sparse staining, 
patient still alive 60 months 
after resection 
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5.2.2 Nlitotic Counting 
Sections containing areas of worst nuclear atypia were initially re-cut and stained 
with Ki-67 using, a haernatoxylin counter-stain. Sections were scanned for areas including 
the highest mitotic activity and a mitotic count was performed on these areas at a final Z-1 
magnification of 40OX. Images were captured onto the screen and M67 positive nuclei L- -- 
were counted and expressed as a percentage of total nuclei in the field of vision. L- 
Coefficient,, of error were calculated to ensure adequate sample sizes were attained (<5'/c 
variability) and Lip to 20 fields, randomly selected within the larger most atypical areas, LI 
were counted producing a count of greater than 1000 nuclei per case (See Graph 5a: MAI 
Coefficient ot'Error). 
Graph 5a: MAI - Coefficient of Error 
\11: Coellicient of* Fri-ors. 
Z. 
1 
Pe rce nt 
10 
Coefficients of error were calculated to ensure adequate sample sizes were 
attained. Up to 20 visual fields were counted, encompassing a count of greater than 
1000 nuclei per case 
5.3 Results 
5.3.1 Patients 
01' a total 132 cases, 2 were excluded from MAI assessment as they were referral 
cases and ori(yinal tissue blocks were not available for further assessment. Of those 
analysed 16%, were Stage 1,15% stage 11,62% stage III and T/c stage IV as determined by t-1 C- 
FIGO. 17% were (Yrade one, 39(/(, grade two and 44(/(, orade three. Thirty t'OLII' Pel-CCIII had Z7) -- 
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-1 
an estimated disease residUL1111 Of <2cm and 66% > 2cm as defined by the operator. Mean 
age was 61.4 years (range 26-82 years). Cause of death was determined from patient Ll L- 
records or via the West Midlands Cancer Registry. Overall 5year survival was 26Y(,. (See Z- 
Table 5a: Summary of clinicopathologgic data) Z- 
Analysis was performed Using mean valUes for each measurement parameter (see 
Table 5b: MAI mean values and chnicopatliologic data). P values <0.05 were regarded as 
significant. 
Table 5a: Summary of Clinicopathologic Data 
Parameter n % 
Mean Age 130 61.4vi-s (20-82yi-s) 
FIGO Stage 
21 16 
19 15 
81 62 
IV 9 7 
I'Frade 
17 
2 51 39 
3 57 44 
Residual Disease 
<2cm 44 34 
>2cm 86 60 
Table 5h: MAI Mean Values and Clinicopathologic Data 
Clinical Parameters MAI (range) 
FICrO Stage 
1 20.329 (7.889-45.011 
11 35.432 (10.27-70.087) 
111 36.755 (10.814-70.544) 
IV 41.81 (8.36-61.139) 
Tumour Grade 
1 20.766 (10.02-48.349) 
2 35.676 (7-899-70.544) 
3 38.837 (8.36-70.097) 
Residual Disease 
<2cm 28.581 (7-889-60.415) 
>2cm 37.599 (8.36-70.544) 
07 
5.3.2 Reproducibility 
Intraobserver reproducibility was performed at a 6-month interval. Both intra- and 
interobserver reproducibility were performed on 10 cases. Intra- and interobserver 
reproducibility was excellent for MAI. (See Table 5c: Reproducibility MAI). 
Table 5c: Reproducibility of MAI 
Parameter r r2 p Spearman 2- tailed p 
Intraobserver 
0.996 0.9914 <0.000 1 0.9879 <0.000 I Error MAI 
Interobserver 
Error 0.9910 0.9821 <0.000 1 0.9879 <0.000 I 
Table 5c illustrates reproducibility of mitotic counts. Ten cases were counted at a 6month 
interval. Reproducibility was found to be excellent at both intra- and interobserver level. 
5.3.3 Correlations 
On linear regression analysis MAI was found to correlate strongly with extent of L, 
residual disease, tumour grade, presence of ascites and FIGO stage. (See Table 5d: MAI - Cý 
correlation with clinicopathologic data). 
Table 5d: MAI Correlation with Clinicopathologic Data. 
Parameter r r2 p Significant 
Age 0.05568 0.003100 0.5292 No 
Residual Disease 0.3352 0.1123 <0.000 I Yes 
Grade 0.3789 0.1436 <0.000 I Yes 
Ascites 0.3244 0.1052 0.0002 Yes 
Cal 25 pre-op 0.1526 0.02328 0.1488 No 
FIGO stage 0.3585 0.1285 <0.000 I Y" 
Table 5d illustrates correlations between MAI and clinicopathologic parameters. 
MAI was found, on linear regression analysis, to strongly correlate with FIGO stage, tumour 
grade, ascites status and residual disease status 
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5.3.4 Survival Analysis 
OS data was available for all 130 cases and DFS data was available for 94 cases. 
P values below 0.05 were regarded as significant. Z7, 
Clinicopathologic variables and MAI were analysed using the univariate Cox r-, 
model. Of the clinicopathologic data, FIGO stage (p=<0.01), turnour grade (p=0.002), pre- 
operative Ca125 levels (p=0.016), presence of ascites (p=<0.01) and extent of disease 
residuum (p=<0.01) were found to be significant predictors of OS and DFS. Age (p=0.065) t, 
was found to be insignificant. MAI was also found to be both a significant predictor ofOS 
and DFS. For results of univariate survival analysis see table 5e. 
Table 5e: Univariate Analysis: OS & DFS - Clinicopathologic and MAI Data 
Parameter n 
Mean 
p n 
Mean Time 
Survival to Relapse p 
Time 
FIGO Stage <. O I <. O I 
Stage 1 21 64.9 <. O 1 19 69.1 0.037 
Stage 11 19 49.53 0.003 15 40.73 0.417 
Stage 111 83 31.65 0.158 56 23.52 0.555 
Stage IV 9 22.56 4 36.5 
Tumour Grade 0.002 0.00 1 
Grade 1 22 56.55 0.004 20 60.5 0.00 1 
Grade 2 53 34.26 0.846 33 33.76 0.384 
Grade 3 57 34.72 41 25.93 
Age 132 0.065 94 0.722 
Ascites 132 <. O 1 94 <. O I 
Pre-op Ca125 91 0.016 94 0.004 
Residual Disease 
<2cm 46 28.29 <. O 1 40 51.63 <. O I 
>2cm 86 58.69 54 24.48 
MAI 130 <. 0 1 94 <. 0 1 
Table 5e illustrates results of Cox univariate survival analysis for MAI and clinicopathologic 
parameters. MAI was found prognostically significant for both OS and DFS. 
(p values <0.05 were regarded as significant). 
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To estimate the simultaneous influence of prognostic factors all variables were C, 
entered into Cox regression analysis. This analysis revealed MAI (p=0.003) and residual 
disease (p=<0.01) to retain independent prognostic significance for OS. FIGO stage 
(p=<0.01) and MAI (p=0.01 1) retained independent prognostic significance for DFS. The 
other factors were not of additional prognostic relevance. (See table 5f Multivariate 
analysis: survival - MAI & clinicopathologic data). tn 
Table 5f: Multivariate Analysis: OS & DFS - MAI & Clinicopathologic Data 
Ove rall Survival (OS) Disease Free Survival (DFS) 
Parameter 95% 95% 95% 95% Tdf 
Sig. Exp ci ci Parameter Sig. Exp ci ci (B) (B) Lower Upper Lower Upper 
Residual I <. O 1 . 290 . 209 . 576 MAI .01 1.02 
_ 1.005 1.039 
Disease 
MAI 1 003 1.01 1.006 
ý1.033 Stage 
< OI 9 . 
Age 1 . 326 Stage(l) 172 . 369 . 088 1.544 Grade 2 . 090 Stage(2) . 653 . 747 . 209 2.667 Grade(l) 1 . 761 Stage(3) . 308 1.85 . 567 6.034 Grade(2) 1 . 045 Age . 174 Stage 3 . 150 
_ Grade _ . 438 Stage(l) 1 . 352 Grade(l) . 278 Stage(2) 1 . 077 Grade(2) . 285 
- 
Stage(3) 1 . 052 Ascites . 610 Ascites Ca 125 pre- 1 . 415 . 357 op 
Ca125 1 . 348 
Residual 
. 506 pre-op Disease I 
Table 5f illustrates results of Cox multivariate survival analysis for MAI and 
clinicopathologic parameters. MAI was found to retain independent prognostic 
significance for both OS and DFS. 
(p values <0.05 were regarded as significant). 
5.3.5 Prediction of Chemotherapy Response - Results 
Univariate logistic regression analysis found turnour grade (p=0.02), FIGO stage 
(p=0.004), extent of residual disease (p=<0.01) and presence of ascites (p=0.004) to be 
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significant predictors of chemotherapy response, with correct classification to 
chemotherapy response group being 70.3%, 68.8%, 68.8% and 67.2% respectively. MAI zn CD 
was not found to be a significant predictor of chemotherapy response. 
Multivariate logistic regression analysis found extent of residual disease (p=0.009) 
an independent predictor of chemotherapy response with the remaining factors not 
retaining independent significance. (See Table 5g for analysis of chemotherapy response 
data) 
Table 5g: Logistic Regression Analysis: MAI and Clinicopathologic Data 
& Chemotherapy Response 
Parameter 
df Sig. 
(p) 
Correct 
Classification 
95% CI 
Lower 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Variables 
Grade 2 . 002 68.81, ý( Grade(l) 2.412 67.919 
Grade (2) 
. 729 7.917 Stage 3 . 004 68.8 11c Stage(l) 1.029 560.178 
Stage(2) 
. 
385 79.573 
Stage (3) 
. 121 17.913 Residual Disease I <. O 1 7 0.3 cl( 2.420 29.383 
Presence of Ascites 1 . 004 6 7.2 1.566 13.922 Pre-operative 
Ca125 1 . 
093 
Age 1 . 554 
MAI 
MAI_ 1 . 352 
Multivariate Analysis 
MAI & Clinicopat ologic Data 
Residual Disease 1 . 005 66.1 f1c I. 52 4 19.849 
Table 5g illustrates univariate and multivariate logistic regression analysis 
results for MAI & clinicopathologic parameters and prediction of chemotherapy 
response. MAI was not found to be of significance. 
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5.4 Discussion 
For prognostic factors to be reliable they must be reproducible, and MAI has shown 
excellent intra- and interobserver reproducibility. 
[145-61 
Higher MAI estimates were found to strongly correlate with increasing tumour 
grade, worsening FIGO stage, greater extent of residual disease and the presence of ascites. 
In prior study data on ovarian turnours, increasing levels of Ki67 have been found with 
increasing grade, [149,152-41 with the highest Ki67 values being found in grade 2 and 3 as 
compared to grade I turnours. 11551 This suggests a possible correlation of high proliferative 
activity with mainly poorly differentiated turnours. Although high Ki67 values have been 
correlated with advanced stage, [1531 numerous other studies dispute this finding. 
[142,149,152,154-61 Theoretically, if greater mitotic activity correlates to a turnours potential to 
invade and metastasise then correlation to advanced turnour stage, worsening turnour 
grade, the presence of ascites, and increasing amounts of residual disease is unsurprising. 
A study in borderline ovarian turnours showed high MAI to be a strong negative 
prognosticator for survival [1571 and generally low values of MAI seem to have good 
prognosis concerning survival. 
J1581 
In early and late stage ovarian turnours results have been conflicting. Mitotic 
activity has shown varying importance as a prognostic factor, and in advanced stage 
disease, in some studies, has seemed to be prognostically less important than other factors 
for survival. [6,1 591 Nonetheless in other studies, both univariate and multivariate analyses 
have shown high Ki67 scores to be significantly associated with decreased survival, both in 
early 
[1601 
and advanced stage turnours. 
[149,152-3,158,1611 In early stage turnours, high Ki67 
[1601 
scores have correctly predicted cancer recurrence in 84% of cases and, in general, 
significant disease free survival correlation has been shown for patients with low 
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proliferation indices. [155,1603 This study clearly agrees with these findings, showing MAI to 
be a strong independent prognosticator not only for OS (0.003), but also for DFS (p=0.01) 
with higher MAI values conferring a worse prognosis. 
Although there seems relatively little data, in ovarian carcinoma, regarding the 
value of MAI as a prognosticator for chemotherapy response, prior multivariate analysis 
has shown MAI able to independently differentiate patients on a basis of responders and 
non-responders to chemotherapeutic agents. j 1621 In another study however, MAI has also 
been found to be insignificant with regard to prediction of chemotherapy outcome, 11581 
which agrees with our findings. Discrepancies may exist as these studies have considered 
mixed histological sub-types, advanced stage (FIGO III & IV) disease only, and have 
comprised relatively small study populations. Due to the recruitment dates of these studies, 
varying chemotherapeutic regimes have also been employed in patient treatment, whereas 
our study has considered a well-selected group of serous ovarian turnours treated with 
primary carboplatin or carboplatin / paclitaxel regimes. 
Overall MAI was found a very simple and highly reproducible investigation to 
perform, capable of providing independent prognostic information for survival. Results 
suggest that MAI certainly surpasses tumour grade in both its reproducibility, and value, as 
a prognostic factor in this group of patients and may have a significant role to play in 
future therapeutic decision-making. Larger studies of stage I& II ovarian turnours, would 
further clarify the role of MAI in earlier stage disease. 
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Chapter 6. Volume Percentage Epithelium. 
6.1 Introduction 
6.1.1 VPE Introduction 
The estimation of the percentage epithelial area of a tumour or volume percentage of 
epithelium (VPE) has been used as a prognostic factor for survival in epithelial. ovarian 
cancer. Estimation has been calculated by both manual and semi-automated techniques. 
Increased epithelial. percentage denotes a more solid turnour with reduced areas of stroma, 
i. e. tightly packed sheets of cells, which are purportedly correlated to the invasive and 
metastatic potential of a tumour. In ovarian cancer neoplasms with relatively high VPE 
counts tend to be associated with extra-ovarian spread. [1571 
Epithelial. percentage has traditionally been estimated manually, by point counting, 
i. e. the number of points in a grid falling onto epithelium denotes the point fraction of the 
epithelium. The point fraction is an estimate of the area fraction, which is an estimate of the 
volume fraction where: - 
Volume fraction of epithelium = Volume occupied by epithelium [1631 
Total volume of tissue. 
Manual estimation of epithelial percentage, or point counting technique, is a rather 
tedious and time-consuming method with some degree of subjectivity. 11641 It has however 
shown good overall intra- and interobserver reproducibility. 
[145,165) Any lack of 
reproducibility may be due to differences in sampling of visual fields between observers, 
or due to an insufficient number of points being measured per tumour section. [1661 
Due to the time consuming and tedious approach of manual point counting, scmi- 
automated techniques have been developed for the determination of VPE. Good correlation 
has been found between manual and semi-automated techniques [165,16771 with 
measurements being reproducible, cheap and easy to perform. [1671 
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6.1.2 Epithelial Markers 
6.1.2.1 Cytokeratin 
Cytokeratins (CK) occur in most normal epithelial tissues and antibodies against 
them have been used to characterise a wide variety of epithelial turnours. [ 1681 The 
cytokeratins belong to the intermediate filaments, which create a cytoskeleton in almost all 
eukaryotic cells. They are made up of a highly complex multigene family of polypeptides 
with molecular masses ranging from 40 to 68 kDa. [1691 Anti-human cytokeratin (Clone 
MNF 116) is a broad spectrum anti-keratin reagent reacting with intermediate and low- 
molecular-weight keratins. 
(1691 
6.1.2.2 Epithelial Membrane Antigen 
Epithelial Membrane Antigen (EMA) belongs to a heterogeneous group of heavily 
glycosylated proteins with a molecular mass range of 250-4OOkDa known as human milk 
fat globule (HMFG) membrane proteins. [1701 These proteins are present in a variety of 
epithelia in both normal and neoplastic tissues. EMA is a useful tool for the identification 
of neoplastic epithelia, labelling epithelial cells in a wide variety of tissues. 11711 Anti- 
human EMA (Clone E29) labels bands of 265-400 kDa. 
The detection of cytokeratin intermediate filaments is widely used to identify 
turnours of epithelial origin with CK and EMA often used together in a diagnostic panel. 
11681 As CK and EMA are the most widely and successfully used epithelial markers, 
certainly in prior ovarian cancer studies, this study utilises both CK and EMA for VPE 
estimation purposes. 
6.2 Method 
6.2.1 Immunostaining Technique 
IHC studies were performed on 4-6gm formalin-fixed, paraffin-embedded tissue 
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using the peroxidase-and peroxidase (PAP) complex technique. Areas representative of the 
invasive component of the turnour were selected from archival sections stained with H&E. 
Two sections containing areas of worst atypia were selected and immunostained from each 
case. Sections were immunostained using CK (Monoclonal Mouse Anti-Human 
Cytokeratin, Clone MNF116, Code No M 0821) and EMA (Monoclonal Mouse Anti- 
Human Epithelial Membrane Antigen, Clone E29, Code No M0613). A positive and 
negative control slide was included in each staining run. No counter-stain was used for CK 
and EMA so as to optimise image analysis. (Fig 6.1 illustrates CK staining and related 
survival). 
6.2.2 Epithelial Measurements - Manual Point Counting 
Epithelial area was assessed in 30 cases by a standard manual point counting 
method. Using the archival H&E sections, random selection of the most epithelium rich 
area of tumour was performed. A Chalkey graticule (36 point grid) was placed into the 
microscope eyepiece and fields selected randomly, within the epithelial-rich areas, using a 
meandering technique. Measurements were performed at a final magnification of 40OX and 
point counting was performed over 20 visual fields providing a maximum of 720 points per 
case. 
6.2.3 Epithelial Measurements - Automated 
For automated epithelial assessments, sections containing the worst areas of atypia 
were initially re-cut and stained using combined CK and EMA. EMA proved to give more 
background staining than CK making automated analysis problematic. Therefore sections 
were stained with CK alone to perform VPE estimates in all cases. 
The live image was initially set up with regards to white balance to attain even 
illumination. The stained section was then randomly scanned using a set of up to 20 fields 
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at a final on screen magnification of 25X (I pixel = 0.00323 microns). Once live image 
acquisition was attained the image was converted to binary enabling further image zn 
Fig 6.1: Shows CK staining and related survival in Serous Ovarian Tumours 
I'l 
Panel a. Cytokeratin 
staining in a patient 
surviving I month. 
Panel b. Cytokeratin 
staining in a patient 
surviving 26 months. 
Panel c. Cytokeratin 
staining in a patient alive 
at study closure. 
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processing prior to measurement. A grey level detection was ad Listed to correspond well to 
CK positive areas and negate any further unwanted regions. The binary images were 
amended permitting the iniage to be modified in such a manner as to obliterate the holes 
caused by nuclel present in the CK positive epitheliUm by means of dilatation. (Dilatation 
is essentially the expansion of image detail by moving boundaries outwards by a uniform 
amount. Dilatations were therefore performed upon each image in order to close the holes 11 
produced by epithelial nuclei with each dilatation constituting the size of I pixel in L- 
circumferencc). A Ficid measurement was attained (representing a summed value for all L, 
selected regions within the measurement frame) to in turn attain the area fraction. As Z- 
manUal and automated epithellal measurenicnts were I'OLind to highly correlate (i-=0.99), C- 
manual counts were only performed upon the first 30 cases and automated counts 
performed on all cases. Measurements were made using the LFICA Q500MC Iniage 
Analysis System. 
Coefficients of' en-or were used to calculate the nuniher of' fields required I*or 
measurement, per case, to attain adequate sample size. (See Graph 7a: VIT - CoctTicient 
of Error). Intra- and interobserver error was calculated by repeating IIICaSLII-ClIICII(S 1'01' (Cil 
cascs Lit a 6-month interval 
Graph 6a: VPE - Coefficient of Error 
VPE: COEFFICIENT OF ERROR. 
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PERCENT 
CE: 55% Indicates a high level of measurement precision 
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1 
6.3 Results 
6.3.1 Patients 
Of the 132 cases, 2 were excluded from VPE assessment as they were referral cases 
and original tissue blocks were not available foi- further assessment. Of those analysed 1617c, L, l 
were sta(je 1,15% sta-e 11,62% Sta,, e III and 717c Stage IV Lis determined by FIGO. 17% 
were grade 1,39% grade 2 and 44% grade 3. Thirty fOL11- pet-cent had an estimated disease :7 Z-1 
residuum of <2cm and 661'/c > 2cm as defined by the operator. Mean age was 61.4 years 
(range 26-82 years). Cause of death was determined from patient records or via the West 
Midlands Cancer Registry. Overall 5year SUrvival was 261k. (See Table 6a: SLI111111ary 01' L- 
chnicopathologic data) 
Analysis was performed using mean values for each nicasurcment parameter (see 
Table 6b: VPE mean valLies and clinicopatholocic data). P values <0.05 were regarded as ?I LI 
significant. 
Table 6a: Summary of Clinicopathologic Data 
Parameter n % 
Mean Age 130 61.4yrs (26-82yi-s) 
FIGO Stage 
1 21 16 
Il 19 15 
111 81 62 
IV 9 7 
Grade 
I Y) 17 
2 51 39 
3 57 44 
Residual Disease 
<2cm 44 34 
>2cm 86 66 
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Table 6b: VPE Mean Values and Clinicopathological Data 
Clinical Parameters VPE (%) 
(range) 
FIGO Stage 
45.183 
(15.059-69.14) 
59.824 
(27.015-83.463) 
58.866 
(21.143-80.275) 
62.629 
IV 
(15.83-94.02) 
Tumour Grade 
42.135 
1 (15.059-73.74) 
59.165 
2 
(28.06-72.8) 
61.253 
3 
(12.646-84.027) 
Residual Disease 
52.404 
<2cm (26.544-72.8) 
62.093 
>2cm 
L (12.646-90.859) 
6.3.2 Reproducibility 
Intra- (p=<0.0001) and inter-observer (p=<0.0001) reproducibility was excellent 
for VPE parameters. (See Table 6c: Reproducibility of VPE parameters). 
Table 6c: Reproducibility of VPE Parameters 
Parameter r r2 p Spearman 
2- tailed 
p 
VPE 
Manual vs. 0.990 0.9805 <0.000 1 0.9831 <0.000 I Automated Intra- 
Automated Error 0.992 0.9844 <0.000 1 0.9636 0.000 1 Technique 
Automated Inter- 0.9866 0.9734 <0.000 1 0.9515 <0.000 I Technique I Error 
Table 6c illustrates reproducibility of VPE. 
Manual assessment was found to strongly correlate with the semi-automated 
technique. Ten cases were counted at a 6month interval. Reproducibility was found 
to be excellent at both intra- and interobserver level. 
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6.3.3 Correlation between parameters 
On linear regression analysis VPE was found to correlate with extent of residual 
disease, turnour grade, presence of ascites, FIGO stage, patient age and pre-operative 
Cal 25 levels. (See Table 6d: VPE correlation with clinicopathologic data). 
Table 6d: VPE Correlation with Clinicopathologic Data 
VPE r r2 p Significant 
Age 0.2010 0.04038 0.0219 Yes 
Residual 
Disease 
0.3345 0.1119 0.000 1 Yes 
Grade 0.3335 0.1112 0.0001 Yes 
Ascites 0.2778 0.07715 0.0014 Yes 
Ca 125 pre-op 0.2812 0.07905 0.0080 Yes 
FIGO Stage 0.3241 0.1051 0.0002 Yes 
Table 6d illustrates correlations found between VPE and clincopathologic 
parameters on linear regression analysis. VPE estimates were found to strongly 
correlate with FIGO stage, tumour grade, pre-operative Cal 25 levels, ascites 
status, residual disease status a, and patient age at presentation. 
6.3.4 Survival Analysis 
OS data was available for all 130 cases and DFS data available for 94 cases. P 
values below 0.05 were regarded as significant. 
Clinicopathologic variables and VPE were analysed using the univariate Cox 
model. Of the clinicopatholgic data, FIGO stage, tumour grade, pre-operative Ca125 
levels, presence of ascites and extent of disease residuum were found to be significant 
predictors of OS and DFS. Age was found to be insignificant. VPE was also found to be a 
significant predictor for both OS and DFS. (See table 6e for results of univariate survival 
analysis). 
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Table 6e: Univariate Analysis Survival -VPE & Clinicopathologic Data 
O verall Survival ( OS) Disease Free Survival (DFS) 
Mean Mean Relapse 
Parameter n Survival Time p n Time P 
(months) (months) 
FIGO Stage <. O I <. () I 
Stage 1 21 64.9 (8-123) <. O 1 19 69.1 (19-123) 0.037 
Stage 11 19 49.53 (7-96) 0.003 15 40.73 (8-96) 0.417 
Stage 111 81 31.65 (1-106) 0.158 56 23.52 (1-100) 0.555 
Stage IV 9 22.56 (1-104) 4 36.5 (9-104) 
Grade 
Grade 1 22 56.55 (6-123) 
0.002 -)o 60.5 (9-123) 
0.00 1 
Grade 2 51 34.26 (1-119) 
004 ()* 
0 846 
33 33.76 (1-119) 
0.00 1 
0.384 
Grade 3 57 34.72 (1-106) . 41 25.93 (4-96) 
Age 130 0.065 94 0.722 
Ascites 130 <. O 1 94 <. O I 
Pre-op Ca125 91 0.016 94 0.004 
Residual Disease 
<2cm 44 28.29 (1-104) <. O 1 40 51.63 (1-123) <. 0 I 
>2cm 86 58.69 (1-123) , 1 
54 
1 
24.48 (2-104) 
, I 
VPE 
1 
130 1 <. O 1 1 94 1 1 0.013 
] 
Table 6e illustrates results of Cox univariate survival analYsis for VPE and 
clinicopathologic parameters. VPE was found a significant prognosticator for 
both OS and DFS. 
p values <0.05 were regarded as significant. 
To estimate the simultaneous influence of prognostic factors, VPE and all 
clinicopathologic variables were entered into Cox regression analysis. Both VPE (p=0.03) Z7, 
and extent of residual disease (p=<0.01) achieved independent prognostic significance for L, -- 
prediction of OS whereas FIGO stage alone retained independent prognostic significance 
for prediction of DFS. (See table 6f for multivariate survival analysis). 
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Table 6f: Multivariate Analysis: Survival - VPE & Clinicopathologic Data 
O verall Survival D isease Free Survival 
Parameter df Sig. Exp (B) 
95% 
CI 
Lower 
95% 
CI 
Upper 
Parameter 
Sig. Exp (B) 
95% 
CI 
Lower 
95% 
CI 
Upper 
Residual 
Tumour 
1 1 
. 
331 . 
178 
. 
615 
I 
Stage 
VPE 1 
. 03 1.02 
1.002 1.038 Stage(l) 
. 
00 1 
. 
090 
. 
021 
. 
391 
Age 1 
. 319 
Stage(2) 
. 019 . 198 . 051 . 
767 
Grade 1 
. 297 
Stage(3) 
. 348 . 566 . 173 
1.859 
Grade(l) 1 
. 527 
Age 
. 059 Grade(2) 1 
. 12 
Grade 
. 145 Stage 3 
. 
150 Grade (1) 
. 05 Stage(l) 1 
. 
174 Grade (2) 
. 374 Stage(2) 1 
. 235 
Ascites cat 
. 195 Stage(3) 1 
. 
098 Cal 25 cat 
. 516 Ascites cat 1 
. 225 
Residual 
Tumour . 183 
Cal 25 cat 1 
. 442 
VPE 
. 095 
Table 6f illustrates results of Cox multivariate survival analysis for VPE and clinicopathologic 
parameters. VPE was found to be of independent prognostic significance for OS, but not for DFS, 
being superseded by FIGO stage. p values <0.05 were regarded as significant. 
6.3.5 Prediction of Chemotherapy Response 
Univariate logistic regression analysis found tumour grade FIGO stage, extent of 
residual disease and presence of ascites to be significant predictors of chernotherapy 
response, with correct classification to chemotherapy response group being, 70.3'7c, 68.9%, 
68.8% and 67.2% respectively. VPE was also found to be significant (p=0.002) for L- 
prediction of chemotherapy response with an overall correct classification to chemotherapy 
response group of 76.3%. 
Multivariate logistic regression analysis found extent of residual disease (p=0.042) Cý 
and VPE (p=0.003) to be independent predictors for chemotherapy response with a correct 
overall classification to chemotherapy response group of 75%. (See table 6c, foi- logistic l, 
regression analysis and prediction of chemotherapy response. 
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Table 6g: Logistic Regression Analysis: VPE and Clinicopathologic Data & 
Prediction of Chemotherapy Response 
3arameter df 
I Sig. ý 
(P) 
Correct 
Classification 
95% CI 
L 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Vari ables 
Grade 2 . 002 68.8 "Ic _ Grade(l) 2.412 67.918 
_ Grade (2) . 728 
7.917 
_ Stage 3 . 004 68.8% _ Stage(l) 1.028 560.178 
_ Stage(2) . 385 
78.573 
_ Stage (3) . 121 
17.913 
_ Residual Tumour I <. O 1 70.3(/(- 2.420 29.383 
Presence of Ascites 1 . 004 67.2% 1.566 
13.922 
_ Pre-operative Ca 125 1 . 
093 
Age 1 . 
554 
VPE 
VPE II I <. O 1 1 76.3% 1 0.899 1 0.976 
Multivariate Analysis 
VPE & Clinicopathologic Data 
VPE 1 . 003 Group 
1=63.2% 
. 892 . 997 
Residual Tumour 1 
1 
. 042 
C. roup 2=8 1.1 % 
0% crall = 75.0 cl, 
1.009 15.840 
Table 6g illustrates results of univariate and multivariate logistic regression analysis for VPE 
& clinicopathologic parameters, and prediction of chemotherapy response. VPE was found of 
independent prognostic significance. 
(Group I= no / partial response: Group 2= Complete Remission) 
6.4 Discussion 
Like other studies, 
1145,165,1671 
this study, on a well-selected group ofserous ovarian 
turnours, has shown VPE assessment techniques to have both excellent intra and inter 
observer reproducibility and good correlation between manual and serni-autoniated 
techniques, with se rni -automated measurements not only being highly reproducible but L_ 
also faster, easier and cheap to perform. 
Higher VPE estimates were found to strongly correlate with increasing tuniour 
grade, worsening FIGO stage, greater extent of residual disease and the presence of ascites. 
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Prior study data on ovarian turnours has shown a tendency for VPE to increase with 
turnour grade, [1571 but considerable variability has been found. Strong linear correlation 
however has been found between VPE and FIGO stage. [1721 Prior studies have found VPE 
to both exceed the prognostic value of histological sub-type and extent of residual disease 
in borderline turnours of the ovary, [1571 and to be a valuable prognosticator for survival in 
both borderline and invasive carcinomas of the ovary. 
Although VPE estimation in FIGO stage I epithelial ovarian cancer has not shown 
prognostic value in all studies, (1731 other studies have shown VPE scores of < or > 65% to 
be strong positive or negative predictors of survival respectively, especially when 
combined with mitotic activity indices (MAI). [1741 VPE in advanced stage epithelial 
ovarian carcinoma has shown strong associations with survival, 11721 with VPE scores 
>70% and 76% respectively being associated with poor prognosis in terms of patient 
survival. 
[157,1721 The epithelial percentage, as established with digital image processing, 
also appears to be a strong prognosticator for survival. [1721 This study found VPE, as 
determined by semi-automated analysis, a strong prognosticator, on univariate analysis, for 
both OS (p<0.01) and DFS (p=0.013) with higher VPE estimates conferring poorer 
prognosis. VPE estimates also retained independent prognostic value on multivariate 
analysis for prediction of OS (p=0.030). 
In borderline, [1571 early, 
[1741 
and advanced stage 
[1581 
epithelial ovarian turnours the 
combination of VPE and MAI has been used as a successful prognosticator for survival 
with lower values related to enhanced survival and low values of mitoses seeming to 
confer better prognosis when related to cisplatin chemosensitivity. J1751 In this study, when 
using a scoring system for MAI and VPE (Group A- MAI <30, VPE <65; Group B- MAI 
<30, VPE > 65; Group C- MAI >30) as per Baak et al, (1571 mean survival per group was 
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found to be 57 months, 39 months and 30 months respectively. This MAINPE scoring 
system showed prognostic significance on univariate analysis for OS (p=<0.01) and DFS 
(p=<0.01), but grouped combinations of VPE and MAI however, failed to achieve 
independent prognostic significance on multivariate analysis thus offering little benefit 
over analysing VPE and MAI as prognostic factors in their own right. 
When considering the value of VPE as a prognostic factor to predict chemotherapy 
response, there appears to be a paucity of literature. This study finds VPE estimation not 
only to be an independent predictor of chemotherapy response, but also to attain a 
relatively high degree of, and to surpass the predictive capabilities of traditional 
clinicopathologic parameters such as extent of disease residuum. 
This study found automated VPE estimates, not only extremely easy to perform and 
highly reproducible, but also to have independent prognostic ability for not only survival 
prediction, but also for prediction of chemotherapy response, which certainly seems an 
area worthy of further investigation. 
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Chapter 7. Nuclear Morphometry 
7.1 Introduction 
7.1.1 Morphometry Background 
Morphometry, literally meaning the measurement of form or 'the quantitative 
description of a structure' 11761 is generally used to denote measurement of geometric cell 
and tissue features, where morphometric measurements essentially aim at 2d (planimetric) 
or 3d (stereologic) descriptions of tissues. [1631 
Quantitative techniques can improve assessment and provide highly reproducible 
and objective measurements, [1731 hence morphometric approaches to evaluating changes in 
tissue are likely to be more reproducible than ordinal grading because they are quantitative. 
Morphometry may provide an exact and objective system of malignancy grading [61 and is 
likely to decrease variability in quantitating features of cells and tissues. It may provide a 
numerical, reproducible scale of quantitative features and increase sensitivity in detecting 
minimal change. 11771 It is possible that morphometric analysis of turnours may enhance the 
observation and interpretation of morphologic features and thus lead to greater accuracy 
and precision of diagnosis. [1781 
Accurate evaluation of the primary tumour is important to determine prognosis and 
treatment strategies in any cancer. Prognostic tools should ideally allow an individualised 
therapy that minin-ýises the risk of severe side effects, [31 whilst maximising survival. As 
overall survival in epithelial ovarian carcinoma is poor and therapeutic strategies such as 
platinum chemotherapy agents have considerable side effects (see appendix 1), 
morphometry used as a prognostic tool may enable accurate patient selection, and select 
only those patients who will benefit from therapy. [41 Patients with advanced ovarian cancer 
may have only a very short- term survival (FIGO stage IV <5% 5 year survival) thus less 
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toxic palliative therapy may be favourably selected. Conversely 20%-40% of FIGO stage I 
patients, who are traditionally not felt to benefit from adjuvant therapy, will die from 
recurrent disease 151 and these patients may potentially be identified as benefiting from 
more aggressive therapy. Current therapeutic results in ovarian cancer are reached at the 
expense of severe side effects with most patients undergoing radical treatment. Knowledge 
of predictive factors could lead to a better selection of patients who will benefit from 
aggressive therapy. [61 Morphometric data may not only be used to correlate with traditional 
tumour classification, but it has been argued that it could also be used as a prognostic 
parameter in survival and chemotherapy response. 11581 
7.1.2 Nuclear Morphometry 
Neoplasms differ histologically from their corresponding normal tissue by various 
features including loss of differentiation, loss of nuclear cohesion, nuclear enlargement and 
increased mitotic activity, and therefore may exhibit nuclear pleomorphism (greater variety 
in size, shape and polarity), hyperchromatism (denser, coarser chromatin staining) and 
increased mitotic index etc. Cancer consists of cells with uncontrolled growth, resulting in 
cell nuclei that deviate from the size and shape of a normal nucleus, these differences can 
be studied and quantified by morphometric image analysis. 11793 Although nuclear size may 
alter with respect to cell cycle position, nuclear size as measured through the entire cell 
cycle has been shown as an independent prognostic indicator of survival in epithelial 
ovarian cancer. 
[1791 
Prior studies on nuclear measurements have concentrated upon nuclear area, 
diameter, perimeter and form factors. These quantitative features may be correlated to more 
traditional qualitative features of proliferation, abnormal differentiation or invasion and 
metastatic potential. High nuclear area measurements (mean nuclear area and standard 
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deviation of nuclear area) correlate with enlarged, pleornorphic nuclei, abnormal L- 
differentiation and increased metastatic potential as do other shape parameters such Lis 
nuclear diameter, shortest nuclear axis and longest nuclear axis. (See Table 7a: Qualitative L- 
and Quantitative Pathological Features) lls()' 
Table 7a: Qualitative and Quantitative Pathological Features. 
118()l 
Qualitative Feature Quantitative Feature 
Proliferation 
Mitosis nurnerow, and ohen abnormal MAI. '/( Ki-07 positive cell,. -,. 
Nuclei enlarged and pleomorphic Higher \alues ot'MNA, sdNA. longest and 
shortest axes T, Othcrshape factors chatwed. 
Nucleoli usually large TMean nucleolar area 
Coarse and clumped chromatin Quantitative chromatin features and/or ploidy 
abnormal 
Cytoplasmic chan., es TN: C ratio 
_ Hacniorrhage and Necrosis Volume percentage ol'i-ed blood cells or necrosis 
T 
Abnormal Differentiation 
Little micro,, copic rcscinblmcc to normal tissue MNA. sdNA and other nuclear and 11LICICOlar 
features changed. Volume pcrccn(a,, c ofolands 
T, shape factor ot'glands changed 
Function may be retained, lost or abnormal Ocstropen and/or proocstcroric receptor content Z- Zý 
different. Abnormal immunoplicnotype. 
Quantitative Sub-ccllular changes. 
Invasion and metastatic Potential 
Cap"LlIc InLwl or not: SurfaccAolunic ratio ofepithelial fields 'in 
local imasion Ircquem turnour, EpIthelial pmentape, large MNA, 
Metastases present irre-ular cell and nuclear shape 
Previous studies suggest a potentially important role for morphonletry ovar, L- L- Iý Icill 
cancer bUt there have been few confirniatOry StUdies Litilising well-selected, and staged I- t, 
tumours with a single epithelial type, and a fUlly piatinum-based ti-catnient regime. This L, 
study therefore ainis to assess the prognostic and predictive VZIILIC Of IIUCICM' lll()I*PIIOIIICII*IC L- 
features in well-staged, platinum treated, serous ovarian tuniours. Z-1 
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7.2 Methodology 
7.2.1 Tissue Processing 
Nuclear morphometry was performed on archived, paraffin-embedded, H&E 
stained, sections. Morphometric measurements were made using the LEICA Q500MC 
Image Analysis System. 
7.2.2 Nuclear Measurements 
ME stained archival specimens were selected for sections representing the most 
atypical areas of tumour. Randomly selected fields were focused using the microscope, 
then interactively captured onto the computer screen avoiding areas of inflammation, 
necrosis and calcification. Prior to acquisition, the live image views were white balanced 
ensuring even image illumination and optimal light intensity. Images had been calibrated 
from pixels to micrometers allowing lens selection and hence the associated calibration 
value (using Mag. 63X, IOX objective -1 pixel = 0.00725gm). The selected image was 
then acquired enabling the image to be frozen and stored as a single frame ready for 
measuring. 
Nuclei were measured using the edit mode of the image program with the mouse 
being used to trace the perimeter of each nucleus. Nuclei were then systematically 
measured within the captured field avoiding overlapping nuclei and concentrating upon 
nuclei with clearly defined edges to improve accuracy of measurement. 
Defined nuclei were measured using the feature measurement tool of the image 
analysis program using the pre-determined measurement parameters of mean nuclear area 
(MNA) (the total number of detected pixels within the feature), nuclear breadth (NB) (the 
breadth of the longest feret), equivalent circle diameter (ED) (i. e. the diameter of a circle 
having the same area as the feature), fullness ratio (FR) (a shape factor, equal to the square 
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root of the ratio of area to circumscribed area), nuclear length (NQ (the length of the 
longest feret), orthogonal feret (the length of the feret that is at right angles to the longest 
feret), nuclear perimeter (NP) (the total length of the boundary of the feature), nuclear 
roundness (NR) (a shape factor which gives a minimum value of unity for a circle 
calculated from the ratio of perimeter squared to area), XFCP (the X co-ordinate of the 
feature count point), and YFCP (the Y co-ordinate of the feature count point). (See 
appendix 2: Nuclear Morphometry Parameter Definitions). 
Nuclei were initially measured at an on screen magnification of 120OX (40X 
Objective). This resulted in a single intra-observer correlation of 93.68% when used to 
measure 50 consecutive nuclei. As a mouse is used to trace the nuclear outline, a hand 
tremor factor was evident and measurement at the higher on screen magnification of 190OX 
(63X objective) was found to give an improved correlation of 97.56%. 100 nuclei per case 
were measured at a final on screen magnification of 190OX. (See Fig 7.1 for morphometry 
methodology 
Coefficients of error were used to calculate the number of nuclei and fields required 
for measurement per case to attain adequate sample size. When measurement's remained 
stable over several fields (<5% variation), this was accepted as a representative sample. 
(See fig 7.2: Morphometric Parameters - Coefficients of Error) 
Intra-observer error was calculated by repeating measurements for ten cases at a6- 
month interval. Inter-observer error was calculated over ten cases for each measurement 
variable. Two observers without prior knowledge of patient characteristic's or outcome 
made assessments. 
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Fig 7.1: Morphometry Methodology 
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Nuclei were measured using the edit 
mode of the image program with the 
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of each nucleus. Nuclei were then 
systematically measured within the 
captured field avoiding overlapping 
nuclei and concentrating upon nuclei C 
with clearly defined edges to improve 
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Defined nuclei were measured using the 
feature measurement tool of the image 
analysis program using the pre-determined 
measurement parameters of area, breadth, 
equivalent circle diameter, fullness ratio, 
length, orthogonal feret, perimeter, 
roundness. 
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7.3 Results 
Analysis was performed using mean values for each measurement. All 132 cases were 
examined for nuclear morphometric parameters. P values <0.05 were regarded as being 
significant. (See Table 7b for mean morphometric parameters and clinicopathologic data). 
XFCP and YFCP were eliminated from analysis as these simply represent nuclear 
positional measurements within each field. 
7.3.1 Reproducibility 
With the exception of nuclear roundness and fullness ratio, nuclear morphometric 
parameters were found to be highly reproducible for both inter and intra-observer 
calculations (see Table 7c: Reproducibility - Morphometric Parameters). 
7.3.2 Correlations between parameters 
On linear regression analysis nuclear morphometric parameters were found to 
strongly correlate with extent of residual disease, tumour grade, FIGO stage and the 
presence of ascites. (See Table 7d: Correlations Between Parameters). 
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7.3.3 Survival Analysis 
OS data was available for all 132 patients and DFS data for 94 patients. P values 
below 0.05 were regarded as significant. 
Morphometric and clinicopathologic variables were analysed using the univariate 
Cox model. Of the clinicopatholgic data, FIGO stage (p=<0.01), tumour grade (p=0.002), 
pre-operative Ca125 levels (p=0.016), presence of ascites (p=<0.01) and extent of disease 
residuum (p=<0.01) were found to be significant predictors of OS. FIGO stage (p=<0.01), 
tumour grade (p=0.001), pre-operative Ca125 levels (p=0.004), presence of ascites, 
(p=<0.01) and extent of disease residuum (p=<0.01) were found to be significant 
predictors of DFS. For morphometric variables sdNA (p=0.001), NP (p=0.001), sdNP 
(p=0.038), NL (p=0.001), NB (p=0.001), orthoferet (p=0.003), and ED (p=<0.01) were 
found to be significant predictors of OS, with higher values of these being prognostically 
less favourable. sdNA (p=0.018), NP (p=0.003), NL (p=0.003), NB (p=0.003), orthoferet 
(p=0.003) and ED (p=0.015) were also found to be significant predictors of DFS, again 
with higher values of these being prognostically less favourable 
Using the Cox multivariate model for morphometric parameters alone, ED showed 
to be a significant predictor of OS (p=0.001) and orthoferet a significant predictor of DFS 
(p=0.003). 
To estimate the simultaneous influence of prognostic factors all clinicopathologic 
and morphometric variables were entered into Cox regression analysis. This analysis 
revealed extent of disease residuum (p=<0.01) and ED (p=0.002) to be significant 
predictors for OS in this group of patients. FIGO stage (p=<0.01) and ED (=0.039) were 
found to be a significant predictor for DFS. The other factors were not of additional 
prognostic relevance. (See table 7e for univariate and multivariate survival analysis). 
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Table 7e: Positive Findings - Univariate and Multivariate Survival Analysis 
95% 95% 
Parameter df Sig. Exp 95% CI 95% CI Parameter 
Sig. Exp Lower Upper 
(p) (B) Lower Upper (p) (B) C1 CI 
Univariate Ana ysis 
Overall Survival (OS) Disease Free Survival (DFS) 
Clinicopathologi Variables Clinicopathologic Va i ables 
Grade 2 . 008 Grade . 11114 
Grade(l) 1 . 004 
1 
. 344 . 168 . 705 Grade(l) . 001 . 
288 . 138 . 603 
1 Grade(2) . 384 . 798 . 
479 1.327 
Stage 3 <. Ol Stage <. O I 
Stage(l) I <. 01 . 151 . 056 . 403 Stage(l) . 037 . 
229 . 057 . 913 
Stage(2) . 003 . 256 . 103 . 639 Stage(2) . 417 . 
592 . 167 2.101 
Stage(3) . 555 1.421 . 442 
4.568 
Residual <. Ol . 341 . 204 . 568 Residual <. O 1 . 
341 . 204 . 569 
Disease Disease 
Ascites I <. O 1 . 
377 
. 
237 
. 
599 Ascites . 
359 . 
212 . 605 
Pre-operative 1 . 016 1.000 1.000 1.000 Pre- . 001 1.000 
1.000 
Ca125 operative 
Ca125 
Morphometric Variables 
NINA 1 
. 
071 2.799 0.916 8.550 NINA . 104 
2.657 0.817 9.647 
sdNA 21457 37524 
1 
. 00 1 
92907. 5434.46 9E+O 14 sdNA . 016 
95240. 63.515 2E+017 
524 3 
Nuclear Length I AOI 78.318 5.662 1093 29 Nuclear . 004 93.287 4.266 
2039.772 
. Length 
Nuclear Breadth 1 . 00 1 
266.78 9.342 7618 82 Nuclear . 003 380.06 7.511 
19232.1 
14 . Breadth 
Nuclear 
1 . 001 4.420 1.773 022 11 
Nuclear 
. 004 
4.929 1.690 14.457 
Perimeter . Perimeter 
sd perimeter 1 . 038 16.662 1.174 236.571 sd perimeter . 
852 1.410 0.036 55.243 
Nuclear 
1 
. 
926 
. 
841 021 0 33 254 Nuclear 
. 
316 
. 
045 0.000 19.573 
Roundness . . Roundness 
sd roundness 1 1 . 673 . 411 
0.007 25.43 sd roundness . 164 . 
014 0.000 5.785 
orthoferet 1 00 355.71 7.423 3938.88 orthoreret . 003 
355.72 7.423 17046.04 
Fullness Fullness 31285 
Ratio 
I 
. 
627 
. 
()()1 000 1 E+009 Ratio 
. 
102 
41574 00) 1 
1.21-1+03 
. 39642 4 
I 6.0 
- Equivalent 
I <. Ol 22.403 791 4 769 104 
Fqui%, alent- 006 
F 
67 932 9 1.955 50.46 diameter . 1 . diameter . . 1 
Multivariate An lysis 
Morphometric Data 
Equiv 22.40 Orthoferet 355.7 17046.0 ) f7 
Diameter 1)(11) 4,791 104.76 003 7.421 
T 
4 7 
Morphometric & Ch icopat hologic ata 
Residual Equivalent 
Disease 
I <. 0 1 . 
337 
. 
209 
. 
542 
Diameter . 039 
9.409 1.114 79.479 
Equivalent 1 
. 002 16.60 
2.783 99-088 Stage 
Diameter <. O I 
Stage(l) . 08 9 . 090 0 . 072 1.205 Stage(2) . ýL9 . 15 
ýý 
. 198 
( 
'19 . 154 1.972 Stage(3) 5 4 . 6 . 566 . 4-: 
T9 5 5.042 
Table 7e illustrates univariate and multivariate Cox survival analysis results for nuclear morphometry features 
and clinicopathologic parameters. At multivariate level, equivalent nuclear diameter was found of independent 
prognostic significance for both OS and DFS 
p values <0.05 were regarded as significant. 
7.3.4 Response to Chemotherapy 
Of the clinicopathologic data, turnour grade (p=0.02), FIGO stage (p=0.004), extent 
of residual disease (p=<0.01) and presence of ascites (p=0.004) were found significant 
predictors of chemotherapy response with overall correct classification to chemotherapy 
response group being 70.3%, 68.8%, 68.8% and 67.2% respectively. For the morphometric 
data, sdNA (p=0.017), NP (p=0.004), NL (p=0.005), NB (p=0.005) and orthoferet 
(p=0.005) were found to be significant predictors of chemotherapy response with correct 
overall classification to chemotherapy response group being 64.1 % for sdNA, NP and NL, 
65.6% for NB and 65.6% for orthoferet diameter. 
Multivariate logistic regression analysis of morphometric parameters alone 
revealed NP to be a significant predictor of survival (p=0.009) with a correct overall 
classification rate of 64.1 %. 
To estimate the simultaneous influence of prognostic factors all clinicopathologic 
and morphometric variables were entered into multivariate logistic regression analysis. 
This analysis showed extent of residual disease (p=0.003) and NL (p=0.041) to be the 
strongest predictors of chemotherapy response with correct classification rates of 61.5% to 
group 1 and 73.7% to group 2, and an overall correct classification rate to chemotherapy 
response group of 68.8%. (See Table 7f Logistic Regression Analysis: Morphometric and 
Clinicopathologic Data & Chemotherapy Response). 
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Table 7f: Logistic Regression Analysis: Morphometric and Clinicopathologic 
Data & Chemotherapy Response 
Parameter df Sig (p)* 
ý Correct 
Classification 
95% CI 
Lower 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Vari ables 
Grade . 002 68.8% 
Grade(l) 2.412 67.918 
_ Grade (2) . 729 
7.917 
_ Stage 3 . 004 6 8.8 c1c _ Stage(l) 1.028 560.179 
_ Stage(2) . 
385 79.573 
_ Stage (3) . 121 
17.913 
_ Residual Disease I <. O 1 70.3% 2.420 29.383 
Presence of Ascites 1 . 004 67.2% 1.566 
13.922 
_ Pre-operative 
Ca125 1 . 093 
Age 1 . 
554 
Morphometric Va riab les 
sdNA 1 . 017 6 4.1 c/., . 000 . 
001 
Nuclear Length 1 . 005 64.1% . 000 . 
076 
Nuclear Breadth 1 . 005 65.6 cl, . 000 . 
044 
Nuclear Perimeter 1 . 004 1 64.1 cl., 
1 
. 002 . 
407 
orthoferet I 
t 
. 005 65.6 (4 . 000 . 
042 
MNA 1 . 060 
sd perimeter 1 . 
290 
Nuclear Roundness 1 . 523 
sd roundness 1 . 
305 
Fullness Ratio 1 . 414 
Equivalent 
diameter 1 I . 
076 
Multivariate Ana lysis 
Morphometric Data 
Nuclear Perimeter I11 . 004 64.1 (4 . 002 . 
407 
Morphometric & Clinicopathologic Data 
Nuclear Length 1 . 041 
Grotip I= 61.5; . 
000 
. 
691 
Residual Disease 1 . 003 
G roti p2= 73.71 ( 
ON, erall = 68.8% 
1.960 25.738 
Table 7f illustrates univariate and multivariate logistic regression analysis 
results for nuclear morphometry features, clinicopathologic parameters and 
prediction of chemotherapy response. Numerous morphometry parameters were 
found significant at univariate level. Nuclear length was found to retain 
independent prognostic significance, and, in combination with residual disease 
status, provide an overall 69% correct classification to chemotherapy response 
group. 
(Group I= no / partial response: Group 2= Complete Remission) 
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7.4 Discussion 
Morphometric analysis has been applied to various turnours (eg breast, prostate, 
colon) and used to predict outcome. Like this study nuclear morphometric measurements 
have, on the whole, shown good intra- and interobserver reproducibility 
[4,146,1811 
and mean 
nuclear area has shown to be more reproducible than grade and to give more accurate 
prediction of survival. 
11731 
Correlation of nuclear morphometric variables with clinicopathologic data has been 
less widely studied. In general smaller nuclei have been found in lower stage and grade 
turnours, and mean nuclear volume (MNV) has also been found as significantly lower in 
lower grade turnours. [31 This study has found strong correlations between morphometric 
parameters and tumour grade, FIGO stage, the presence of ascites and extent of residual 
disease, showing higher nuclear morphometric measurements to be associated with poorer 
clinicopathologic variables. 
Nuclear morphometry has successfully been used to differentiate benign, borderline 
and malignant ovarian serous turnours with significant differences in nuclear size and 
shape being found. 1181 1 Higher Mean Nuclear Area (MNA) has been found to correlate 
with shorter survival times and rapid progression and to be of prognostic significance 
between lower (I) and higher (H & M) turnour grades. [1791 In borderline turnours 
morphometric techniques were also found capable of predicting, with a high degree of 
accuracy, the outcome of patients. 
(1821 
Studies in FIGO Stage I patients have found MNA and Mean Nuclear Volume 
(MNV) to be objective, and accurate predictors of survival, with NINA and MNV being the 
strongest single prognostic factors for overall survival. 11733 In Stage I clear cell ovarian 
carcinoma the presence of giant nuclear cells or nuclear irregularity has been found 
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positively associated with turnour prognosis. [1831 
In advanced stage (FIGO HI - IV) epithelial ovarian cancer MNA has shown to be a 
most important prognostic factor for survival in both univariate and multivariate analysis. 
[6,158-9,1751 Standard deviation of the nuclear area (sdNA), 
[158,159,162,1751 
nuclear perimeter 
(NP), (158,1621 largest perpendicular axis, 
(158,1621 longest axis, 
[1621 
and shortest axis 
[1581 have 
also shown strong associations with survival. In advanced stage, significantly different 
morphometric features have been found between survivors and non-survivors, (1581 and 
morphometric data has appeared to increase the prognostic power compared to traditional 
morphology. 
A study comparing survival in advanced stage patients having second look 
laparotomy showed variations of nuclear size as significant predictive variables for 
survival with sdNA, MNP, largest perpendicular axis and largest axis all significantly 
correlating with survival. 
11621 
Nuclear morphometry has also been used to predict chemotherapeutic response. In 
advanced stage disease nuclear size has been noted as an important predictor of the 
sensitivity of turnour cells to cisplatin, [1841 with MNA and sdNA having significant 
correlation, and MNA the strongest prognostic factor in multivariate analysis. 11751 
Morphometric features have also been found to be predictors of survival in advanced 
ovarian cancer after cisplatin treatment, especially when combined with FIGO stage and 
preoperative turnour load. 11591 For prediction of chemosensitivity, morphometric data 
seems a stronger discriminator than subjective histological grading and staging (1841 
For prediction of OS and DFS this study on serous ovarian turnours has shown 
several nuclear morphometric parameters of significance on both univariate and 
multivariate analysis with high levels of measurement reproducibility 
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Prior studies have largely been performed with patients recruited from the late 
1970's to 1980's [6,145,158,159,162,173,175,1831 using relatively small population sizes, 
[6,145,158,159,162,1751 
advanced stage disease (HI-IV) only, 
[6,145,158,159,162,1751 
and have 
incorporated mitotic activity index 
[6,145,158,159,162,1751 
and epithelial area estimates 
(145,158,1751 
into their analysis and not concentrated purely on nuclear morphometry. Numerous studies 
have also been performed incorporating mixed histological sub-qTes. 
[6,158,173,159,162,1751 
Comparisons between studies are therefore fraught with difficulties and this may be 
reflected in morphometry and outcome. See table 7 for a summary of prior morphometric 
studies. 
There is increasing evidence suggesting that the molecular pathogenesis of the 
various histological sub-types of ovarian cancer may be distinct. A study performed by 
Miller 1991 [184] showed mucinous ovarian tumours to significantly differ in NINA 
estimations as compared to endometrioid and serous type turnours. A previous study on a 
pure serous group of ovarian turnours failed to show nuclear morphometry as an 
independent prognosticator for survival when results were corrected for clinical variables 
[1453 This suggests that perhaps histological sub-types should be considered as separate 
entities, certainly when considering nuclear morphometric analysis. 
Few prior studies have investigated the value of nuclear morphometry to predict 
chemotherapy response. [158,1621 Again these prior studies have been small, considered 
advanced stage disease only, with different histological sub-types, and, due to the 
recruitment dates of these studies, varying chemotherapeutic regimes have been employed 
in patient treatment. This is one of the few studies to consider patients treated with primary 
carboplatin or carboplatin / paclitaxel regimes. For prediction of chemotherapy response 
nuclear morphometric measurements were shown to achieve independent prognostic 
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significance. 
This study revealed extent of disease residuum to be an important factor for both 
survival and chemotherapy response prediction. Although the volume of residual tumour 
after debulking surgery appears to relate well to the clinical outcome there is no accurate 
measure and the critical volume for long-term survival remains unknown i. e. the precise 
definition of 'what is optimal surgery' has not been established. Present methods of 
quantifying residual tumour are imprecise [261 and the maximal diameter of residual disease 
is a very crude estimate. [321 This study regarded the extent of residual disease on the basis 
of < or >2cm total residuum. As variation exists in the meaning of optimal cytoreduction 
and estimation of extent of disease residuum caution must be taken in its interpretation 
with regards to survival benefit. 
Objective methods of turnour assessment are required as accepted prognostic factors 
should be reproducible. This study found nuclear morphometric measurements not only to 
be fast, easy to perform and highly reproducible, but results to also suggest that nuclear 
morphometry can provide significant information to predict both survival and 
chemotherapy response in platinum treated serous ovarian cancer. Interactions between 
various morphological and clinical variables are clearly complex and merit studies on 
larger patient groups and more stage I turnours, but our results suggest that morphometry 
may have a significant role to play in future therapeutic decision-making. 
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Chapter 8: Syntactic Structure Analysis 
8.1 Introduction 
8.1.1 Background 
Based on the theory of attributed graphs, [1851 syntactic structure analysis (SSA) 
deals with properties of cells or higher order structures. 
[1861 It is a fast, interactive, 
quantitative microscope technique used for describing the organisation of histologic 
[1871 
structures. SSA reduces a structure to points and interconnecting lines according to a 
certain mathematical function, [1871 and measures the arrangement (texture) of cells, 
independent of single cell properties. 11853 By choosing certain reproducible basic units of 
major interest, a geometric network can be constructed by graph theory i. e. nuclei (vertices 
or points) connected by lines (edges or intercellular bridges). 11881 
Malignant cells are identified primarily by their cellular atypia (abnormal size, 
shape etc) but, in cases with minimal atypia, disordered cell-to-cell arrangement may give 
[1891 
a clue in the diagnosis of malignancy. Carcinoma cells can be considered as single I 
points (vertices) described in a 2d space. The geometric arrangement of carcinoma cells 
(nuclei) can be analysed by connecting the points (nuclei) with related features by 
construction of a network graph. 
8.1.2 The Minimum Spanning Tree and Neighbourhood. Conditions 
The minimum spanning tree (MST) is a tree that connects all objects in a 
population in such a way that the sum of the length of the lines is minimal, 11901 It is a graph 
in which every point is interconnected by a line to one or more neighbouring points, 
without forming loops (per definition - the sum of the length of all lines must be minimal). 
1187,1 911 Therefore cell nuclei represent the vertices and the MST connects the vertices by 
lines (i. e. inter-nuclear distance). 
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Fig 8.1. Schematic Diagram - Computation of Neighbouring Nuclei: 
(Adapted from Fig 1. Scheme of computation of neighbouring glands, Kayser K, 
Shaver M, Modlinger K et al 1986) 11881 
Nuclei interactively marked and 
b d 000 num ere 
0 
Compute: nearest nuclei (nucleus 2) of (D---C) nucleus 1: Ist neighbour 
00 
Compute: 2" nearest nuclei (nucleus 4), 2 
not hidden beyond neighbours already 
computed (nucleus 2): 2 
nd Neighbour. 4 
Compute: 3 rd nearest nuclei (nucleus 5), 
situated between neighbours already 2 
computed (nucleus 2 and 4). Distance 
nuclei 2-4 < nuclei 1-5. Therefore 
nucleus 2 is a neighbour of nucleus 4: no 
neighbour. 
Compute: 41ý n-earest nuclei (nucleus 3), 
hidden beyond neighbour already 2 
computed (nucleus 2): no neighbour. 
2 
4 
To construct an MST, the centres of gravity of all nuclei are first marked and the 
distance between these vectors is calculated hence forming the first branch of' the tree by 
connecting the 2 nuclei having the shortest distance apart. The nuclei closest to either one 
of these points are then selected forming the second tree branch. The procedure continues 
until all nuclei are connected and linked in a tree. Spanning tree analysis may be used to 
compute the number of nuclei, the MST and varying inter-nuclear features (length MST - 4: ) 
total line length between nuclei; max. MST - the maximum distance between nuclei, min 
MST - the minimum distance between nuclei with standard deviations per parameter). 
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Another possibility in analysing relationships in the geometrical arrangement of 
cells is neighbourhood conditions. [1881 In normal human tissue every cell has at least one 
neighbour, in solid structures the number of neighbours is ideally normally distributed, [1921 
with the presence of 3 to 5 neighbours being typical of solid tissue. [1931 (See Fig S. 1: 
Computation of neighbouring nuclei). In cancer, structures become disordered and cell 
neighbourhoods are found to alter. 
Increasing evidence exists that the construction of attributed graphs is a suitable 
technique for the analysis of n-&roscopic growth patterns [1941 and can provide a powerful 
tool for objectifying tumour morphology. 11953 Because each tissue has a specific 
arrangement of cells with respect to each other (i. e. a specific architecture), SSA may be 
used to determine tissue origin. 11961 As malignant transformation occurs from well to more 
anaplastic, SSA could be considered a potent tool for recognising either turnour type or 
grade, [1961 and as SSA deals with properties of the geometric arrangement of cells it may 
well be used to reflect the biological behaviour of malignancies. [1861 
Construction of the MST can provide quantitative data that can be used for tumour 
classification and prognosis prediction, 11951 and, non-oriented complete graphs, based on 
neighbourhood condition have been found closely related to the histopathologic diagnosis. 
[1971 
8.2 Methods 
8.2.1 Tissue Processing: Immunostaining Technique 
MST analysis was performed on archived, paraffin-embedded, H&E stained sections 4- 
6ým thick. Sections were chosen containing the worst areas of atypia, as confirmed by 2 
pathologists. 
8.2.2 Computer-Aided Image Analysis System 
Computer aided image analysis was performed using a digital interactive video overlay 
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system (Qprodit, version 6.1; Leica, Cambridge, UK). MST measurements were performed 
in the department of pathology, Stavanger University Hospital, Stavanger, Norway under 
the supervision of Professor Jan Baak. 
8.2.3 MST Measurement 
To calculate the MST, archival H&E stained sections, 4-6microns thick, were used 
for each case. The MST was calculated from areas containing the worst atypia avoiding 
areas of necrosis, inflammation or calcification. Areas were selected, captured and frozen 
onto the screen and in each field of vision the centres of gravity for turnour cell nuclei were 
marked with an interactive graphic tablet. The minimal total line length then automatically 
connected these points without forming loops, thus forming the MST. MST measurement 
parameters included length (length MST), average length (mean MST), minimum length 
(min MST), maximum length (max MST), standard deviation (sdMST), and percentage 
connectivity to 1,2,3,4 and 5 nearest neighbours. (See Fig. 8.2 for MST Calculations). 
MST was calculated at a final on screen magnification X1200 (objective X40). Intra- 
field reproducibility was correlated as 97.6% for each turnour grade thus deemed adequate 
as turnour cells and non-turnour cells could be easily differentiated at this level. 
MST was calculated over an average of 10 fields of vision (marking an average 
of 870 points per case). The number of visual fields required to achieve adequate 
measurement precision were calculated by conducting running means and coefficients of 
error (CE). Measurements of MST parameters were conducted until a CE of <5% 
variability was achieved. (See Fig 8.3 for Coefficient of Error Graph's). 
The systematic sample of, on average 87 points per field over an average of 10 
fields was also used to cope with inter-field heterogeneity and to counteract boundary 
effects, (1951 as, the size of the MST may be limited by the borders of the visual field. 
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Fig 8.2: Calculation of the minimum spanning tree 
F 71 El t- Alo Fl 
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Fig 8.2 - Panel a. Shows initial tumour selection 
Panel b. marking of centres of gravity, and 
Panel c. MSTcomputation 
in grades 1-3 serous ovarian tumours. 
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8.3 Results 
SSA parameters were conducted on all available 132 cases. Analysis was performed 
using mean values for each measurement parameter (see Table ga: Mean SSA Parameters Z, 
and Clinicopathologic Data). P values <0.05 were regarded as being significant. 
Table 8a: Mean SSA Parameters and Clinicopathologic Data 
Clinical Mean sd Min Max I Nearest 2 Nearest 3 Nearest 
Parameters MST MST M ST MST Neighbour Neigbbours 
Neigbbours 
(R) (R) (R) (R) (%) (%) (%) 
FIGO Stage: - 7.793 1. () 1 3.932 13.477 22.4 47) 0 59.164 17.305 
7.7 24 1. '8ý00 3.680 13.145 24.099 7S. 819 41.748 
7.2 1S 1.742 1.483 11.946 24.011 55.9 16 18.714 
7.308 3.220 13.947 24.2 
T3 55.130 19.356 
Grade: 
1. ý, -, 0 'S, 3.733 12.974 -1.5 54 50.44-) 
17. OS4 
1 
7.27 0 1.762 3.514 12.207 1.78 0.3, S2 1". S()() 
2 
7.38S 1.7 9S 3.513 12.474 24.211 55.331 19.01 
Residual 
Disease: 7.55S L'I"'O'), -1.6())() 12.987 
1 ý'. I (y) 
<2cm 
7.336 1.774 3.529 12.266 1 S. 69-' 
. 
ýý2cm 
- 1 8.3.1 Reproducibility 
Intra- and interobserver reproducibility for SSA analysis was asscssed over 9 cases. 
Marking every nucleus in each field of vision was initially performed for MST 
calculations. This niethod was discounted however due to failure of reproducibility. 
IIII )I'd areas Problems of reprodLiCibility were encountered where fields of vision contained s( I 
Of tUnIOUr separated by glandular acim. Methodology for MST calculation was therefore Z-1 -- 
changed and nuclei in turnour areas were measured without crossing, lunlina and a fixed C- Z, 
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number of nuclei were marked for each field of vision (50-100 vertices). Intra observer 
reproducibility was excellent for mean MST (p=<0.0001), sd MST (p=<0.0001), max MST 
(p=<0.0001), min MST (p=0.002) and percent connectivity to I nearest neighbour 
(p=0.004). Inter observer reproducibility was excellent for mean and max MST only 
(p=0.02), but not significant for the remaining parameters. (See Table 8b: Reproducibility 
SSA). 
8.3.2 Correlations 
On linear regression analysis increase in mean, min, max MST and percent 
connectivity to 1&2 nearest neighbours were found to strongly correlate with FIGO stage. 
Percent Connectivity to I&2 nearest neighbours, were also found to strongly correlate with 
turnour grade, presence of ascites and the extent of residual disease. (See Table 8c: 
Correlations Between Parameters). 
8.3.3 Survival analysis 
OS data was available for all 132 cases. DFS data was available for 94 cases. P 
values below 0.05 were regarded as significant. 
8.3.3.1 Significance of single parameters to predict survival / Univariate Analysis 
SSA and Clinicopathologic variables were analysed using the univariate Cox model. Of 
the clinicopathologic data, FIGO stage (p=<O. O 1), ý turnour grade (p=0.002), pre-operative 
Ca125 levels (p=0.016), presence of ascites (p=<0.01) and extent of disease residuum 
(p=<0.01) were found to be significant predictors of OS. For SSA variables max MST 
(p=0.036), percent connectivity of 1 nearest neighbour (p=0.003) and 2 nearest neighbours 
(0.013) were also found to be significant predictors of survival with min MST being of 
borderline significance (p=0.053). The remaining variables were not significantly 
correlated. 
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For DFS, of the clinicopathologic data, FIGO stage (p=<0.01), turnour grade 
(p=0.001), pre-operative Ca125 levels (p=0.004), presence of ascites (p=<0.01) and extent 
of disease residuum (p=<0.01) were found to be significant predictors. For SSA variables 
min MST (p= 0.044), percent connectivity to I nearest neighbour (p=0.014) and 2 nearest 
neighbours (p=0.009) were also found to be significant predictors of DFS. Max MST 
reached borderline significance (p=0.057). The remaining variables were not found to be 
significant. 
8.3.3.2 Multivariate Survival Analysis 
SSA variables were analysed using the Cox multivariate model. Overall max MST 
(p=<0.01), sd MST (p=0.001), percent connectivity of 1 nearest neighbour (p=<0.01) and 2 
nearest neighbours (p=0.021) showed to be a significant predictor's of OS, with the 
remaining SSA variables adding no additional prognostic relevance. 
To estimate the simultaneous influence of all prognostic factors clinicopathologic and 
all SSA variables were entered into Cox regression analysis. This analysis showed 
overwhelmingly that extent of disease residuum was found to be a significant predictor for 
OS (p=<0.01) in this group of patients. The other factors did not achieve independent 
significance. 
Min. MST (p=0.016) and percent connectivitY to 2 nearest neighbour's (p=0.005) 
showed to be significant predictors of DFS, with the remaining SSA failing to achieve 
independent significance. Using Multivariate Cox models all clinicopathologic and SSA 
variables were considered. Overwhelmingly FIGO stage was found to be a significant 
predictor for DFS (p=<0.01) in this group of patients. The other factors did not achieve 
independent significance. (See Table 8d for positive findings on univariate and multivariate 
OS & DFS analysis. ) 
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8.3.4 Prediction of Chemotherapy Response 
Ca125 data was available for 69 cases, 5 of which did not receive primary 
chemotherapy so results of 64 patients were analysed. All patients were treated with 
primary carboplatin or carboplatin / paclitaxel regimes. 
Table 8d: Positive Findings - Univariate and Multivariate Survival Analysis SSA 
Parameter df Sig. 
(p) 
Exp 
(B) 
95% CI 
Lower 
95% CI 
Upper Parameter 
Sig. 
(p) 
Exp 
(B) 
95% 
Lower 
C1 
95% 
Upper 
C1 
Univariate A alysis 
Overall Survival Disease Free Survival 
Clinicopathol gic Variables Clinicopatho ogic Va riables 
Grade I1 -008 Grade . 004 
Grade(l) 1 . 004 . 344 . 168 . 705 Grade(l) . 00 1 . 
288 . 138 . 603 
I Grade(2) . 384 . 798 . 479 
1.327 
Stage 3 <. O I Stage <. O I 
Stage(l) I <. 0 1 . 151 . 056 . 403 Stage(l) . 037 . 
229 . 057 . 913 
Stage(2) 11 . 003 . 256 . 103 . 639 Stage(2) . 
417 . 592 . 167 1 
2.101 
11 Stage(3) . 555 1.421 . 442 
4.569 
Residual 
Disease 
I <. Ol . 341 . 204 . 568 Residual Disease 
<. O 1 . 341 . 204 . 569 
Presence of 
Ascites 
I <. O 1 . 377 . 237 . 599 Presence of Ascites 
<. O 1 . 358 . 212 . 605 
Pre-operative 
Ca125 
I 
1 
I 
. 016 
I 
1.000 
I 
1.000 
1 
1.000 Pre-operative 
Ca125 
MOI 1.000 1.000 1.000 
_SSA 
Variables SSA Variables 
Length NIST 1 0.29 Length NIST 0.407 
sdMean MST 1 0.49 sdMean MST 0.151 
Mean MST 1 0.092 Mean NIST 0.093 
Min MST 1 0.051 Min NIST 0.044 . 704 . 497 
Max MST 1 0.036 . 925 . 861 . 995 Max MST 0.057 
sd MST 1 0.125 sd NIST 0.136 
1 Nearest 
_Neighbour 
1 0.003 I 
1.187 1.057 1.333 
1 Nearest 
Neig bour 0.014 
1.161 1.032 1.307 
2 Nearest 
_Neighbours 
1 0.017 . 928 . 873 . 997 
2 Nearest 
Neighbours 0.009 . 
915 
1 . 
954 . 
980 
3 Nearest 
Neighbours 1 . 189 
3 Nearest 
Neighbours 0.130 
Multivariate Analysis 
_SSA 
Data 
_Max 
NIST (11 . 541 . 391 . 749 Min NIST . 016 . 647 . 454 . 
923 
sdMST 01 29.54 3.848 211.638 2 Nearest Neighbours . 005 . 901 . 939 . 
968 
I nearest 
neighbour 
I <. 01 1.48 1.241 1.764 
2 nearest 
neighbours 
1 . 021 832 
I- 
. 712 . 97-1 
SSA & Clinico ath logic Data 
Residual 
Disease 7 I 7 <. () 1 272 1. 150 1- . 494 Stage < . 1) 1 
Stage(l) (A) 1 . 090 . 021 . 
391 
j 
Stage(2) 
.01 . 199 . 0.1 
51 . 
767 
L I Sta", 
Of the clinicopathologic data, turnour grade (p=0.02), FIGO stage (p=0.004), extent 
of residual disease (p=<0.01) and presence of ascites (p=0.004) were found significant 
predictors of chemotherapy response with an overall correct classification to chemotherapy 
response group being 70.3%, 68.8%, 68.8% and 67.2% respectively. For the spanning tree 
data 2 nearest neighbours (p=0.006) was found to be a significant predictor of 
chemotherapy response with an overall correct classification to chemotherapy response 
group of 53.1 %. The remaining spanning tree parameters were insignificant. 
To estimate the simultaneous influence of prognostic factors all clinicopathologic 
and SSA variables were entered into multivariate logistic regression analysis. This analysis 
showed extent of residual disease (p=0.005) to be the strongest predictor of chemotherapy 
response with correct overall classification rates of 66.1%. The remaining parameters did 
not retain significance. (See Table 8e Logistic Regression Analysis: SSA & 
Clinicopathologic Data and Chemotherapy Response). 
8.4 Discussion 
Variability of intercellular arrangement may be an important clue to the diagnosis 
of malignancy. In the differential diagnosis of lung turnours prior studies showed SSA to be 
a valuable tool in the classification of mesotheliorna and a supplement to visually appraised 
diagnosis, [1961 with malignant mesothelioma being readily distinguishable from 
adenocarcinorna by internuclear distances. [1981 Studies have found MST able to easily 
distinguish small cell from non-small cell anaplastic carcinoma. [1971 SSA was also shown 
to provide a powerful tool for specifically assessing, at least partially, some of the 
cytonuclear changes in dysplasia of colorectal adenornatous polyps. [1871 
Prior SSA studies in lung carcinoma revealed patient survival to be strongly related to 
structural features, (1941 and smaller inter-nuclear distances to have worse prognosis than 
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Table 8e: Table 8e Logistic Regression Analysis: SSA & Clinicopathologic Data 
and Chemotherapy Response 
Parameter 
df 
ý Sig 
(p)* 
I Correct 
Classification 
95% CI 
Lower 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Vari ables 
Grade 2 . 002 68.81( 
Grade(l) 2.412 67.918 
Grade (2) . 728 7.917 
Stage 3 . 004 68.81/( 
Stage(l) 1.028 560.178 
Stage(2) 
. 385 78.573 
Stage (3) . 121 17.913 
Residual Disease I <. O 1 70.3 "/, r 2.420 29.383 
Presence of Ascites 1 . 004 67.2 cl, 1.566 13.822 
Pre-operative 
Ca 125 1 . 093 
Age 1 . 554 
SSA Variables 
2 Nearest 
Neighbours 1 . 006 53.114 1.042 1.460 
Length MST 1 . 508 
Mean MST 1 . 900 
sd Mean MST 1 . 663 
sdNIST 1 . 848 
Max NIST 1 . 751 
Min MST 1 . 797 
1 Nearest 
Neighbour 1 . 059 
Multivariate Analysis 
SSA & Clinicopathologic Data 
Residual Disease 1 . 005 66.114 1.524 19.849 
Table 8e illustrates univariate and multivariate logistic regression analysis of 
SSA features, clinicopathologic parameters and prediction of chemotherapy 
response. Although number of nuclei with 2 nearest neighbours showed 
significance at univariate level, independent prognostic significance was not 
achieved. (p values <0.05 were regarded as significant). 
larger distances in small cell anaplastic carcinoma of the lung. 11971 Mean and max MST 
have also exhibited significance for survival in breast carcinoma. 1")"I With regard to 
neighbourhood parameters the maximum number of nuclei with 2 or 3 neighbours, were 
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found to be the best prognosticators in breast carcinoma, [2001 in uveal melanoma, 11933 and 
in predicting the development of metachronous cancer in colorectal adenomas. [2011 
The present study of serous ovarian turnours encountered reproducibility problems 
whilst computing both the MST and neighbourhood features. Although intra-observer 
reproducibility was generally excellent for MST parameters, interobserver reproducibility 
was less impressive. Neighbourhood features remained overall poorly reproducible. It thus 
may be better to replace interactive morphometric SSA and MST analysis, by automated 
digital image analysis. 
In invasive breast cancer both MST and neighbourhood features have been reported 
as highly reproducible. [199-2001 Some measurements however were repeated using the same 
static field of vision by both observers. In uveal melanomas, intra-observer reproducibility 
was found acceptable with a mean correlation coefficient of 0.70, yet no inter-observer 
correlations were reported. 11931 In advanced ovarian cancer reproducibility has been quoted 
as high for intra-observer and as acceptable for inter-observer analysis with, as in this 
study, neighbourhood variables remaining less well reproducible. [190] 
Use of image analysis should essentially offer reduced disagreement and a possibility 
to compare inter-laboratory data. [196] Computation of the MST may become difficult where 
nuclei overlap i. e. when no agreement is met as to whether overlapping nuclei should be 
counted as 1 or 2 discrete entities, and where visual fields include glandular acini. Serous 
ovarian tumours represent a markedly heterogeneous group with ovarian cancer certainly 
having more variation in nuclear spacing than for example melanomas or breast carcinomas. 
Such variations in tumour area, cyst size and e. g. papilla formation may reflect the finding of 
high inter-observer variation and hence limit the use of these methods when applied to 
serous ovarian turnours. Also for MST and neighbourhood analysis to offer the possibility to 
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compare study data, analysis should not be performed on identical static images, as in reality 
no pathologist would choose precisely the same region for analysis as another. 
This study found MST and neighbourhood parameters to strongly correlate with 
FIGO stage, with nearest neighbour parameters also strongly correlating with tumour 
grade, extent of residual disease and the presence of ascites. It therefore appears that MST, 
and neighbourhood parameters, are associated with tumour aggression. Univariate analysis 
revealed several SSA parameters of significance with wider inter-nuclear distances being 
associated with improved OS and DFS, and able to predict response to chemotherapy. 
Multivariate combination of SSA parameters improved the prognostic capability of 
standard deviation MST suggesting that variability in nuclear arrangement may be a more 
important finding for the prediction of OS. Multivariate analysis combining SSA and 
clinicopathologic parameters however did not reveal SSA features as independent 
prognosticators for either survival or prediction of chemotherapy response. 
Further SSA sub-group analysis in this turnour set of early (FIGO I& 11) and late 
stage turnours (FIGO 1H & IV) (see appendix 3) also failed to achieve independent 
significance on multivariate analysis. This may reflect that this data set contained only 31% 
early stage turnours (16% were Stage 1,15% stage H) with the majority of cases being of 
more advanced stage (69%) and grade (83%). Clearly a large study of FIGO stage I turnours 
might be of particular use here in differentiating the real value of SSA parameters when 
freed from the effects of advanced disease. 
Where marked tumour heterogeneity occurs, we must consider that the set of points 
representative of the biological sample is derived from a larger set of points, so has to be 
large enough to enable recognition of the biological sample. [2011 In practice the size of the 
MST will always be limited by the borders of visual field, 11951 be it from natural boundary 
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effects such as size of tumour area, cystic walls, the presence of papillae or from system- 
induced boundary effects. Magnification must be large enough to adequately differentiate 
the areas and points of interest from non-tumour areas but increased magnification in turn 
reduces the size of the visual field and hence the size of the MST. It is therefore not possible 
to eliminate all of the boundary effects of an MST. 12021 A prior study had suggested that 
boundary effects were observed mainly when the number of points in the MST was smaller 
than 64.11951 Our study assessed an average of 870 points over 10 fields giving a mean count 
of 87 points per field. Sub-analysis of only those cases containing >65 points per field also 
failed to achieve independent prognostic significance for SSA features. As acceptable 
intraobserver reproducibility and significant results on univariate analysis were achieved 
with this method we feel that if such systematic error occurred then it is likely to be a 
limiting factor in the practical application of this technique. 
Use of lower magnification, combination of adjacent visual fields, or larger field 
sizes may be the ultimate answer but this would reduce operator precision at accurately 
identifying points of interest and have obvious time implications. Again automated image 
analysis probably must be used for highly reproducible SSA and MST analysis. 
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Chapter 9. Angiogenesis 
9.1 Introduction 
9.1.1 Background 
Angiogenesis is the formation of new blood vessels by proliferation of new capillaries 
from pre-existing vessels. [2031 Angiogenesis is linked to physiological conditions such as 
ovarian and endometrial alterations during the menstrual cycle, wound healing and tumour 
growth. [2041 When considering turnour proliferation, the 'pre-vascular' phase is associated 
with limited turnour growth with few or no metastases, the 'vascular' phase with increased 
turnour growth and metastatic spread. [2031 Pre-vascular turnours may remain dormant in-situ 
for months or years. [2051 
Tumour angiogenesis is thought initiated by an increase in the level of angiogenic: 
stimuli and a concomitant decrease in the level of angiogenic inhibitors. [2061 'Once tumour 
has occurred, every increase in tumour cell population must be preceded by an increase in 
new capillaries that converge upon the tumour. ' [2061 The pre-vascular phase can maintain 
tumour only up to a tumour size of <2mm. [2071 Beyond this critical volume the onset of 
angiogenesis permits rapid expansion of the tumour population, if the tumour cells are 
capable of rapid proliferation. [2081 Micro vessels supplying turnours are strikingly hyper 
permeable to circulating plasma proteins (2031 and neoplastic capillaries have fragmented, 
leaky basement membranes making them more accessible to tumour cell migration and 
facilitation of haernatogenous metastasis. (2091 Highly angiogenic turnours may therefore 
facilitate a rapidly increasing volume of turnour cells, provide access to the circulatory 
system and promote the development of lymphatic channels. [2101 
There is mounting evidence that, in general, turnour progression and metastasis are 
angiogenesis dependent [2111 with studies demonstrating direct correlation between the 
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degree of angiogenesis in turnours and more aggressive tumour biology. J2103 It is possible 
therefore that the degree of angiogenesis may be a marker for the aggressiveness of ovarian 
cancers [2101 and could be used as a prognostic factor for survival. 
9.1.2 Assessment of Angiogenesis 
Angiogenesis is assessed quantitatively by measuring intraturnoral micro vessel 
density (IMVD or MVD). J2123 IMVD is assumed to reflect the intensity of tumour 
angiogenesis. The most commonly used antibodies or endothelial cell markers, used to 
highlight blood vessels by IHC are anti-factor VIII antigen, CD31 and CD34, being assessed 
under high power microscopy. Gross examination, angiography, and vascular injection 
techniques could conceivably be used to evaluate the degree of turnour vascularity, [2131 but 
practically, angiogenesis assessment is conducted by observing and quantifying 
vascularization histologically, to provide an estimate of the final product of a complex 
process. 
(2141 
Several methods of IMVD measurement have been used including manual counting of 
micro vessels in turnour regions of greatest vascularity, estimation using point counting, 12141 
and multipararnetric computer analysis systems. The most conventional method of IMVD 
estimation is by 'hot spot' counting as defined by Weidner and associates. [2151 The 
heterogeneity of tumour vasculature is well recognised and most prognostic studies evaluate 
MVD in regions of high MVD or areas termed as vascular 'hot spots. ' [2161 Angiogenesis is 
assessed in areas of turnour stroma., with the highest angiogenic density in areas surrounded 
by solid tumour. [2171 These areas of greatest MVD would theoretically be more likely to 
disseminate cells and produce rapidly growing, clinically detectable metastases. J2181 Once 
regions with elevated vascular density, or 'hot spots', are identified then positive lHC 
staining is counted as a microvessel. Small vessels are counted including capillaries, 
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arterioles and venules. 12171 Any highlighted endothelial or endothelial cell cluster, clearly 
separate from adjacent microvessels, tumour cells and other connective tissue elements is 
considered as a single countable vessel 12121 (i. e. no lumen or red blood cell's required). 
Larger arteries with thick smooth muscle walls and widely distended venous sinuses should 
be excluded. [2171 
Problems may arise in variations of vessel counting techniques. Visual counting at 
high magnification is tedious and may be subject to poor reproducibility. [2191 Manual 
counting may certainly have limitations. Single tortuous vessels may be counted as several 
vessels, distinguishing individual vessels may not be possible in areas of tangled capillaries, 
[2201 and no agreement may be met if only luminal structures are counted. Further limitations 
may result from observer error or sampling error as marked heterogeneity in MVD may be 
observed in different areas of the same tumour. [2041 Since identification of the neovascular 
'hot spot' relies upon the judgement of the 'pathologist' the relative skills and experience of 
different pathologists may be problematic, with the inexperienced pathologist having a 
tendency to overestimate the number of vessels. [2211 
Image analysis techniques are used as an objective method of quantifying angiogenesis 
to overcome the potential subjectivity of manual counts. [2201 Application of computer-aided 
image analysis may help to standardise microvessel counts and help eliminate observer 
variables such as inexperience and 'hot spot' selection bias, [2221 but, image analysis may 
also result in multiple counts of the same vessel and background noise may read as falsely 
positive. [2201 Based on the assumption that the maximally vascular area within a tumour 
determines metastatic potential, automated morphometric techniques that provide an average 
micro vessel count may give less prognostic information. [2141 Standardisation of 
angiogenesis quantification is necessary to facilitate confirmation of the suggested 
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prognostic value of IN4VD in different tumour types. [2121 
9.1.3 Angiogenesis Markers 
Anti Factor VH1 antigen (von Willebrand Factor Antibody), CD31 (PECAM-1, 
platelet endothelial cell adhesion molecule-1) and CD34 are the most commonly used 
antibodies, or endothelial cell markers, used to highlight blood vessels by IHC. [2231 
9.1.3.1 Anti Factor VIII Antigen 
Factor VIH is a glycoprotein present in human plasma. Factor VIII is reported 
present in human endothelial cells, megakaryocytes and platelets. As Factor VHI related 
antigen is present in plasma and platelets, positive staining of intravascular plasma 
inevitably occurs in areas of haemorrhage, vascular damage and leakage of plasma. [2241 In 
cases of ovarian cancer anti-factor VHI has occasionally been shown to stain lymphatics, 
[2031 and has appeared to stain fewer microvessels. [2161 Generalised background staining at 
the site of exudation, haemorrhage and necrosis has seemed to make some cases un- 
interpretable for vWF. [2251 Therefore anti factor VIII is not used in this study. 
9.1.3.2 Anti CD31 
CD31, also known as PECAM-1 (platelet endothelial cell adhesion molecule 1), is a 
130kDa integral membrane protein mediating cell-to-cell adhesion. CD31 is expressed on 
the surface of adult and embryonic endothelial cells and is weakly expressed on many 
peripheral leucocytes and platelets. It has also been detected on bone marrow-derived 
haernatopoietic stem cells and embryonic stem cells. [2261 In ovarian cancer CD31 has been 
found more sensitive for identification of vessels, but not specific i. e. can bind to 
granulocytes, monocytes, megakaryocytes, platelets and occasional plasma cells, in addition 
to endothelial cells. [2101 CD31 has also been found to occasionally stain inflammatory cells. 
[2031 Anti CD31 showed stronger staining in small vessels and capillaries than in large 
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vessels with no connective tissue elements positive. [2251 
9.1.3.3 Anti CD34 
CD34 antigen is a single chain trans-membrane glycoprotein, Mr 105 to 120 kDa. 
The CD34 antigen is present on immature haernatopoietic precursor cells and all 
haernatopoietic colony-forming cells in bone marrow and blood. 12271 In ovarian cancer 
studies, anti CD34 has shown to react with endothelia of arteries, venules and capillaries and 
to be more intense in small vessels, especially capillaries. 12251 Anti CD34 has shown 
positivity in some stromal elements, [203,2161 but antibodies to CD31 and CD34 have been 
shown to highlight similar numbers of micro vessels. (2161 In image analysis of epithelial 
ovarian carcinoma anti CD34 was found to have the highest specific staining and least 
background stain. [2201 It has been implied that anti-CD34 may be a more reproducible and 
reliable antibody for routine studies. 
[2121 
Increased IMVD appears to adversely effect prognosis suggesting that angiogenic 
properties are correlated with turnour aggressiveness. [2051 Evidence of angiogenesis 
dependence in carcinoma of the ovary is apparent in peritoneal metastasis. Metastasis to 
the peritoneal membrane, as tiny avascular seeds, rarely grows beyond a limited size until 
after vascularisation. [2081 The early and extensive metastatic dissemination of ovarian 
cancer suggests that angiogenesis may be an early and important event. 12071 This could be 
of use in identifying those patients at increased risk of relapse or more distant 
dissemination. [2071 
9.2 Methods 
9.2.1 Tissue Processing: Immunostaining Technique 
IHC studies were performed on 4-6gm formalin-fixed, paraffin-embedded tissue 
using te peroxidase-anti peroxidase (PAP) complex technique. Areas representative of the 
127 
invasive component of the tumour were selected from archived paraffin-embedded sections 
stained with Haernatoxylin &Eosin (H&E). 2 sections containing areas of worst atypia 
were selected and immunostained from each case. Sections were immunostained, using 
antibodies to the endothelial cell marker CD34 (Mouse Anti-CD34 (Clone MyIO)(Beckton 
Dickinson, Cat#347660) and CD31 (Rat Anti-Mouse CD31 (PECAM-1) (Pharmingen, 
Cat#553370). A positive and negative control slide was included in each staining run. No 
counterstain was used. Sections were again washed then dehydrated, cleaned and mounted. 
9.2.2 Manual Counting 
An initial 10 cases were randomly selected from the study group for staining with 
both CD31 and CD34 with a methylene blue counter-stain. Counts were performed using 
both staining techniques. Anti CD34 was found to have the highest specific staining and 
least background staining compared to CD3 1. Therefore all cases were stained with CD34 
without counter-stain to be further used for both manual counts and image analysis 
techniques. 
9.2.3 Intratumoral Microvessel Density Determination 
Sections were scanned under light microscopy for areas of most intense 
neovascularisation at low magnification (100X). Microvessel density for CD34 was 
heterogeneous throughout the tumour sections, but occurred most frequently at the 
periphery of the invasive turnour. Sections were scanned in parallel to the original H&E 
stained slides to assure analysis was restricted to invasive carcinoma. 
Once neovascular 'hot spots' were identified, individual microvessels were counted 
in a 20OX and 40OX field. 'Any brown staining cluster that was clearly separate from 
adjacent microvessels, tumour cells and other connective tissue elements was considered as 
a single countable microvessel. ' [141 Luminal structures or the presence of red blood cells 
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was not deemed necessary to define a micro vessel. Each count was expressed as the mean 
number of micro vessels per field (mean MVD) or the highest count (max MVD) identified 
within any X200 or X400 field. Two observers without prior knowledge of patient 
characteristic's or outcome made assessments. 
9.2.4 Computer-Aided Image Analysis 
9.2.4.1 Computer-Aided Image Analysis System 
Computer aided image analysis was performed using a digital interactive video 
overlay system (LEICA Q500MC, Leica, Cambridge, UK) for image analysis microvessel 
counts and estimation of endothelial areas. A digital interactive video overlay system 
(Qprodit, version 6.1; Leica, Cambridge, UK) was used for angiogenesis spanning tree 
estimates. 
9.2.4.2 Image Analysis Microvessel Determination 
For each case, image analysis was performed on the same 'hot spot' area as manual 
micro vessel density determination, using a X25 objective. Each pixel was calibrated at 
0.00323g. The live image was initially set up with regards to white balance to attain even 
illumination. The selected area was then scanned using a set of initially 3 and up to 10 
fields. A set of 10 fields was used to ensure maximum 'hot spot' areas were included and 
to reduce area selection bias. Once acquisition of the live image was attained the image 
was converted to binary to enable further image processing prior to measurement. Grey 
level detection was ad usted to corresponded well to CD34 positive areas and negate any j 
background 'noise. A Field measurement was automatically attained (representing a 
summed value for all selected regions within the measurement frame) to attain the area 
fraction. This area occupied by endothelial cells, automatically detected by the image 
analysis system, expressed as a percentage of total examined area, equated the endothelial 
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area. Pixel counts were used for the endothelial area measurement. 
Sections were scanned in parallel to the original H&E stained slides to ensure 
analysis was restricted to invasive carcinoma. 2 observers without prior knowledge of 
patient characteristic's or outcome made assessments. 
9.2.4.3 Spanning Tree analysis 
To calculate the MST and neighbourhood parameters anti CD34 stained sections 
were examined adjacent to original H&E sections to ensure analysis was restricted to 
invasive carcinoma. The MST was calculated from areas of highest microvessel density. 
Areas were selected, captured and frozen onto the screen. In each field of vision the centres 
of gravity for each microvessel were interactively marked with a graphic tablet and the 
area of interest chosen. Points were automatically connected by the minimal total line 
length, without forming loops, thus forming the MST. An average of 27 points per field 
were analysed over an average of 14 fields per case. 
MST parameters measured included mean (mean MST) length (length MST), min 
length (min MST), max length (max MST) and standard deviation (sdMST) thus denoting 
mean, min and max intercapillary distances. Percent connectivity to 1,2,3 and 4 nearest 
neighbours was also calculated. ConnectivitY to 4 nearest neighbours was a rare event and 
thus excluded from further analysis. 
MST was calculated at XIOO final magnification. Intra-field reproducibility was 
calculated as >95% thus deemed adequate as microvessels could be easily identified at this 
level. The number of visual fields required to achieve adequate measurement precision 
were calculated by conducting running means and coefficients of error. Measurements of 
mean MST were conducted until a CE of <5% variability was achieved. The systematic 
sample of, on average, 14 fields of vision was also used to cope with inter-field 
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heterogeneity (i. e. confronts variation of microvessel density in different fields of vision) 
and to counteract boundary effects [1951 as the borders of visual fields may limit the size of 
the MST. 
9.3 Results 
Analysis was performed on all available 132 cases using mean values for each 
measurement parameter (see Table 9a: Mean Microvessel Parameters and 
Clinicopathologic Data). P values <0.05 were regarded as significant. Figure 9.1 illustrates 
CD34 staining as related to patient survival. 
Fig 9.1: CD34 Staining and Survival: shows CD34 staining as related to patient 
Survival 
Fig 9.1 a 
Fig 9.1 c 
Fig 9.1 b 
f 
Fig 9.1 d 
Fig. 9.1 
Panel a- Survival 6 months -FIGO 111, Grade 1; 
Panel b- Survival 21 months - FIGO 111, Grade 3; 
Panel c- Survival 72 months -FIGO IV, Grade 2; 
Panel d- Alive at study closure- FIGO 111, Grade 3 
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9.3.1 Reproducibility 
9.3.1.2 Reproducibility CD31 and CD34 
Ten cases were selected and stained for CD31 and CD34. Manual counts were 
performed and assessed for reproducibility of technique at 40OX magnification. Both CD31 
and CD34 showed good reproducibility for MVD determination (r=0.9957 and r=0.9996 
respectively). High Correlation (r= 0.993) was also achieved between CD31 and CD34 C 
counts (see table 9b: CD31 & CD34 Correlations). CD31 was found to be more difficult to 
count due to stain intensity and more prominent background staining. Further cases were 
therefore only stained with CD34 to enable use in both manual counting and image analysis 
techniques. 
Table 9b: CD31 and CD34 Correlation 
Patient number 
CD34 Round CD34 Round CD31 Round CD31 Round 
1 2 1 2 
5 18.75 19 17.25 16.75 
6 34.5 35.75 30.25 31 
13 40.75 40.25 48.25 48 
15 40.75 41.5 30.5 31 
17 18.5 18.25 18.75 18.25 
18 40.5 40.75 25.5 25.75 
19 67.5 66.75 65.5 66.25 
21 15.25 16 14.75 14.75 
22 30.5 30.5 28.75 28.75 
28 10 10 10.75 10.75 
Single 
Observer 0.9996 r= 0.9957 
Reproducibility 
Correlation 
CD34 + CD31 i-=0.993 
9.3.1.3 Reproducibility CD34 Manual Count 
Ten cases were randomly selected as stained with CD34- Manual counting was 
performed at 20OX and 40OX and intra and interobserver reproducibility calculated for 
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both mean micro vessel density and highest count. All parameters were highly 
reproducible. (See table 9c: Intra- and Inter-observer Reproducibility CD34). 
Table 9c: Intra- and Inter-observer Reproducibility CD34 
40OX Mean 40OX Max 20OX Mean 20OX Max 
MVD Count MVD Count MVD Count MVD Count 
Observer 1 2 1 2 1 2 1 Ei 2 
Correlation Intra ' Inter Intra Inter I Intra Inter ntra 
1 
Inter 
r 0.8097 0.868 0.8303 0.8595 0.9758 0.9771 )g 9 (0.98 0.978 
r2 0.6556 0.7534 0.6893 0.7388 0.9521 0.9457 0.978 0.9566 
p 0.045 0.0011 0.029 0.0014 <0.000 I <0.000 I <0.000 I <0.000 I 
Spearman 0.679 0.679 0.8511 0.772 0.8024 0.8424 0.9362 0.8632 
2 Tailed p_ 0.0306 0.0029 0.0126 0.0072 0.0037 0.0037 <0.0001 <0.000 I 
Table 9c illustrates reproducibility of manual MVD counts. All manual counts, irrespective of 
magnification (X200 or X400) were shown to be highly reproducible at intra- and interobserver 
level 
9.3.1.4. Reproducibility: Image Analysis Microvessel Counts 
Ten randomly selected cases stained with CD34 were counted and intra and interobserver 
reproducibility calculated for both mean and max image analysis micro vessel counts and 
mean and maximum endothelial areas. Intra and inter observer reproducibility for mean 
and max microvessel counts and mean endothelial area were highly reproducible Z, 
p<0.0001. Intra observer (p<0.0001) and inter-observer (p=0.0014) counts for max 
endothelial area were also highly reproducible. (See table 9d Reproducibility Image C- LI 
Analysis Microvessel Counts). 
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Table 9d: Reproducibility Image Analysis Microvessel Counts 
Mean MVD Max MVD Mean Max 
Countimage Countimage Endothelial Endothelial 
ana ysis analysis Area Area 
Observer 1 2 1 2 1 2 _ 1 2 
Correlations Intra Inter Intra Inter Intra, Inter Intra Inter 
r 0.9984 0.9908 0.9969 0.9948 0.9945 0.9231 0.9802 0.8598 
r2 0.9967 0.9817 0.9939 0.9895 0.989 0.8552 0.9608 0.7393 
1) <0.000 I <0.000 I <0.000 I <0.000 I <0.000 1 0.0001 <0.000 1 0.0014 
Spearman 0.9879 0.9152 0.9879 0.8788 0.9758 0.8909 0.9636 0.903 
2 Tailed p <0.000 1 0.0005 <0.000 1 0.0016 <0.0001 0.0011 <0.000 1 0.0008 
Table 9d illustrates reproducibility of image analysis microvessel counts, and endothelial area 
estimates. All counts were shown to be highly reproducible at intra- and interobserver level. 
9.3.1.5 Reproducibility: Spanning Tree Analysis Angiogenesis 
Five randomly selected cases, stained with CD34, were measured for spanning tree 
and nearest neighbour parameters and intra and inter observer reproducibility calculated 
for mean MST, max MST, min MST, sdMST and 1,2 and 3 nearest neighbours. Max L- 
MST, min MST, sdMST and I nearest neighbour showed to be highly reproducible (see 
table 9e: Anoiouenesis MST - Reproducibility). Z. ý t7l 
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9.3.2 Correlations between Parameters 
On linear regression analysis the manual angiogenesis parameters, of increasing 
mean and maximum counts at 20OX and 40OX, were found to strongly correlate with 
increasing automated microvessel counts, endothelial area estimates and angiogenesis 
spanning tree factors. Correlation with the extent of residual turnour was also highly 
significant (p<0.0001) as was correlations with FIGO stage and presence of ascites. Manual 
angiogenesis parameters were also found to correlate with pre-operative Ca125 levels. 
Neither age, nor tumour grade correlated with any of the angiogenesis parameters. For all 
angiogenesis correlations see table 9f and 9g. 
9.3.3 Survival Analysis 
Survival data was available for all 132 cases. P values below 0.05 were regarded as 
significant. 
9.3.3.1 Significance of single parameters to predict survival / Univariate Analysis 
Angiogenesis and clinicopathologic variables were analysed using the univariate 
Cox model. Of the clinicopathologic data, FIGO stage, tumour grade, pre-operative Ca125 
levels, presence of ascites and extent of disease residuum were found to be significant 
predictors of OS and DFS. All angiogenesis parameters were found to be highly significant 
predictors for OS and all except number of capillaries with 3 nearest neighbours, were 
found to be highly significant predictors for DFS. 
9.3.3.2 Multivariate Analysis: Manual Counts and Survival 
To estimate the simultaneous influence of prognostic factors all clinicopathologic 
and manual count angiogenesis variables were entered into Cox regression analysis. This 
analysis showed mean count at X400 magnification p=<0.01) and mean count at X200 
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magnification (p=<0.01), and FIGO stage (p=0.002) to be significant predictors for DFS. The 
other factors were not of additional prognostic relevance. 
9.3.3.3 Multivariate Analysis: Angiogenesis Image Analysis and Survival 
To estimate the simultaneous influence of prognostic factors all clinicopathologic and 
angiogenesis image analysis variables were entered into Cox regression analysis. This analysis 
showed mean endothelial area (p=<0.01) and extent of disease residuum (p=0.001) to be 
significant predictors for OS and mean endothelial area (p=<0.01) and stage (p=0.001) to be 
significant predictors for DFS. The other factors were not of additional prognostic relevance. 
9.3.3.4 Multivariate Analysis: Angiogenesis Spanning Tree Analysis and Survival 
To estimate the simultaneous influence of prognostic factors all clinicopathologic and 
angiogenesis spanning tree variables were entered into Cox regression analysis. This analysis 
showed max MST (p=<0.01) and number of capillaries with 2 Nearest Neighbours (p=O. <0.01) 
to be significant predictors for OS and max MST (p=<0.01), number of capillaries with 3 
Nearest Neighbours (p=0.032) and FIGO stage (p=<0.01) to be significant predictors of DFS. 
The other factors were not of additional prognostic relevance. 
9.3.3.5 Multivariate Analysis: All Angiogenesis Variables and Survival 
To estimate the simultaneous influence of prognostic factors all clinicopathologic and all 
angiogenesis variables were entered into Cox regression analysis This analysis showed Max 
MST (p=0.009), Length MST (p=0.005), 1 Nearest Neighbour (p=<0.01) and X400 Mean count 
(o=0.0001) to be significant predictors for OS and mean endothelial area (p=<0.01) and FIGO 
stage (P=0.001) to be significant predictors for DFS. The other factors were not of additional 
prognostic relevance. Table 9h illustrates positive results for univariate and multivariate analysis. 
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Table 9h: Positive Findings - Univariate and Multivariate Analysis 
Clinicopathologic & Angiogenesis Parameters 
df Sig. Exp 
(B) 
95% cl 
Lower 
95% 
CI 
Upper 
Parameter Sig. Exp 
(B) 
95% 
Lower 
CI 
9% 
Upper 
CI 
Univariate An lysis 
Overall Survival Disease Free Survival 
Clinicopathologic Va iables Clinicopathologic ariables 
Grade 2 . 
008 Grade 
. 004 --Er-ade(l) 1 
. 
004 
. 
344_ 
. 
168 
. 
705 Grade (1) 
. 00 
1 
. 
289 
. 
138 
. 603 
I Grade (2) 
. 
384 
. 
798 
. 
479 1.327 
Stage 3 < Stage <. 01 
Stage (1) 1 
. 
151 
. 
056 
. 
403 Stage (1) 
. 037 . 
228 
. 
057 
. 
913 
Stage (2) 1 . 
003 1 . 
256 
. 
103 
. 
639 Stage (2) 
. 417 . 
592 1 . 
167 2.101 
I Stage (3) 
. 
555 1.421 
. 
442 4.568 
Residual Disease 1 
. 
341 
. 
204 
. 
568 Residual Disease <. 01 . 
341 
. 
204 
. 
569 
-Fr-esence of Ascites 1 . 
377 
. 
237 
. 
599 Presence of Ascites . 
358 
. 
212 
. 
605 
-ýrc operative CaI25 1 
1 
. 
016 1.000 1.000 1. ()()0 Pre-operative Ca125 
. 001 
LOW I- 
000 f -I . (X)() Angiogenesis Variables Angiogenesis Varia bles 
X2(K) mean NIVI) Count I <. O 1 1.021 1.017 1.025 X200 mean NIVI) <. O 1 1.013 1.008 1 1.019 
-jý2-oo max MVD Count <. j) 1 1.018 1.015 1.0-)-) X200 ma-xM'v'l) 1.011 1.007 1.015 
5ý4-(W -an MVD Count I <. O 1 1.041 1.033 1.049 X400 mean MVI) <. O 1 1.031 1,020 1.042 
X400 max MVD Count 
- 
I <. 0 1 1.036 1.029 1.044 1 X400 max MVD <. O 1 1.023 1,014 1.033 
Endothelial Area ýican 
- 
I <. O 11 1.451 1.329 1.584 1 Mean End <. O 1 1,635 1.334 2.004 
ndothelial Area -ýjax I 
- - 
I <. O 1 1.2 34 1.165 1.307 Max Endo Area <. O 1 1.226 1.119 1 1.343 
MVD count image ean ýi 
analysis 
I <. O 1 1.008 1.006 1.009 Mean image analysis 
count 
<. O 1 1.005 HX)2 HX)8 
Max image analysis 
count 
I <. O 1 1.006 1.005 1. ()()8 Max image analysis 
count 
<. O 1 1.226 1.119 1.343 
Mean MST I <. Ol . 
790 
. 
750 
.8 
32 Mean MST <. O 1 . 
901 
. 
857 . 947 
WMST I <. O 1 . 636 . 570 . 710 sdMST <. O 1 . 905 . 715 . 
907 
Max MST 
- 
I <. O 1 . 
866 
. 
940 
. 
992 Max MST <. O 1 . 929 . 
9(X) . 959 Kiin MST I 
<. O 1 . 
719 
. 660 . 782- 
Min MST <. O 1 . 
867 
. 
900 . 
939 
I nearest neighbour I <. O 1 . 756 . 698 - . 
919 1 nearest neighbour 1 . 00 1 . 986 I . 825 1 . 951 
2 nearest neighbours I <. O 1 1.137 1.0 79 1.197 2 nearest neighbours; 1 . 019 
1 1.074 1 1.012 1.141 
3 nearest neighbours 1 
. 037 1.089 1.005 1.181 
Multivariate Analysis 
--ýianual Angiogenesis & Clinicopatholopic Variables 
- idual Disease iie7s 1 1 . 002 
1 
. 
379 203 I 
. 
707 X200 mean NIVI) 
Count 
<. O 1 1.010 1. (X)5 1.016 
X4oO Mean MVD Count I <. Ol TO, 1 1-018 1 1.027 1.050 Stage . 002 Stage(l) 016 129 
. 024 . 087 
Image Analysis Angi & Clinicopathologic Variables 
Residual Disease 
- 
1 
. 001 . 347 . 185 . 653 
X2(K) mean MVD 
Count 
<. O 1 1.010 1 1.005 1.016 
N/j eanFndothelial Area I <. O 1 1.434 1.270 1.619 Stage . 002 
Stage(l) 
- 016 . 
129 - F 024- T 
. 
6H7 
Spanning Tree Angio enesis & Clinicopathologic Variables I 
, %lax 
MST II I <. 01 1 . 871 
1 
. 819 
1 
. 908 
Stage <. O I 
2 nearest neighbours <. O I 1 1.144 1.064 1.230 Max MST <. O 1 . 
924 
. 
887 . 
963 
3 nearest neighbours . 032 . 
875 
. 
775 . 
999 
- All AP iogenesis &C 4ý inic pathol gic Variables 
Ma. . NIST 1 
'1104) . 
934 
. 
887 
. 
983 Stage 
. 41111 1 
. 005 . 
995 
. 
991 
. 
999 Stage(l) 
. 092 . 
231 
. 042 
1.272 
1 nearest neighbour I <. O 1 . 770 . 
675 
. 877 
Mean Endothelial 
Area <. 
O 1 1.627 1.277 2.073 
1 . 001 1.029 1.012 1.044 
9.3.4 Prediction of Chemotherapy Response - Results 
Of the clinicopathologic data turnour grade (p=0.02), FIGO stage (p=0.004), extent 
of residual disease (p=<0.01) and presence of ascites (p=0.004) were found significant 
predictors of chemotherapy response with overall correct classification to chemotherapy 
response group being 70.3%, 68.8%, 68.8% and 67.2% respectively. For the angiogenesis 
data all measurement parameters except percent connectivity to 3 nearest neighbours were 
significant. See table 9i for univariate analysis of angiogenesis parameters and 
chemotherapy response. 
Multivariate logistic regression analysis of clinicopathologic and manual 
angiogenesis parameters revealed max count at 20OX magnification (p=0.004) and the 
presence of ascites (p=0.046) to be of independent prognostic significance with an overall 
76.4% correct classification rate to chemotherapy response group. Analysis of 
clinicopathologic and image analysis angiogenesis parameters revealed max image 
analysis vessel count (p=0.018) and presence of ascites p=0.021) to retain significance 
with an overall 80.9% correct classification rate to chemotherapy response group. Analysis 
of clinicopathologic and MST angiogenesis parameters revealed sdMST (p=<0.002) and 
turnour grade (p=<0.041) to retain significance with an overall correct classification to 
chemotherapy response group of 88.5% respectively. 
Multivariate logistic regression analysis of all clinicopathologic and angiogenesis 
parameters revealed tumour grade (p=<0.057) and sdMST (p=<0.003) of independent 
prognostic significance with an overall 82.2% correct classification to chemotherapy 
response group. (See table 9j for multivariate analysis of clinicopathologic & all 
angiogenesis parameters and prediction of chemotherapy response). 
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Table 9i: Angiogenesis Parameters and Prediction of Chemotherapy Response: 
Univariate Analysis 
Parameter df Sig. 
I 
(p) 
Correct 
Classification 
95% CI 
Lower 
95% CI 
Upper 
Univariate Analysis 
Clinicopathologic Variables 
Grade . 002 68.8(( 
Grade(l) 2.412 67.919 
Grade (2) . 
729 7.917 
Stage 3 . 004 68.8(-/( 
Stage(l) 1.029 560.178 
Stage(2) . 385 
78.573 
Stage (3) . 121 
17.913 
Residual Disease I <. O 1 7 0.3 (1c 2.420 29.393 
Presence of Ascites 1 . 004 67.2 c1c 1.566 
13.922 
Pre-operative Ca125 1 . 093 
Age I A 
Angiogenesis Varia bles 
X200 Mean MVD 
Count I <. O 1 
I 
71.0(/( . 926 . 
982 
X200 Max MVD 
Count I <. O 1 71.0% . 
932 . 984 
X400 Mean MVD 
Count <. O 1 74.2% . 
819 . 
954 
X400 Max MVD 
Count <. 01 7 1.0 c1c . 847 . 960 
Mean MVD Count 
Image Analysis . 027 63.017c . 
4021 
Max MVD Count 
Image Analysis <. O 1 68.5% . 
979 . 
997 
Mean Endothelial 
Area . 027 63.0% . 
402 HX)6 
Max Endothelial 
Area . 033 6 3.0 c1c . 599 1.031 
Mean MST <. O 1 75.8% 1.094 1.436 
Sd MST <. O I 79.017c 1.230 2.347 
Max MST <. O 1 79.0% 1.057 1.270 
Min MST I <. O 1 71.7% 1.145 1.791 
I nearest neighbour I <. O 1 7 4.6 (7c 1.156 1.775 
2 nearest neighbours 1 . 013 64.4 (It . 734 . 976 
Table 9i illustrates univariate logistic regression analysis of angiogenesis & clinicopathologic 
parameters and prediction of chemotherapy response. 
For the angiogenesis data all measurement parameters, except percent connectivity to 3 nearest 
neighbours, were found to be significant. 
p values <0.05 were regarded as significant. 
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Table 9j: Multivariate Analysis - clinicopathologic & all angiogenesis parameters and 
prediction of chemotherapy response 
Parameter B S. E. Wald df Sig. Exp(B) 
95.0% C. I. for 
EXP(B) 
- 
Correct 
Classification 
Low-e-r-F Upper 
Cli icopat hol gic &Manual An ioge esis Para meters 
- 53ý2- 0 -OM ax 
MVD Count -. 040 . 016 8.414 1 1111-4 . 955 . 920 . 
985 (1rotip I= 52.0'1 
9 Group 2= 88 
)ýscites 1.414 . 717 1.996 1 . 046 4.195 
1.028 17.112 . (herall = 76.4 
Constant 3.2 5 -1 
1 1.170 7.055 1 . 111)o 25.85 ý 
Clinico pathol gic & Ima ge Analy sis Angiogenesis arameters 
-ýia-x -MVD 
Count Image 
analysis 
-. 013 . 005 5.558 1 . 018 - 987 . 
977 . 998 
(. roup 1 =55.0 
Grou p2= 96.6 
H= 80 9 
Ascites 1.757 . 760 5.344 1 . 021 5.798 1.307 
25.72 . 
Constant 2.052 . 990 1 4.293 1 1 1 . 038 
1 7.784 
Cl nicopa thologic MST A ngiogenesis Para meters 
Sd MST 
. 869 . 277 918'37 
11 1 
. 0112 2.385 
1 L; 85 4.105 
Grade 6.413 2 . 041 
1- 
I= 70 0 Grou 
Grade(l) 2.967 1.172 6.411 1 . ()11 19.439 1.955 193.286 
. p 
rou 1) 2= 97.1 
Grade(2) 1.229 . 955 1.657 1 . 1()8 3.418 . 
526 22.215 ON erall 88.5 
Constant 
-7.53 2.504 1 9.060 1 003 00 1 1 
Clinico ath ologic & All A n iogenesis Para meters 
Grade 5 .7 13 1 - . 057 
Grade(l) 2.794 1.172 5.686 1 . 017 16.349 
1.645 102.545 70.0,, 
3 99 Grade(2) 1.091 1.028 1.105 1 . 293 2.949 . 393 
0 22,120 (),. II 
. (Iroup 2 
(herall 821.2 
sdMST 0.917 . 310 8.749 1 . 003 2.501 1.362 
4.590 
Constant 2.276 1 9.512 11 . 004 764.894 
Table 9j illustrates multivariate logistic regression analysis of angiogenesis & clinicopathologic 
parameters and prediction of chemotherapy response. 
Angiogenesis parameters retained significance at multivariate level, and, for all combinations, 
angiogenesis parameters remained the strongest predictiors of chemotherapy response. 
(Group I= no / partial response: Group 2= Complete Remission) 
9.4 Discussion 
Statistically significant differences in MVD counts have previously been reported 
between benign, borderline and malignant tumours of the ovary, 12021 with analysis ofMVD 
perhaps being helpful in the distinction of these turnours. However, in ovarian carcinoma, Z-- 
prior studies of angiogenesis in relation to clinicopathologic criteria have largely reported 
contradictory results. Increased MVD has been found by some to correlate with increasing C- 
age, 
[228-3( " FIGO stage, 
[204.207.229,230-311 
and worsening turnour grade. 
1204,230-311 Other 
t-- Ll 
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studies have, however, shown no correlation to age, 
[205,210-11,217,2321 
stage, 
[205,209-11,217,2321 or 
grade. [207,209-11,232] With regard to histological type, increased MVD counts have been 
reported more frequently in mucinous as compared to serous and endometrioid turnours, 
[211,229,2321 
serous as compared to other types, 
[204,2311 
and some have reported no correlation. 
[205,207,209,2321 When considering residual disease, increased MVD counts have also shown 
contradictory findings. Theoretically, less vascular turnours should have a lesser tendency 
to metastasise and therefore be easier to surgically resect. Increased MVD has been 
correlated with both high 
[205,2291 
and low amounts of residual tumour. 
[205,217,2321 
Turning to survival analysis, increased MVD counts have been associated with a 
worse prognosis for survival and disease-free survival in both univariate 
[209,211,229,231,2331 
and multivariate analysis. 
[204,207,209-10,221,228,2341 By image analysis techniques, increased 
mean vessel area / mean endothelial area per mm 
3 has also shown worsening prognosis for 
survival. 
[220-2211 Micro vessel density has shown to correlate well to metastasis with 
significant correlation of MVD to size of metastasis, 
[2051 
and, micro vessel counts in 
metastases significantly predictive of survival. [2171 Numerous other studies have however 
reported no correlation of MVD counts with survival. 
[205,216-7,232,2353 Heterogeneity of 
ovarian turnours may decrease the prognostic value of angiogenesis in epithelial ovarian 
cancer [2321 and differences in measurement techniques may have affected results. The lack 
of standardisation of methodology, patient selection and variation in treatment and 
outcome data make these studies very difficult to compare. 
The area of drug sensitivity and angiogenesis is a particularly interesting one. Anti 
cancer drugs gain access to solid turnours via the blood supply and must penetrate through 
the extra vascular space to reach cancer cells in sufficient concentration to cause lethal 
toxicity. [2361 Essentially while increased IN4VD may promote tumour growth and spread, it 
might also be expected to facilitate the delivery of cytotoxic chemotherapy to the turnour 
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site. [2301 Neovascularisation however has been suggested counter-intuitively to reduce 
turnour accessibility to chemotherapeutic drugs as compared to normal tissues. Turnours 
may not outgrow their blood supply, but instead compress it, i. e. vascular compression 
causing eventual central necrosis. 12371 Blood flow in turnours is often irregular and the 
intercapillary distance in neovascularised areas may be relatively large compared to normal 
tissue. Penetration of some chemotherapeutic drugs, through such tissue, may be slow and 
slow tissue penetration may contribute to the development of clinical resistance. 12341 
It is perhaps not surprising, in view of this balance of potential effects, that studies 
on IMVD and chemotherapeutic response have shown conflicting results. Studies have 
found increased IMVD to be a significant predictor of improved chemotherapeutic 
response and complete response. 
[211,2281 Conversely increased IMVD has also been 
reported as a predictor for unfavourable chemotherapeutic response. [2341 
It may be that intrinsic cell properties are more important with regard to survival in 
ovarian cancer [2351 and the confounded literature reflects the fact that angiogenesis may 
not prove a practically useful technique in outcome prediction in ovarian cancer. This 
study however, in a well-selected patient group with robust follow-up and outcome data 
has shown angiogenesis variables to be highly reproducible with strong correlations 
between techniques used. 
Increasing angiogenesis parameters were all found to strongly correlate with 
increased extent of residual disease, worsening FIGO stage and presence of ascites, and on 
univariate analysis all angiogenesis parameters strongly correlated with OS with increased 
counts reflecting worsening survival. Angiogenesis parameters also strongly correlated 
with DFS where increased counts again reflected shorter times to relapse. For each set of 
angiogenesis variables, whether determined manually, by semi-automated technique or by 
spanning tree methods, multivariate analysis showed them to be by far the strongest 
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prognosticators for OS and stronger than FIGO stage for relapse prediction. 
This study has also found angiogenesis parameters, irrespective of measurement 
techniques applied, to be strong predictive factors for chemotherapy response on univariate 
analysis. When combined with clinicopathologic data, multivariate analysis has also shown 
angiogenesis parameters to retain independent significance, to supersede the predictive 
ability of such traditional pathologic markers as tumour grade, stage and extent of disease 
residuum, and to identify those patients likely to achieve complete remission, with a high 
degree of accuracy. 
This study has used a well-selected group of single histological sub-type, platinum- 
treated serous ovarian turnours with varied angiogenesis measurement techniques applied 
to the same tumour sections. Irrespective of measurement technique applied, angiogenesis 
parameters were found to be strong predictive factors for chemotherapeutic outcome in this 
group of turnours. This would certainly seem to be an area worthy of further study. 
We therefore feel that such measurements should be further investigated in 
carefully chosen prospective series of ovarian carcinomas of single histological type, 
preferably in a clinical trial setting where prospective clinical data collection is likely to be 
more precise. We would suggest that such selection problems and inconsistencies in 
clinical data might well have confounded previous studies. 
f 
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Chapter 10. Final Analysis 
10.1 Reproducibility of Parameters 
Intraobserver analysis revealed semi-automated parameters to be highly 
reproducible. Interobserver reproducibility was also impressive on the whole, yet analysis 
of nuclear spanning tree parameters showed to be less reliable. Table 10a illustrates overall 
reproducibility of all measurement parameters. 
Table 10a: Reproducibility of Parameters 
Parameter intra-observer Reproducibilit r Repr ducibility ter-observer Repr 
r r2 P r r2 P 
p53 - - - 7 71 1,0.00111 P53 percent expression 6.9983 0.9966 1- 11.1ýlw 1 (). 998-1; 0.4 
Mitotic Activity Index 
Mitotic Activity Index 0.996 0.9914 1-10.421 <0.0001 
M rphomet y Parameters 
VPE 0.992 0.9844 . 0.000 1 0.9866 0.9734 <0.000 I 
MNA 0.995 0.9890 <0.000 1 0.9648 0.9308 <0.000 I 
SdNA 0.993 0.9867 <0.000 1 0.7707 0.5939 0.0091 
Nuclear Length 0.994 0.9872 <0.000 1 0.9606 0.9227 <0.000 I 
Nuclear Breadth 0.994 0.9888 <0.000 1 0.9504 0.9033 <0.000 I 
Orthoferet 0.993 0.9865 <0.000 1 0.9501 0.9028 <0.000 I 
Nuclear Perimeter 0.994 0.9881 <0.000 1 0.9649 0.9311 <0.0001 
Nuclear Roundness 0.895 0.8003 0.0005 0.2223 0.04941 0.5371 
Equivalent Diameter 991; 0.9896 <0.000 1 0.9620 0.9254 10.0001 
Fullness Ratio 
L 
-4; =ý8 0.8 069 0.0004 0.2629 0.06913 0.4630 
Spanning Tree Parameters 
Mean MST 0.9832 0.9668 1 <0.000 1 0.9384 0.8806 0.0182 
sdMST 0.9856 0.9714 <11.0001 0.4517 0.204 0.309 
MaxMST 0.9905 0.981 <0.000 1 0.8524 0.7266 0.0 148 
Min MST 0.7855 0.6218 0.0201 0.4936 0.2437 0.2603 
1 Nearest Neighbour 0.6405 0.4102 0.0871 0.6631 0.4397 0.1044 
2 Nearest Neighbours 0.6158 0.3792 0.1042 0.2803 0.07855 0.5427 
3 Nearest Neighbours 1 0.5039 0.2539 1 0.2030 0.1973 0.03894 1 0.6715 
Manual Angiogenesis Para meters 
20OX Mean MVD 0.9758 0.9521 <0.000 1 0.9771 0.9457 <0.000 I 
20OX max MVD 0.989 0.978 <0.000 1 0.978 0.9566 <0.000 I 
40OX Mean MVD 0.8097 0.6556 0.045 0.868 0.7534 0.0011 
40OX Max MVD 0.8303 0.6893 101 19 0.8 5 1) 5 0.7388 0.0014 
ngiogenesis Image Analysis Parameters_ 
Mean MVD Count 0.9984 0.9967 1 0.111101 0.9908 0.9817 <0.0001 
Max MVD Count 0.9969 0.9939 <0.000 1 0.9948 0.9895 <0.000 I 
Mean Endothelial Area 0.9945 0.989 <0.000 1 0.9231 0.8552 0.000 1 
Max Endothelial area 0.9802 0.9608 <0.000 1 0.8598 0.7393 1 0.0014 
Angiogenesis Spann ing Tree P rameters 
Mean MST 0.9819 0.9642 0.0021) 0.9774 0.9553 0.0041 
sdMST 9958 9917 0.0003 9975 9991 9 0.000 1 
MaxMST 0.9995 0.999 <0.000 1 0.9973 0.9945 0.0002 
Min MST 0.9432 0.8931 0.0153 0.8939 74 0.799 11.11 0.040ý 
1 Nearest Neighbour 0.9694 0.9397 0.0064 0.9656 0.9325 0.0070 
2 Nearest Neighbours 0.6439 0.4146 
-- 
--6-. 2-41 0.4087 0.167 0.4,94-5 , 
0.6057 6-. 1669 0.2-79 0.7583 0.575 1 0.137i 
10.2 Correlations between parameters 
Percent expression of p53 and p53 staining grade were found to strongly correlate 
with MAI, and numerous nuclear morphometric parameters, yet not with angiogenesis 
parameters. MAI was also found to strongly correlate with numerous nuclear 
morphometric and angiogenesis parameters. Correlations between measurement 
parameters are illustrated in appendix 5. 
10.3 Survival Analysis 
Multivariate Cox logistic regression analysis was performed on all parameters 
showing positive associations on univariate analysis for OS and DFS (see table 10b for 
univariate OS analysis results). 
10.3.1 Multivariate Overall Survival Analysis 
Multivariate analysis revealed MAI (p=<0.01), and the angiogenesis parameters of 
X400 mean MVD (p=0.029), mean endothelial area (p=0.035), and number of 
microvessels with one nearest neighbour (p=<0.01) to retain independent prognostic 
ability. The remaining parameters were insignificant. Table 10c illustrates multivariate 
results for OS analysis. 
10.3.2 Multivariate Disease Free Survival Analysis 
Multivariate analysis revealed FIGO stage (p=0.02), MAI (p=0.046) and mean 
endothelial area (p=<0.01) to retain independent prognostic ability. The remaining 
parameters were not significant. Table 10c Illustrates, multivariate results for DFS 
analysis. 
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Table l0b: Univariate Analysis: OS and DIFS - All Parameters 
Parameter 
df Sig. 
(p) 
Exp 
(B) 
95% C1 
Lower 
Sig. 
(p) 
Exp 
(B) 
95% 
Lower 
C1 
95% 
Upper 
C1 
Overall Survival Disease Free Survival 
Grade 2 ms, . 004 
Grade(l) I ow . 344 . 168 . 705 . 
001 . 288 . 
138 . 603 
1 . 384 . 
799 . 479 
1.327 
Stage 31 <. O I <. O I 
Stage(l) I <. O 1 . 151 . 056 . 403 . 
037 . 
228 . 057. . 
913 
_ Stage(2) I . (H)3 . 
256 
. 
103 . 619 . 
417 . 592 . 
167 2.101 
_ 1 . 
555 1.421 . 442 
4.568 
Residual Disease I <. O 1 . 341 . 
204 1 . 
568 <. O 1 . 
341 . 
204 . 
568 
Ascites I <. O 1 . 377 . 
237 . 599 <AII . 
359 . 
212 . 605 _ Pre-op Cal 25 1 . 016 1.000 1. ooo 1.0oo Af) 1 
1.000 1 1. (XX) HXX) 
Age 1 0.065 0.722 
_ p51 Percent 
Expression 1 0.74 OAH 1 1.013 
I 
I. (X)3 
I 
1.024 
p53 Grade 1 1 0.28 0.040 1.046 [. oil 1.08-) 
p53 Positive 1 0.91 0.216 
bcI-2 Grade 1 0.88 0.257 
bcl-2 Positive 1 0.98 0.658 
p53/bcl-2 
combined 
1 0.94 0.607 
MAI <. 0 I <. O I 
VPE - <. 01 0.013 1 
MNA I 
. . 
071 2.799 0.916 8.550 . 
104 2.657 0.817 8.647 
sdNA I AN) 1 
21457928 
07'. 524 
5414469 8E+014 . 016 
3752495240.3 63.515 2E+017 
Nuclear Length I AN) 1 _ 78.318 5.662 1 1083.29 . 004 93,297 4.266 
2039.772 
Nuclear Breadth 1 . 00 1 266.784 9.342 7619.82 . 
003 380.06 7.511 19232.1 
Nuclear Perimeter 1 0) 1 4.420 1.773 11,022 AW 4.928 1.690 14.457 
sd perimeter 1 . 038 16.662 1.174 236.571 . 852 1.416 0.016 
55.243 
Nuclear Roundness 1 . 
926 . 841 0.021 
33.254 . 316 . 045 O. O(H) 
19.573 
sd roundness 1 . 
673 . 
411 0.007 25.43 . 164 . 014 (). (KX) 
5.785 
orthoferet 1 AW 355.719 7.423 3938.98 
-. 
(K)3 355.72 7.423 17046.047 
Fullness ratio 1 . 627 . 
102 
3128541574396 
426.0 
WI 1.2E+034 
Equivalent 
diameter I <. 01 I 
22.403 4.791 104.768 Aft 9.932 1.955 50.46 
Length MST 1 0.29 0.407 
sdMean MST 1 0.48 0.151 
Mean MST 1 0.092 0.093 
Min MST 1 0.053 0.044 . 
704 
. 
497 
. 
990 
Max MST 1 0.036 . 
925 
. 
861 T . 995 0.057 
sd MST 1 0.125 0.136 
1 Nearest 
Neighbour 1 0.003 1.187 1.057 1.333 0.014 
1.161 1.032 1.307 
2 Nearest 
Neighbours 1 I 
0.017 
1 . 
928 
. 
873 . 987 
0.009 
1 . 
915 . 
854 . 
990 
3 Nearest 
Neighbours 189 0.130 
Table 10c: Multivariate Analysis: OS and DFS - All Parameters 
Parameter Sig. Exp 
95% 95% Parameter Sig. Exp 95% 95% df 
(p) (B) 
Ci 
I 
C1 (p) 
Ci C1 
Lower Upper Lower Upper 
Multivariate A alysis 
Overa ll Survival Dise ase Free Survival 
Mitotic Activity Stage 
Index I <AII 1.037 1.017 1.058 . 11112 
X400 mean MVD 1 . 029 1.018 1.002 1.033 Stage(l) . 148 . 282 . 051 1.567 
Mean endothelial Stage(2) 1 . 03; 1.210 1.014 1.444 . 
148 . 275 . 048 1.582 area I I I I II 
I nearest neighbour Stage(3) F1 
<. O 1 739 652 836 . 698 1.331 . 314 5.642 angiogenesis 
Mitotic 
Activity . 046 1.022 HHH) 1.045 
Index 
Mean 
endothelial AII 1.579 1.226 2.014 
area 
Table 10c illustrates Cox multivariate survival analysis results for all parameters. 
Overall the angiogenesis parameters, as determined by image analysis, were the strongest 
independent prognosticators for both OS and DFS. 
p values <0.05 were regarded as significant. 
10.4 Response to Chemotherapy 
Multivariate logistic regression analysis was performed on all parameters showing 
positive associations on univariate analysis for prediction of chernotherapy response. (See 
table 10d for overall univariate results). 
10.4.1 Multivariate analysis: prediction of chemotherapy response 
Multivariate logistic regression analysis revealed turnour grade, VPE (p=0.013), 
nuclear length (p=0.009) and number of microvessels with one nearest neighbOL11- 
(P=0.005) to retain independent predictive significance with overall correct classification 
to chemotherapy response group of 84.6%. The remaining, parameters were not significant. 
(See table l0e for multivariate analysis of prediction of chemotherapy response). 
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Table 10d: Univariate Prediction of Chemotherapy Response: All Parameters 
Parameter df P 
95.0% C. I. for 
EXP(B) 
Correct 
Classification 
Lower Upper 
Grade 2 . 11111 
Grade(l) 1 . 003 2.412 67.918 
Grade(2) I .1 15 1 . 728 7.917 1 
FIGO Stage 3 . 02; 
1 68.81 i 
Stage(l) 1 . 048 1.028 
560.178 
Stage(2) 1 . 209 . 385 78.573 
Stage(3) 1 . 761 . 121 17.913 
Residual Disease I oll 2.420 29.383 70.31 
Ascites 1 . 0416 1.566 
13.822 67.2 (i 
Age 1 . 554 
Pre-op Cal, 25 1 . 093 
p53(; rade 1 . 217 
P53 Positive 1 . 235 
p53 Percent Expression 1 . 663 
bcl-2 Positive 1 . 771 
bcl-2 Grade 1 . 718 
Mitotic Activity Index 1 . 352 I VPE II . <. Ol , 
0.899 1 0.976 1 76.3; ý i 
NINA 1 . 060 
1 1 
sdNA 1 . 017 
1 
. 000 . 
001 64.1 '4 
Nuclear Length I J . (H)5 
1 Olt) . 076 64.1 
'ýt 
Nuclear Breadth 1 . 00; ooo . 044 65.6'i 
Nuclear Perimeter 1 . 1004 . 
002 . 407 64.1 
sd nuclear perimeter 1 . 290 
Nuclear Roundness 1 . 523 
sd nuclear roundness 1 305 
Orthoferet I I mo; I . (H)() 
1 
. 042 
1 05.0 1i 
- Fullness Ratio 
Equivalent diameter 
Length NIST nuclear 
sd Mean Nisf nuclear 
Mean msf nuclear 
Min MST nuclear 
Max MST nuclear 
sd MST nuclear 
1 Nearest Neighbour 
nuclear 
1 
1 
1 
1 
1 
-1 1 
1 
1 
. 414 
. 076 
. 508 
. 663 
. 900 
. 797 
. 751 
. 848 
. 059 
2 Nearest Neighbours; 
nuclear 
1 
I . 
006 1.042 
I 
1.460 
I 53.1'( I 
X200 mean MVD I <. o 1 . 926 . 982 
7 1.0 
X200 max MVD I <. 0 1 . 932 . 984 
71.0(i 
X400 mean MVD I <. O 1 . 819 . 954 74.2'i 
X400 max MVD I <. O 1 . 847 . 960 71.0"1 
Mean Endothelial Area 1 . 027 . 402 1.006 63.014 
Max Endothelial Area 1 . 033 . 599 1.031 6.1.0(, i 
Mean MVD image 
analysis count 
1 . 027 402 1.006 I I 
63.01, ( 
I 
Max MVD image 
anal sis count *, s 
I <. O 1 . 978 . 997 68.5 IZ( 
Mean MST an enesis ,I, io I <. O 1 1.094 1.436 75.8(,, 
d MST an io enesis sTc I <. O 1 1.230 2.347 79.01 
MS. ax MST an io enesis 'L F I <. O 1 1.057 1.270 79.01 
j, T - Min MLS. NT an io enesis io I <. O 1 1.145 1.781 71.7 'ý'i 
I nearest neighbour 
angiogenesis 
. I <. O 1 1.156 1.775 74.614 
2 nearest neighý 
angiogenesis 
ý 
- 
. 013 I- . 
734 . 976 I 
64.411i 
Table 10d illustrates univariate logistic regression analysis results for all 
parameters and prediction of chemotherapy response 
Significant parameters were used in multivariate analysis 
p values <0.05 were regarded as significant. 
153 
Table l0e: Multivariate Analysis: Prediction of Chemotherapy Response 
- All Parameters 
Parameter Sig. Correct 95% Cl 95% Cl df 
(p) Classification Lower 
_Upper Grade 2 . 100 
G rade(l) 1 . 043 1 
1.119 1757.396 
Grade(2) 1 . 651 . 
081 4.796 
. VPE I- . 013 
Group I= 82.614 . 673 . 955 _ Nuclear length 1 . 009 
Group 2= 86.21", 
. 000 . 000 
I nearest neighbour 1 
O%erall = 84.67( 1.314 4.679 
angiogenesis 
Constant 1 322 
Table l0e illustrates multivariate logistic regression analysis results for all 
parameters and prediction of chemotherapy response. 
Overall tumour grade, VPE, nuclear length, and number of microvessels with one 
nearest neighbour (p=0.005) were found to retain independent predictive 
significance with overall correct classification to chemotherapy response group of 
84.6%. 
p values <0.05 were regarded as significant. 
(Group I= no / partial response: Group 2= Complete Remission) 
10.5 Discussion 
The application of quantitative morphometric assessments airns to reduce 
variability in quantifying features of cells and tissues, with an overall aim to reduce intra- C, 
and interobserver variability, and to provide a numerical, reproducible scale of quantitative 
features. '"' As previously discussed, studies on traditional, qW111tative, clinicopathologic 
parameters, such as tumour grade, have shown considerable intra and interobserver LI 
variability, 
[87,83.94,85.86,981 
and present methods of quantifying residual turnour are imprecise 
1261 with definitions of optimal cytoreductive surgery markedly varying. 1411 This Study, I L- 
with the exception of nuclear spanning tree parameters, found senil-autoniated image 
analysis techniques to be not only highly reproducible, but also to surpass the variation 
found in grading techniques. The analyses were also relatively fast and inexpensive, and 
did not require a learned pathologist to perform them. 
This study found strong correlations between percent expression of p53 
(p=0.0032), p53 staining grade (p=0.0002) and MAI. The correlation of p53 parameters 
and MAI is not surprising. A major feature of cancer is the inappropriate division of cells. 
154 
P53 plays a pivotal role in inducing apoptosis and loss of p53 suppressor function renders 
cells susceptible to uncontrolled growth, with mutation or deletion of p53 believed to result 
in uncontrolled cell proliferation, and failure of apoptosis. Prior IHC based studies have 
found Ki67 negative turnours also negative for p53 staining, [1041 and positive correlations 
found between p53 accumulation and MI13 I LI (MEB I labelling Index), with MIB I being 
a monoclonal antibody directed against Ki67 antigen. E1191 The combination of p53 (nuclear 
accumulation in >10% neoplastic cells) and MEB I counts (MEBI LI >30%) has been 
found strongly predictive of the highest risk ratio of death and the most powerful 
prognostic indicator of reduced survival. 11191 
This study did not to show any correlations between p53 expression and 
angiogenesis parameters. Prior studies of p53 gene mutation in ovarian carcinoma have 
found a significant trend for the MVD count to increase as the p53 status of the cancer 
progressed from wild type to missense to null. 12311 Mutation of the Tp53 tumour 
suppressor gene is involved in the down-regulation of angiogenesis inhibitors such as 
thrombospondin-I (TSP-1) and in the up-regulation of angiogenic factors such as vascular 
endothelial growth factor (VEGF). 121 01 Both VEGF and TSP-1 contain p53 response 
elements and are involved in the formation and inhibition of new blood vessels 
respectively. [238-2401 TSP-I is a potent modulator of angiogenesis which has been shown to 
have inhibitory effects on the process of neovascularisation, so in cell culture, loss of p53 
wild-type allele is associated with decreased levels of TSP-1; shifting the balance towards 
angiogenesis. [2401 Despite it being well accepted that there is a concordance between 
genetic methods that detect p53 gene mutations, and IHC methods that measure mutant 
p53 protein accumulation, 
[37,38,39,401 like this study, lHC determination of p53 over- 
expression has previously not been found to correlate with turnour microvessel density 
assessment. [238.2411 
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The finding that p53 expression and numerous nuclear morphometric parameters 
showed significant correlations in this study is also not surprising. Higher values of NINA, 
sdNA, nuclear length and breadth for example relate to enlarged, pleomorphic nuclei, 
which, like MAI are regarded as markers of cell proliferation. As 96% of turnours in this 
study showed positive staining for p53, this explains the lack of correlation between p53 
positivity and other measurement parameters. 
This study found MAI to correlate with numerous nuclear morphometric and 
angiogenesis parameters. Explanation for the correlation of MAI and nuclear 
morphometric parameters is that cycling cells are likely to be larger than non-cycling. A 
prior study in ovarian cancer however had found no association between mitotic counts 
and nuclear features, but this was a relatively small study (n=49). 12351 
The association between turnour cell proliferation and IMVD in endothelial cells 
has been previously recognised in studies of colorectal 
[2421 
and lung 
[2431 
carcinomas, yet 
no such correlation was found in a study on ovarian carcinoma, although this again was of 
a relatively small sample group (n=3 1). [2441 This association between MAI and 
angiogenesis parameters appears to suggest that tumour progression and metastasis are 
angiogenesis dependent. 
The combination of MAI, and the angiogenesis parameters of mean MVD at 
X400 magnification, mean endothelial area, and one nearest neighbour were independent 
prognosticators for OS. Mean endothelial area remained the strongest independent 
prognosticator for DFS. Multivariate analysis for prediction of chemotherapy response also 
revealed the angiogenesis parameter of number of capillaries with one nearest neighbour to 
be the strongest independent prognosticator. Overall, therefore angiogenesis determinants, 
particularly those determined by semi-automated image analysis, were found to be the 
strongest prognosticators in this group of serous ovarian carcinomas. 
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Chapter 11. Summary, Final Conclusion, and Future 
Perspectives. 
11.1 Introduction 
Due to the heterogeneous nature of ovarian turnours, it is probable that no single 
biological parameter will give accurate prognostic information in all ovarian cancer 
patients. Identification, however, of prognostic factors in ovarian cancer, enables an 
improved understanding of the natural history of the disease, provides clinicians with 
guidelines for decisions on treatment strategies, and adjusts for imbalances in comparing 
therapeutic regimens. [2451 Identification of predictive factors, useful in selection of patients 
likely to benefit from a specific treatment such as targeted systemic therapy, has been an 
important goal to optimýise therapy. Patients could be more appropriately stratified within 
treatment protocols if good and poor prognosis patient groups could be identified at initial 
surgery 
This thesis has investigated the reproducibility, prognostic, and predictive value of 
qualitative clinicopathological, and quantitative pathological variables in a well-selected 
group of serous ovarian carcinomas, in an aim to determine whether basic morphometric 
data can predict outcome and chemotherapeutic response in ovarian serous carcinoma, to 
determine whether newer semi-automated methods of tumour morphometry provides 
similar results to older methods, and to determine whether advanced image analysis 
methods can offer further tumour outcome data etc in serous ovarian carcinoma. 
11.2 Summary 
In chapter 1a review is given of clinicopathologic factors in ovarian carcinoma. 
Borderline turnours were not always excluded in the studies exarnined and histological 
sub-types were, most often, not considered as singular entities. The most important 
clinicopathologic prognostic factors in ovarian carcinoma appear to be residual disease 
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status, FIGO stage, and turnour grade, which are all fraught with difficulties in 
reproducibility and classification. The general conclusion, for most of these 
clinicopathologic prognostic factors however, was that conflicting results were obtained 
from different studies. Chapter 3 therefore investigated the prognostic and predictive 
ability of clinicopathologic parameters, in a well-selected group of serous ovarian 
carcinomas, to ensure that this study's findings were comparable to others. Multivariate 
analysis revealed extent of residual disease to be the strongest prognostic factor for overall 
survival (OS) and strongest predictive factor for chemotherapy response, and FIGO stage 
the strongest prognosticator for disease free survival (DFS), which was unsurprising. As 
problems with reproducibility are well documented in tumour grade, and definitions of 
residual disease variable, then close consideration was taken as to reproducibility of all 
further parameters investigated. 
Chapter 4 considered the prognostic and predictive value of p53 and Bcl-2 as 
determined by immunohistochernical techniques. Prior study data again showed conflicting 
results. Bcl-2 was found neither a valuable prognostic nor predictive factor in this group of 
patients. P53 percent expression was found to be highly reproducible. Although p53 
percent expression and p53 grade were found significant predictors of DFS, they failed to 
retain independent prognostic significance, being superseded by FIGO stage. P53 was not 
found to be significant for prediction of chemotherapy response. From these findings it 
may be concluded that p53 is only of limited prognostic value in serous ovarian 
carcinomas. 
Evidence has accumulated for the strong additional prognostic value of quantitative 
pathologic techniques. Such techniques allow greater objectivity than histological grading, 
typing, estimation of residual tumour etc. and have been shown in ovarian turnours to have 
considerable prognostic importance. Chapters 5 and 6 investigated the value of mitotic 
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activity index (MAI) and volume percentage epithelium (VPE) estimates. Traditional point 
counting techniques for assessment of epithelial area were highly correlated to semi- 
automated image analysis techniques. For both parameters, assessment techniques were 
found to be highly reproducible at intra- and interobserver level. In agreement with prior 
study findings both MAI and VPE were found to be strong independent prognosticators for 
both OS and DFS. Although MAI was not significant, VPE was found to retain 
independent significance for prediction of chemotherapy response, superseding the 
prognostic ability of residual disease status. From these findings it may be concluded that 
MAI and VPE are of important value in prognostic determination in serous ovarian 
carcinomas. 
The ability of nuclear morphometric features to predict outcome in serous ovarian 
carcinomas was investigated in chapter 7. Again this quantitative technique was found to 
be highly reproducible. For prediction of survival (OS & DFS), and chemotherapy 
response, multivariate analysis revealed equivalent diameter and nuclear length, 
respectively, to retain independent prognostic significance. It is therefore concluded that 
nuclear morphometric variables have important value in predicting prognosis in serous 
ovarian carcinoma and add to the classical prognostic parameters of residual disease status 
and FIGO stage. 
Minimum spanning tree analysis (MST) is a method to analyse the arrangement of 
nuclei in tissue. In Chapter 8 the reproducibility and prognostic ability of MST variables in 
serous ovarian carcinoma were investigated. Despite amendments in methodology, MST 
variables were not reproducible at interobserver level, and, despite attaining prognostic 
value on univariate analysis, MST variables failed to retain significance on multivariate 
analysis for prediction of OS, DFS and chemotherapy response. In conclusion, MST is of 
limited prognostic value in serous ovarian carcinomas, and the marked heterogeneity 
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observed in ovarian turnours is likely be a limiting factor in the practical application of this 
technique. 
Angiogenesis is the formation of new blood vessels by proliferation of new 
capillaries from pre-existing vessels. Chapter 9 investigated the prognostic and predictive 
abilitY of angiogenesis parameters in serous ovarian carcinoma. Parameters were determined 
by traditional light microscopic counting techniques, semi-automated image analysis 
techniques and by application of syntactic structure analysis techniques. Methods were 
found to be highly reproducible and to highly correlate with one another. Multivariate 
analysis found angiogenesis parameters to exceed the prognostic ability of traditional 
clinicopathologic parameters for the prediction of OS, DFS and chemotherapy response. In 
conclusion angiogenesis parameters have important value in predicting prognosis in serous 
ovarian carcinoma, with particular importance shown by those parameters determined by 
semi-automated image analysis techniques. 
The overall prognostic value of clinical, qualitative, and quantitative pathological 
features were evaluated in chapter 10, in this study of a well-selected group of serous 
ovarian carcinoma patients, treated with primary debulking surgery, and platinum-based 
combination chemotherapy, with long-term follow-up. The determination of quantitative 
features was not only fast and easy to perform, but also relatively inexpensive. 
Reproducibility of quantitative parameters was excellent, and certainly exceeded the 
reproducibility of turnour grade, as reported in prior studies. Multivariate analysis revealed 
the combination of angiogenesis parameters (X400 mean MVD, mean endothelial area and 
percent connectivity of capillaries with one nearest neighbour) and MAI to be independent 
prognostic factors for OS, and the combination of FIGO stage, MAI and mean endothelial 
area to be independent prognostic factors for DFS. For the prediction of chemotherapy 
response, multivariate analysis revealed turnour grade, VPE, nuclear length and percent 
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connectivity of capillaries with one nearest neighbour to be independent prognostic factors. 
At multivariate level angiogenesis parameters, as determined by semi-automated image 
analysis techniques, were found overall to be the strongest prognosticators. 
11.3 Final conclusion 
From these findings it may be concluded that basic morphometric data can predict 
outcome and chemotherapeutic response in ovarian serous carcinoma, that newcr semi- 
automated methods of tumour morphometry provides similar results to older methods and 
that advanced image analysis methods can offer further tumour outcome data in ovarian 
carcimoma. The rationale for the application of semi-automated and automated detection 
and outlining of abnormal regions of a tumour is that it may provide an unbiased sampling 
of a lesion and possibly a more representative estimate of areas that a human expert might 
label. Such determined, quantitative pathological findings were found to have important 
value in predicting prognosis in ovarian carcinoma and, if not to supersede, certainly to add 
to the classical prognostic factors of FIGO stage, turnour grade and residual disease status. 
11.4 Future Perspectives 
Prior studies have suffered from lack of multivariate analysis, use of mixed 
histological sub-types, small population sizes, and outcome analysis performed on patients 
treated with varying chemotherapeutic regimes. Future studies should be performed using 
multivariate analysis, as ideal prognostic classification should be derived from prognostic 
factors, which are identified by multivariate statistical analyses. 12461 This thesis has 
attempted to achieve this. Use of different histological sub-types may have confounded 
prior study findings due to their distinct molecular pathogenesis and biological 
background. This thesis considers serous carcinomas only, and application to singular non- 
serous histological sub-types would be of interest to ensure that the data holds throughout 
the whole spectrum of epithelial ovarian turnours. This study group also contains a 
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relatively lower number of stage I turnours. Careful analysis and development of more 
accurate risk factors is important to indicate the 'high risk' early stage patients hence 
further analysis in a large group of stage I tumours is recommended to ensure these 
findings hold. Angiogenesis determinants were found to be the strongest prognosticators 
for survival and prediction of chemotherapy response. It would be particularly interesting 
to see whether they do so in larger studies and in particular early stage turnours. 
The way forward probably lies in conducting large, well defined retrospective and 
prospective studies of single tumour types, using precisely conducted mitotic counts, well- 
selected nuclear measurements, VPE estimates, and angiogenesis determinants, all under 
careful statistical control. 
This thesis illustrates that there may be no singular parameter uniformally capable 
of predicting patient outcome. However this data suggests that with further refinement and 
control, measurement of a range of parameters may contribute more than current subjective 
measurements. 
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Appendix 2: Glossary of Measurement Parameters: 
1. Feature Measurement Parameters 
Feature: Features are distinct areas within an image having a single continuous 
boundary. Image analysers recognise features rather than objects. 
Area: Feature Area - The total number of detected pixels within the feature. 
Equivalent Diameter: Equivalent Circle Diameter - i. e. the diameter of a circle 
having the same area as the feature. 
Fullness Ratio: The Fullness Ratio - this is a shape factor, equal to the 
square root of the ratio of area to circumscribed area. 
Fullness Ratio= sqrt ( Area 
Convex Area 
Length The length of the longest feret. 
Feret Diameters 
Sometimes known as calliper diameters, may be known as the orthogonal 
distance between a pair of parallel tangents to the feature at the specified angle 
to the scan. eg feret 0 corresponds to the feature width and feret 90 corresponds 
to the feature height. 
Orthoferet Orthogonal feret - the length of the feret that is at right angles to the longest 
feret. 
Perimeter The total length of the boundary of the feature. This is calculated from the 
horizontal and vertical projections, with an allowance for the number of 
comers. 
Roundness A shape factor which gives a minimum value of unity for a circle. This is 
calculated from the ratio of perimeter squared to area. 
Feature Count Point 
Defines the X and Y co-ordinate for the feature. The Feature Count Point is the 
last (rightmost) pixel of the last (bottom) line contained in the object. An object 
whose FCP is out of the measurement frame will not be measured by a feature 
measurement, and will not be counted by a field or a feature measurement. 
Feature measurements produce results relating to a wide range of parameters 
for each isolated feature. 
X FCP The X co-ordinate of the Feature Count Point. 
Y FCP The Y co-ordinate of the Feature Count Point. 
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Appendix 3: Sub-group analysis of MST Parameters- 
Grouped FIGO stage I& 11 and III & IV. 
Sig. Exp 
95% 95% Sig. Ex P 
95% 95% 
df cl ci Parameter Lower Upper 
Parameter (p) (B) Lower Upper (p) (B) cl ci 
Univariate Analysis FIGO! & Il 
Overall Survival Disease Free Survival 
Clinicopatholo ic Variab les Clinicopatho ogic Variab les 
Max MST 1 . 031 . 780 . 622 . 
977 Length MST 11 . 154 
Length MST 1 . 395 
Mean MST 1 . 434 
Mean MST 1 . 108 Min MST 1 . 166 
Min MST 1 . 169 Max 
MST 1 . 568 
sd MST 1 . 107 sd 
MST 1 . 512 
1 Nearest 
1 161 
1 Nearest 
. 025 1.229 1.026 1.473 Neighbour . Neighbour 
2 Nearest 
1 549 
2 Nearest 
. 038 . 872 . 766 . 992 Neighbours . Neighbours 
3 Nearest 
1 163 
3 Nearest 
. 015 1.287 1.050 1.577 Nei hbours . I Neighbours 
Univariate Analysis F IGO III & IV 
Length MST 1 . 724 
Length MST . 943 
Max MST 1 . 686 
MaxMST . 916 
Mean MST 1 . 942 Mean 
MST . 976 
Min MST 1 . 748 
Min MST . 751 
sd MST 1 . 756 sd MST . 966 
1 Nearest 1 Nearest 
Neighbour 1 . 162 Neighbour . 453 
2 Nearest 2 Nearest 
Neighbours 1 . 295 Neighbours . 546 
3 Nearest 3 Nearest 
Nei hbours 1 . 394 Neighbours . 454 
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Appendix 4: Sub-group analysis spanning tree parameters - 
field count >65 points per field 
95% 95% 
95% 95% 
df Sig. Exp C1 C1 Sig. Exp 
Lowe Upper 
Parameter (p) (B) Lower Upper 
Parameter (p) (B) r 
C1 
Univariate A alysis 
Overall Survival Disease Free Survival 
Clinicopath logic Variab les Clinicopatho ogic V ariables 
Mean MST I AOISI . 821 . 692 . 989 Mean MST . 100 Min MST 1 . 014 . 638 . 447 . 912 Min MST . 083 Max MST 1 . 019 . 904 . 831 . 983 Max MST . 071 
sd MST 1 . 070 sdNIST . 133 I Nearest 1 Nearest 
Neighbour 1 . 057 Neighbour . 396 
2 Nearest 2 Nearest 
Neighbours 1 . 154 Neighbours . 397 
3 Nearest 3 Nearest 
Neighbours 1 . 714 Neighbours . 715 
Length MST 1 . 137 Length MST . 146 
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